Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain

ABSTRACT

The present invention relates to compounds of general formula (I) having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

FIELD OF THE INVENTION

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor (MOR or mu-opioid) and more particularly to diazaspiro-undecane derivatives having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of Pain.

BACKGROUND OF THE INVENTION

The adequate management of pain constitutes an important challenge, since currently available treatments provide in many cases only modest improvements, leaving many patients unrelieved [Turk D C, Wilson H D, Cahana A. Treatment of chronic non-cancer pain. Lancet 377, 2226-2235 (2011)]. Pain affects a big portion of the population with an estimated prevalence of around 20% and its incidence, particularly in the case of chronic pain, is increasing due to the population ageing. Additionally, pain is clearly related to comorbidities, such as depression, anxiety and insomnia, which lead to important productivity losses and socio-economical burden [Goldberg D S, McGee S J. Pain as a global public health priority. BMC Public Health. 11, 770 (2011)]. Existing pain therapies include non-steroidal anti-inflammatory drugs (NSAIDs), oploid agonists, calcium channel blockers and antidepressants, but they are much less than optimal regarding their safety ratio. All of them show limited efficacy and a range of secondary effects that preclude their use, especially in chronic settings.

As mentioned before, there are few available therapeutic classes for the treatment of pain, and opioids are among the most effective, especially when addressing severe pain states. They act through three different types of opioid receptors (mu, kappa and gamma) which are transmembrane G-protein coupled receptors (GPCRs). Still, the main analgesic action is attributed to the activation of the μ-opioid receptor (MOR). However, the general administration of MOR agonists is limited due to their Important side effects, such as constipation, respiratory depression, tolerance, emesis and physical dependence [Metdrum, M. L (Ed.). Opioids and Pain Relief: A Historical Perspective. Progress in Pain Research and Management, Vol 25. IASP Press, Seattle, 2003], Additionally, MOR agonists are not optimal for the treatment of chronic pain as indicated by the diminished effectiveness of morphine against chronic pain conditions. This is especially proven for the chronic pain conditions of neuropathic or inflammatory origin, in comparison to its high potency against acute pain. The finding that chronic pain can lead to MOR down-egulation may offer a molecular basis for the relative lack of efficacy of morphine in long-term treatment settings [Dickenson, A. H., Suzuki. R. Opioids in neuropathic pain: Clues from animal studies. Eur J Pain 9, 113-6 (2005)]. Moreover, prolonged treatment with morphine may result in tolerance to its analgesic effects, most likely due to treatment-induced MOR down-regulation, internalization and other regulatory mechanisms. As a consequence, long-term treatment can result in substantial increases in dosing in order to maintain a clinically satisfactory pain relief, but the narrow therapeutic window of MOR agonists finally results in unacceptable side effects and poor patient compliance.

The sigma-1 (σ₁) receptor was discovered 35 years ago and initially assigned to a new subtype of the oploid family, but later on and based on the studies of the enantiomers of SKF-10,047, its independent nature was established. The first link of the σ₁ receptor to analgesia was established by Chien and Pastemak [Chien C C, Pasternak G W. Sigma antagonists potentiate opioid analgesia in rats. Neurosci. Lett. 190, 137-9 (1995)], who described it as an endogenous anti-opioid system, based on the finding that σ₁ receptor agonists counteracted opioid receptor mediated analgesia, while σ₁ receptor antagonists, such as haloperidol, potentiated it.

Many additional preclinical evidences have indicated a clear role of the T receptor in the treatment of pain [Zamanillo D. Romero L Merlos M. Vela J M. Sigma 1 receptor A new therapeutic target for pain. Eur. J. Pharmacol, 716, 78-93 (2013)]. The development of the a receptor knockout mice, which show no obvious phenotype and perceive normally sensory stimuli, was a key milestone in this endeavour. In physiological conditions the responses of the σ₁ receptor knockout mice to mechanical and thermal stimuli were found to be undistinguishable from WT ones but they were shown to possess a much higher resistance to develop pain behaviours than WT mice when hypersensitivity entered into play. Hence, in the σ₁ receptor knockout mice capsaicin did not induce mechanical hypersensitivity, both phases of formalin-induced pain were reduced, and cold and mechanical hypersensitivity were strongly attenuated after partial sciatic nerve ligation or after treatment with paclitaxel, which are models of neuropathic pain. Many of these actions were confirmed by the use of m receptor antagonists and led to the advancement of one compound, S1RA, into clinical trials for the treatment of different pain states. Compound S1RA exerted a substantial reduction of neuropathic pain and anhedonic state following nerve injury (i.e., neuropathic pain conditions) and, as demonstrated in an operant self-administration model, the nerve-injured mice, but not sham-operated mice, acquired the operant responding to obtain it (presumably to get pain relief), indicating that σ₁ receptor antagonism relieves neuropathic pain and also address some of the comorbidities (i.e., anhedonia, a core symptom in depression) related to pain states.

Pain is multimodal in nature, since in nearly all pain states several mediators, signaling pathways and molecular mechanisms are implicated. Consequently, monomodal therapies fail to provide complete pain relief. Currently, combining existing therapies is a common clinical practice and many efforts are directed to assess the best combination of available drugs in clinical studies [Mao J, Gold M S. Backonja M Combination drug therapy for chronic pain: a call for more clinical studies. J Pain 12, 157-166 (2011)]. Hence, there is an urgent need for innovative therapeutics to address this unmet medical need.

As mentioned previously, opioids are among the most potent analgesics but they are also responsible for various adverse effects which seriously limit their use.

Accordingly, there is still a need to find compounds that have an alternative or improved pharmacological activity in the treatment of pain, being both effective and showing the desired selectivity, and having good “drugability” properties, i.e. good pharmaceutical properties related to administration, distribution, metabolism and excretion.

Thus, the technical problem can therefore be formulated as finding compounds that have an alternative or improved pharmacological activity in the treatment of pain.

In view of the existing results of the currently available therapies and clinical practices, the present invention offers a solution by combining in a single compound binding to two different receptors relevant for the treatment of pain. This was mainly achieved by providing the compounds according to the invention that bind both to the μ-opiod receptor and to the σ₁ receptor.

The prior art document DE 10 2005 030051 A1 discloses compounds which are inhibitors of the μ-opioid receptor and differ from compounds of the present invention through the character of the bicyclic core.

Document WO 2008/155132 A1 disclose compounds which are inhibitors of the C receptor and differ from compounds of the present invention through the character of the bicyclic core.

WO 2012/125613 A1 discloses compounds which are modulators of the ion channels and differ from compounds of the present invention through the invariable presence of carboxy group on the nitrogen atom of piperidine.

SUMMARY OF THE INVENTION

In this invention a family of structurally distinct diazaspiro undecane derivatives which have a dual pharmacological activity towards both the sigma (a) receptor, and the μ-opiod receptor was Identified thus solving the above problem of identifying alternative or improved pain treatments by offering such dual compounds.

The invention is in one aspect directed to a compound having a dual activity binding to the σ₁ receptor and the μ-opioid receptor for use in the treatment of pain.

As this invention is aimed at providing a compound or a chemically related series of compounds which act as dual ligands of the σ₁ receptor and the μ-opioid receptor it is a very preferred embodiment if the compound has a binding expressed as K_(i) which is preferably <1000 nM for both receptors, more preferably <500 nM, even more preferably <100 nM.

The invention is directed in a main aspect to a compound of general formula (I).

wherein R¹, R², R⁸ R^(8′), X, Y, Z, m and n are as defined below in the detailed description.

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to a family of structurally distinct diazaspiro undecane derivatives which have a dual pharmacological activity towards both the sigma (σ) receptor and the μ-opiod receptor, thus solving the above problem of identifying alternative or improved pain treatments by offering such dual compounds.

The invention is in one aspect directed to a compound having a dual activity binding to the σ₁ receptor and the μ-opioid receptor for use in the treatment of pain.

As this invention is aimed at providing a compound or a chemically related series of compounds which act as dual ligands of the σ₁ receptor and the μ-opioid receptor it is a preferred embodiment if the compound has a binding expressed as K which is preferably <1000 nM for both receptors, more preferably <500 nM, even more preferably <100 nM.

The applicant has surprisingly found that the problem on which the present invention is based can be solved by using a multimodal balanced analgesic approach combining two different synergistic activities in a single drug (i.e., dual ligands which are bifunctional and bind to μ-opioid receptor and to σ₁ receptor), thereby enhancing the opioid analgesia through the r activation without increasing the undesirable side effects. This supports the therapeutic value of a dual MOR a receptor compound whereby the m receptor binding component acts as an intrinsic adjuvant of the MOR binding component.

This solution offered the advantage that the two mechanisms complement each other in order to treat pain and chronic pain using lower and better tolerated doses needed based on the potentiation of analgesia but avoiding the adverse events of μ opioid receptor agonists.

A dual compound that possess binding to both the μ-opiod receptor and to the n receptor shows a highly valuable therapeutic potential by achieving an outstanding analgesia (enhanced in respect to the potency of the opioid component alone) with a reduced side-effect profile (safety margin increased compared to that of the opioid component alone) versus existing opioid therapies.

Advantageously, the dual compounds according to the present invention would in addition show one or more the following functionalities: σ₁ receptor antagonism and μ-opioid receptor agonism. It has to be noted, though, that both functionalities “antagonism” and “agonism” are also sub-divided in their effect into subfunctionalities like partial agonism or Inverse agonism. Accordingly, the functionalities of the dual compound should be considered within a relatively broad bandwidth.

An antagonist on one of the named receptors blocks or dampens agonist-mediated responses. Known subfunctionalities are neutral antagonists or inverse agonists.

An agonist on one of the named receptors increases the activity of the receptor above its basal level. Known subfunctionalities are full agonists, or partial agonists.

In addition, the two mechanisms complement each other since MOR agonists are only marginally effective in the treatment of neuropathic pain, while n, receptor antagonists show outstanding effects in preclinical neuropathic pain models. Thus, the σ₁ receptor component adds unique analgesic actions in opioid-resistant pain. Finally, the dual approach has clear advantages over MOR agonists in the treatment of chronic pain as lower and better tolerated doses would be needed based on the potentiation of analgesia but not of the adverse events of MOR agonists.

A further advantage of using designed multiple ligands is a lower risk of drug-drug interactions compared to cocktails or multi-component drugs, thus involving simpler pharmacokinetics and less variability among patients. Additionally, this approach may improve patient compliance and broaden the therapeutic application in relation to monomechanistic drugs, by addressing more complex aetiologies. It is also seen as a way of improving the R&D output obtained using the “one drug-one target” approach, which has been questioned over the last years [Bornot A. Bauer U, Brown A, Firth M, Hellawell C, Engkvist O. Systematic Exploration of Dual-Acting Modulators from a Combined Medicinal Chemistry and Biology Perspective. J. Med. Chem, 56, 1197-1210 (2013)].

In a particular aspect, the present invention is directed to compounds of general formula (I):

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉— m is 0 or 1 n is 1, 2 or 3 q is 1, 2, 3, 4, 5 or 6 R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)_(r)—W—R_(1′); r is 0, 1 or 2; W is —CH₂O—, —CH₂C(O)NR_(5′)—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl, R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄; R₄ is H, —OR_(b), substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR₅, —NR₅R_(5′″) or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; R_(4′) is H or substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R_(5′) and R_(5″) are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5′) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc; R₆, R_(6′), R₇, and R_(7′) are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

Please note that “or a corresponding salt thereof” does also mean “or a corresponding pharmaceutically acceptable salt thereof”. This does apply to all below described embodiments and uses of “salt” being thus equivalent to “pharmaceutically acceptable salt”.

In one embodiment the following proviso (P1) is applying,

when W is a bond, then R, cannot be H, alkyl, alkenyl, alkynyl or cycloalkyl.

In another embodiment the following alternative proviso to above proviso P1 is applying:

when W is a bond, then R₁ cannot be hydrogen, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl or unsubstituted cycloalkyl.

In another embodiment the following alternative proviso to above proviso P1 is applying:

when W is a bond, then R₁ cannot be hydrogen, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl or substituted or unsubstituted cycloalkyl.

In another embodiment one or more of the following compounds being further excluded:

In a very preferred embodiment all of the above disclaimers (including all the compounds described above as excluded and either proviso P1 or on of its 2 alternatives) apply. This would then also apply to all below described embodiments (if still applicable).

In another embodiment of the compounds of the invention according to general Formula (I) as described above and herein, the following one or more—preferably all—of the following compounds are excluded:

In another embodiment of the compounds of the invention according to general Formula (I) as described above and herein, the following proviso applies:

if —[CH₂]_(n)—X—R₂ is

Y is

and Z is

then R₁ may not be pyridine or pyrazine substituted with —CN Or —SO₂CH3.

In the context of this invention, alkyl is understood as meaning saturated, linear or branched hydrocarbons, which may be unsubstituted or substituted once or several times. It encompasses e.g. —CH₃ and —CH₂—CH₃. In these radicals, C₁₋₂-alkyl represents C1- or C2-alkyl, C₁₋₃-alkyl represents C1, C2- or C3-alkyl, C₁ ₄-alkyl represents C1-, C2-, C3- or C4-alkyl, C₁ ₅-alkyl represents C1-, C2-, C3-, C4-, or C5-alkyl, C₁₋₆-alkyl represents C1-, C2-, C3-, C4-, C5- or C6-alkyl, C₁-alkyl represents C1-, C2-, C3-, C4-, C5-, C6- or C7-alkyl, C₁₋-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7- or C8-alkyl, C₁₋₁₀-alkyl represents C1-, C2-, C3-, C4-, C5-, C6, C7-, C8-, C9- or C10-alkyl and C₁₋₁₈-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, C10-, C11, C12-, C13-, C14-, C15-, C16-, C17- or C18-alkyl. The alkyl radicals are preferably methyl, ethyl, propyl, methylethyl butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1,1-dimethylpropyl 1,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, if substituted also CHF₂, CF₃ or CH₂OH etc. Preferably alkyl is understood in the context of this invention as C₁₋₈alkyl like methyl, ethyl propyl, butyl, pentyl, hexyl, heptyl, or octyl; preferably is C₁₋₆alkyl like methyl, ethyl, propyl, butyl, pentyl or hexyl; more preferably is C₁₋₄alkyl like methyl, ethyl, propyl or butyl.

Alkenyl is understood as meaning unsaturated, linear or branched hydrocarbons, which may be unsubstituted or substituted once or several times. It encompasses groups like e.g. —CH═CH—CH₃. The alkenyl radicals are preferably vinyl (ethenyl), allyl (2-propenyl). Preferably in the context of this invention alkenyl is C₁₀-alkenyl or C₂-alkenyl like ethylene, propylene, butylene, pentylene, hexylene, heptylene or octylene; or is C₂-alkenyl like ethylene, propylene, butylene, pentylene, or hexylene; or is C₂₄-alkenyl, like ethylene, propylene, or butylenes.

Alkynyl is understood as meaning unsaturated, linear or branched hydrocarbons, which may be unsubstituted or substituted once or several times. It encompasses groups like e.g. —C≡C—CH₃ (1-propinyl). Preferably alkynyl in the context of this invention is C₂₋₁₀-alkynyl or C₂₋₈-alkynyl like ethyne, propyne, butyene, pentyne, hexyne, hep:yne, or octyne; or is C₂₋₆-alkynyl like ethyne, propyne, butyene, pentyne, or hexyne; o″ is C₂₋₄-alkynyl like ethyne, propyne, butyene, pentyne, or hexyne.

in the context of this invention cycloalkyl is understood as meaning saturated and unsaturated (but not aromatic) cyclic hydrocarbons (without a heteroatom in the ring), which can be unsubstituted or once or several times substituted. Furthermore, C₃₋₄-cycloalkyl represents C3- or C4-cycloalkyl, C₃₋₅-cycloalkyl represents C3-, C4- or C5-cycloalkyl, C₃₋₆-cycloalkyl represents C3-, C4-, C5- or C6-cycloalkyl, C₃₋₇-cycloalkyl represents C3-, C4-, C5-, C6- or C7-cycloalkyl, C₃₋₈-cycloalkyl represents C3-, C4-, C5-, C6-, C7- or C8-cycloalkyl, C₄₋₅-cycloalkyl represents C4- or C5-cycloalkyl, C₄₋₆-cycloalkyl represents C4-, C5- or C6-cycloalkyl, C₄₋₅-cycloalkyl represents C4-, C5-, C6- or C7-cycloalkyl, C₅₋₆-cycloalkyl represents C5- or C6-cycloalkyl and C₅₋₇-cycloalkyl represents C5-, C6- or C7-cycloalkyl. Examples are cyclopropyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, and also adamantly. Preferably in the context of this invention cycloalkyl is C₃ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; or is C₃₋₇cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; or is C₃₋₆cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, especially cyclopentyl or cyclohexyl.

In connection with alkyl, alkenyl alkynyl and O-alkyl—unless defined otherwise—the term substituted in the context of this Invention is understood as meaning replacement of at least one hydrogen radical on a carbon atom by halogen (F, Cl, Br, I), NR₅R_(5′″), SR₅, —S(O)R₅, —S(O)₂R₅, OR₅, —C(O)OR₅, —CN, C(O)NR₅R_(5′), haloalkyl, haloalkoxy or —OC₁₋₄alkyl being unsubstituted or substituted by one or more of OR₅ or halogen (F, Cl, I, Br), being R₄, R_(4′), R₅, R_(5′), R_(5″) and R_(5′″) as defined above, and wherein when different radicals R₁ to R₈ are present simultaneously in Formulas I to I′″ they may be identical or different. More than one replacement on the same molecule and also on the same carbon atom is possible with the same or different substituents. This includes for example 3 hydrogens being replaced on the same C atom, as in the case of CF₃, or at different places of the same molecule, as in the case of e.g. —CH(OH)—CH═CH—CHCl₂, when different radicals R, to Re are present simultaneously in Formula I, I′, I″ or I′″ they may be identical or different.

Most preferably in connection with alky, alkenyl, alkynyl or O-alkyl, substituted is understood in the context of this invention that any alky, alkenyl, alkynyl or O-alkyl which is substituted is substituted by one or more of halogen (F, Cl, I, Br), —NR_(5′)R_(5′″), —SR₅, —OR₅, —C(O)OR₅, —CN, C(O)NR₅R₅ haloalkyl, haloalkoxy or —OC₁₋₄alkyl being unsubstituted or substituted by one or more of OR₅ or halogen (F, Cl, I, Br), being R₄, R_(4′), R₅, R_(5′), R_(5″) and R_(5′″) as defined above, and wherein when different radicals R₁ to R₉ are present simultaneously in Formulas I to I′″ they may be identical or different.

More than one replacement on the same molecule and also on the same carbon atom is possible with the same or different substituents. This includes for example 3 hydrogens being replaced on the same C atom, as in the case of CF₃, or at different places of the same molecule, as in the case of e.g. —CH(OH)—CH═CH—CHCl₂.

In the context of this invention haloalkyl is understood as meaning an alkyl being substituted once or several times by a halogen (selected from F, Cl, Br, I). It encompasses e.g. —CH₂Cl, —CH₂F, —CHCl₂, —CHF₂, —CCl₃, —CF₃ and —CH₂—CHCl₂. Preferably haloalkyl is understood in the context of this invention as halogen-substituted C₁₋₄-alkyl representing halogen substituted C1-, C2-, C3- or C4-alkyl. The halogen-substituted alkyl radicals are thus preferably methyl, ethyl, propyl, and butyl. Preferred examples include —CH₂Cl, —CH₂F, —CHCl₂, —CHF₂, and —CF₃.

In the context of this invention haloalkoxy is understood as meaning an —O-alkyl being substituted once or several times by a halogen (selected from F, Cl, Br, I). It encompasses e.g. —OCH₂Cl, —OC₂F, —OCHC₂, —OCHF₂, —OCCl₃, —OCF₃ and —OCH₂—CHC₂. Preferably haloalkyl is understood in the context of this invention as halogen-substituted —OC₁₋₄-alkyl representing halogen substituted C1-, C2-, C3- or C4-alkoxy. The halogen-substituted alkyl radicals are thus preferably O-methyl, O-ethyl, O-propyl, and O-butyl, Preferred examples include —OCH₂Cl, —OCH₂F, —OCHCl₂, —OCHF₂, and —OCF₃.

Aryl is understood as meaning ring systems with at least one aromatic ring but without heteroatoms even in only one of the rings. Examples are phenyl, naphthyl, fluoranthenyl, fluorenyl, tetralinyl or indanyl, in particular 9H-fluorenyl or anthracenyl radicals, which can be unsubstituted or once or several times substituted. Most preferably aryl is understood in the context of this invention as phenyl naphtyl or anthracenyl, preferably is phenyl.

In the context of this invention alkyl-aryl is understood as meaning an aryl group (see above) being connected to another atom through 1 to 4 (—CH₂—) groups. Most preferably alkyl-aryl is benzyl (i.e. —CH₂-phenyl).

In the context of this invention alkylheterocyclyl is understood as meaning an heterocyclyl group (see underneath) being connected to another atom through 1 to 4 (—CH₂—) groups, Most preferably alkylheterocyclyl is —CH₂-pyridine.

In the context of this invention alkylcycloalkyl is understood as meaning an cycloalkyl group (see above) being connected to another atom through 1 to 4 (—CH₂—) groups. Most preferably alkylcycloalkyl is —CH₂-cyclopropyl.

In a general definition a heterocyclyl radical or group is understood as meaning heterocyclic ring systems, with at least one saturated or unsaturated ring which contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring. A heterocyclic group can also be substituted once or several times. Examples include heteroaryls such as furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, benzothiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole and quinazoline. Preferably in the context of this invention heterocyclyl is defined as a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring. Preferably it is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring. Preferred examples include imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, especially is pyridine, pyrazine, indazole, benzodioxane, thiazole, benzothiazole, morpholine, tetrahydropyrane, pyrazole, imidazole, piperidine, pyrazole, thiophene, indole, benzimidazole, pyrrolo[2,3b]pyridine, benzoxazole, oxopyrrolidine, pyrimidine.

In a more specific definition, a heterocyclyl radical or group (also called heterocyclyl hereinafter) is understood as meaning heterocyclic ring systems, with at least one saturated or unsaturated ring which contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring. A heterocyclic group can also be substituted once or several times.

Examples include non-aromatic heterocyclyls such as tetrahydropyrane, oxazepane, morpholine, piperidine, pyrrolidine as well as heteroaryls such as furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, thiazole, benzothiazole, indole, benzotriazole, carbazole and quinazoline.

Subgroups inside the heterocyclyls as understood herein include heteroaryls and non-aromatic heterocyclyls.

-   -   the heteroaryl (being equivalent to heteroaromatic radicals or         aromatic heterocyclyls) is an aromatic heterocyclic ring system         of one or more rings of which at least one aromatic ring         contains one or more heteroatoms from the group consisting of         nitrogen, oxygen and/or sulfur in the ring; preferably is an         aromatic heterocyclic ring system of one or two rings of which         at least one aromatic ring contains one or more heteroatoms from         the group consisting of nitrogen, oxygen and/or sulfur in the         ring, more preferably is selected from furan, benzofuran,         thiophene, benzothiophene, pyrrole, pyridine, pyrimidine,         pyrazine, quinoline, isoquinoline, phthalazine, benzothiazole,         indole, benzotriazole, carbazole, quinazoline, thiazole,         imidazole, pyrazole, oxazole, thiophene and benzimidazole;     -   the non-aromatic heterocyclyl is a heterocyclic ring system of         one or more rings of which at least one ring—with this (or         these) ring(s) then not being aromatic—contains one or more         heteroatoms from the group consisting of nitrogen, oxygen and/or         sulfur in the ring; preferably is a heterocyclic ring system of         one or two rings of which one or both rings—with this one or two         rings then not being aromatic—contain/s one or more heteroatoms         from the group consisting of nitrogen, oxygen and/or sulfur in         the ring, more preferably is selected from oxazepam,         pyrrolidine, piperidine, piperazine, tetrahydropyran,         morpholine, indoline, oxopyrrolidine, benzodioxane, especially         is benzodioxane, morpholine, tetrahydropyran, piperidine,         oxopyrrolidine and pyrrolidine.

Preferably in the context of this invention heterocyclyl is defined as a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring. Preferably it is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring.

Preferred examples of heterocyclyls include oxazepan, pyrrolidine, imidazole, oxadiazole, letrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotnazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, especially is pyridine, pyrazine, indazole, benzodioxane, thiazole, benzothiazole, morpholine, tetrahydropyrane, pyrazole, imidazole, piperidine, thiophene, indole, benzimidazole, pyrrolo[2,3b]pyridine, benzoxazole, oxopyrrolidine, pyrimidine, oxazepane and pyrrolidine.

In the context of this invention oxopyrrolidine is understood as meaning pyrrolidin-2-one.

In connection with aromatic heterocyclyls (heteroaryls), non-aromatic heterocyclyls, aryls and cycloalkyls, when a ring system falls within two or more of the above cycle definitions simultaneously, then the ring system is defined first as an aromatic heterocyclyl (heteroaryl) if at least one aromatic ring contains a heteroatom. If no aromatic ring contains a heteroatom, then the ring system is defined as a non-aromatic heterocyclyl if at least one non-aromatic ring contains a heteroatom. If no non-aromatic ring contains a heteroatom, then the ring system is defined as an aryl if it contains at least one aryl cycle. If no aryl is present, then the ring system is defined as a cycloalkyl if at least one non-aromatic cyclic hydrocarbon is present.

Preferably, the aryl is a monocyclic aryl.

Preferably, the heteroaryl is a monocyclic heteroaryl.

Preferably, the non-aromatic heterocyclyl is a monocyclic non-aromatic heterocyclyl

Preferably, the cycloalkyl is a monocyclic cycloalkyl

In connection with aryl (including alkyl-aryl), cycloalkyl (including alkyl-cycloalkyl), or heterocyclyl (including alkyl-heterocyclyl), substituted is understood—unless defined otherwise—as meaning substitution of the ring-system of the aryl or alkyl-aryl, cycloalkyl or alkyl-cycloalkyl heterocyclyl or alkyl-heterocyclyl by halogen (F, Cl, Br, I), —R₅, —OR₅, —CN, —NO₂, —NR₅R_(5″), —C(O)OR₅, NR₅C(O)R₅, —C(O)NR₅R₅, —NR₅S(O)₂R₅, ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R₅, —NR₅S(O)₂NR₅R_(5′), haloalkyl, haloalkoxy, —SR5, —S(O)R₅ or —S(O)₂R₅; NR_(x)R_(y), with R_(x) and R_(y) independent y being either H or a saturated or unsaturated, linear or branched, substituted or unsubstituted C₁₋₆-alkyl; a saturated or unsaturated, linear or branched, substituted or unsubstituted C₁₋₆-alky; a saturated or unsaturated, linear or branched, substituted or unsubstituted —O—C₁₋₆-alkyl (alkoxy); a saturated or unsaturated, linear or branched, substituted or unsubstituted —S—C₁₋₆-alkyl; a saturated or unsaturated, linear or branched, substituted or unsubstituted —C(O)—C₁₋₆-alkyl-group; a saturated or unsaturated, linear or branched, substituted or unsubstituted —C(O)—O—C₁₋₆-alkyl-group; a substituted or unsubstituted aryl or alkyl-aryl; a substituted or unsubstituted cycloalkyl or alkyl-cycloalkyl; a substituted or unsubstituted heterocyclyl or alkyl-heterocyclyl, being R₄, R₄, R₅, R₅ and R₅ as defined above, and wherein when different radicals R₁ to R₉ are present simultaneously in Formulas I to I′″ they may be identical or different.

Most preferably in connection with aryl (including alkyl-aryl), cycloalkyl (including alkyl-cycloalkyl), or heterocyclyl (including alkyl-heterocyclyl), substituted is understood in the context of this invention that any aryl, cycloalkyl and heterocyclyl which is substituted (also in an alyklaryl, alkylcycloalkyl or alkylheterocyclyl) is substituted by one or more of halogen (F, Cl, Br, I), —R₅, —OR₅, —CN, —NO₂, —NR₅R₅—, —C(O)OR₅, NR₅C(O)R₅, —C(O)NR₅R₅, —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, —OC₁₋₄alkyl being unsubstituted or substituted by one or more of OR₅ or halogen (F, Cl, I Br), —CN, or —C₁₋₄alkyl being unsubstituted or substituted by one or more of OR₅ or halogen (F, Cl, I, Br), being R₄, R₄, R₅, R₅, R_(5″) and R_(5′″) as defined above, and wherein when different radicals R₁ to R₉ are present simultaneously in Formulas I to I′″ they may be Identical or different.

Most preferably in connection with aryl (including alkyl-aryl), cycloalkyl (including alkyl-cycloalkyl), or heterocyclyl (including alkyl-heterocyclyl), substituted is understood in the context of this invention that any aryl cycloalkyl and heterocyclyl which is substituted (also in alkyaryl, alkylcycloalkyl or alkylheterocyclyl) is substituted by one or more of halogen (F, Cl, Br I), —R₅, —OR₅, —CN, —NO₂, —NR₅R_(5′), NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R₅, —OCH₂CH₂OH, —NR₅C(O)NR₅R_(5′), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, —OC₁₋₄alkyl being unsubstituted or substituted by one or more of OR₅ or halogen (F, Cl, I, Br), —CN, or —C₁₋₄alkyl being unsubstituted or substituted by one or more of OR₅ or halogen (F, Cl, I, Br), being R₄, R_(4′), R₅, R_(5′), R_(5′) and R_(5′″) as defined above, and wherein when different radicals R₁ to R₉ are present simultaneously in Formulas I to I′″ they may be identical or different.

Additionally to the above-mentioned substitutions, in connection with cycloalkyl, or heterocycly namely non-aromatic heterocyclyl, substituted is also understood—unless defined otherwise—as meaning substitution of the ring-system of the cycloalkyl or; non-aromatic heterocyclyl with

or ═O.

The term “leaving group” means a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage. Leaving groups can be anions or neutral molecules. Common anionic leaving groups are halides such as Cl—, Br—, and I—, and sulfonate esters, such as tosylate (TsO—) or mesylate.

The term “salt” is to be understood as meaning any form of the active compound used according to the invention in which it assumes an ionic form or is charged and is coupled with a counter-on (a cation or anion) or is in solution. By this are also to be understood complexes of the active compound with other molecules and ions, in particular complexes via ionic interactions.

The term “physiologically acceptable salt” means in the context of this invention any salt that is physiologically tolerated (most of the time meaning not being toxic-especially not caused by the counter-ion) if used appropriately for a treatment especially if used on or applied to humans and/or mammals.

These physiologically acceptable salts can be formed with cations or bases and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention—usually a (deprotonated) acid—as an anion with at least one, preferably inorganic, cation which is physiologically tolerated—especially if used on humans and/or mammals. The salts of the alkali metals and alkaline earth metals are particularly preferred, and also those with NH₄, but in particular (mono)- or (di)sodium, (mono)- or (di)potassium, magnesium or calcium salts.

Physiologically acceptable salts can also be formed with anions or acids and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention as the cation with at least one anion which are physiologically tolerated—especially if used on humans and/or mammals. By this is understood in particular, in the context of this invention, the salt formed with a physiologically tolerated acid, that is to say salts of the particular active compound with Inorganic or organic acids which are physiologically tolerated—especially if used on humans and/or mammals. Examples of physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.

The compounds of the invention may be present in crystalline form or in the form of free compounds like a free base or acid.

Any compound that is a solvate of a compound according to the invention like a compound according to general formula I defined above is understood to be also covered by the scope of the invention. Methods of solvation are generally known within the art. Suitable solvates are pharmaceutically acceptable solvates. The term “solvate” according to this invention is to be understood as meaning any form of the active compound according to the invention in which this compound has attached to it via non-covalent binding another molecule (most likely a polar solvent). Especially preferred examples include hydrates and alcoholates, like methanolates or ethanolates.

Any compound that is a prodrug of a compound according to the invention like a compound according to general formula I defined above is understood to be also covered by the scope of the invention. The term “prodrug” is used in its broadest sense and encompasses those Derivatives that are converted in vivo to the compounds of the invention. Such Derivatives would readily occur to those skilled in the art, and include, depending on the functional groups present in the molecule and without limitation, the following Derivatives of the present compounds: esters, amino acid esters, phosphate esters, metal salts sulfonate esters, carbamates, and amides. Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found e.g. in Krogsgaard-Larsen et a, “Textbook of Drug design and Discovery” Taylor & Francis (April 2002).

Unless otherwise stated, the compounds of the invention are also meant to Include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by ¹³C- or ¹⁴C-enriched carbon or of a nitrogen by N-enriched nitrogen are within the scope of this invention.

The compounds of formula (I) as well as their salts or solvates of the compounds are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. Purity levels for the drug substance are preferably above 50%, more preferably above 70%, most preferably above 90%. In a preferred embodiment it is above 95% of the compound of formula (I), or of its salts. This applies also to its solvates or prodrugs.

In a further embodiment the compound according to the invention of general formula I, is a compound wherein

Y is or

Z is —CH₂—, —C(O)— or —CHR₉— m is 0 or 1 n is 1, 2 or 3 q is 1, 2, 3, 4, 5 or 6 R₁ is —(CH₂)₁—W—R₁ r is 0, 1 or 2 W is —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R₄)—, R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl, R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄; R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R_(5′″) or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R_(5′) and R_(5′) are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5′″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc; R₆, R_(6′), R₇ and R_(7′) are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In a very preferred embodiment of this embodiment r is 1 or 2 when W is a bond.

In another preferred embodiment of the compound according to the invention according to general formula I is a compound wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₅— m is 0 or 1 n is 1, 2 or 3 q is 1, 2, 3, 4, 5 or 6 R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, or substituted or unsubstituted alkylheterocyclyl X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—, R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl, R₃ and R_(3′) are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄; R₄ is H, —OR₉, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R₅, —NR₅COR₅, —NR₅R_(5′) or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C alkynyl; R₅, R₅ and R₅ are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5′) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc: R₀, R₆, R₇ and R₇ are Independently selected from H, halogen, —OR₄, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In one embodiment the one or more of the following compounds are excluded

In a preferred embodiment (EMBODIMENT DA) of the compound according to the invention the compound is a compound according to Formula I

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉—; m is 0 or 1; n is 1, 2 or 3 q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)_(r)—W—R_(1′); r is 0, 1 or 2; W is —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; wherein the aryl, heterocyclyl or cycloalkyl in R₁ or R₁ if substituted (also in alkylaryl or alkylheterocyclyl) are substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5″), —C(O)OR₅, NR₅C(O)R₅, —C(O)NR₅R_(5′), —NR₅S(O)₂R₅, ═O, —OCH₂CH₂OH, —NR₅C(O)NR₅R₅, —S(O)₂NR₅R₅, —NR₅S(O)₂NR₅R_(5′), haloalkyl, haloalkoxy, —SR5, —S(O)R₅ and —S(O)₂R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R₄)—, R₂ is substituted or unsubstituted aryl, substituted or unsubstituted monocyclic heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl, heterocyclyl or cycloalkyl in R₂ if substituted also in alkylaryl or alkyheterocyclyl is substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′), —C(O)OR₅, —NR₅C(O)R₅, —C(O)NR₅R₅, —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R₅, —NR₅S(O)₂NR_(5′)R₅, haloalkyl, -haloalkoxy, —SR₅, —S(O)R₅ and —S(O)₂R₅ R₃ and R_(3′) are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylcycloalkyl and substituted or unsubstituted alkylheterocyclyl, wherein the aryl, cycloalkyl and heterocyclyl as defined in R₃ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)R₅ R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR₅, —NR5R5′″ or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, wherein the aryl, cycloalkyl and heterocyclyl as defined in R₄ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R₅ and R₅ are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R₅ is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc; R₆, R₆, R₇ and R₇ are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; and wherein the alkyl, alkenyl and alkynyl as defined in R₁, R₁, R₂, R₃, R₃, R₄, R₄, R₆, R_(6′), R₇, R_(7′), R₈, R₈ and R₉ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅, —S(O)₂R₅, C(O)OR₅ or C(O)N₅R_(5′); optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In this EMBODIMENT DA the following proviso might apply:

“when W is a bond, then R_(1′) cannot be H, alkyl, alkenyl, alkynyl or cycloalkyl”.

In this EMBODIMENT DA the following proviso might apply:

“the following compound being excluded from the general formula I:

In another preferred embodiment (EMBODIMENT DB) of the compound according to the invention the compound is a compound according to Formula I

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉—; m is 0 or 1: n is 1, 2 or 3: q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl —(CH₂)—W—R_(1′), or —(CH₂)₁—R₁; r is 0, 1 or 2; W is —CH₂O—, —CH₂C(O)NR_(5′)—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; R_(1″) is —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl; wherein the aryl, heterocyclyl or cycloalkyl in R₁, R₁ or R₁ if substituted (also in alkylaryl or alkylheterocycyl) are substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, haloalkoxy, —SR5, —S(O)R₅ or —S(O)₂R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl heterocyclyl or cycloalkyl in R₂ if substituted (also in alkylaryl or alkylheterocyclyl) is substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5″), —C(O)OR₅, —NR₅C(O)R₅, —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, -haloalkoxy, —R₅, —S(O)R₅ or —S(O)₂R₅ R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, and substituted or unsubstituted alkylcycloalkyl, wherein the aryl cycloalkyl and heterocyclyl as defined in R if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅, R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR₅, —NR5R5′″ or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, wherein the aryl, cycloalkyl and heterocyclyl as defined in R₁ it substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R_(5′) and R₁ are independently selected from H, unsubstituted C₂₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc; R₆, R₆, R₇ and R₁ are independently selected from H, halogen, —OR₄, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R₆ are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; and wherein the alkyl, alkenyl and alkynyl as defined in R₁, R₁, R₂, R₂, R₃, R₃, R₄, R₄, R₆, R_(6′), R₇, R_(7′), R₉, R₈ and R₉ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅, —S(O)₂R₅, C(O)OR₅ or C(O)NR₅R₅; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In this embodiment DB the following proviso might apply:

“the following compounds being excluded from the general formula I:

In another preferred embodiment (EMBODIMENT DC) of the compound according to the invention the compound is a compound according to Formula I

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉—; m is 0 or 1: n is 1, 2 or 3; q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, —(CH₂)_(r)—W—R₁, or —(CH₂)_(r)—R_(1″); r is 0, 1 or 2; W is a —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; R_(1′) is —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl; wherein the aryl, heterocyclyl or cycloalkyl in R₁, R₁ or R_(1″) if substituted (also in alkylaryl or alkylheterocyclyl) are substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₁, —NR₅R_(5′), —C(O)OR₅, NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R₅, ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)NR₅R_(5′), —NR₅S(O)₂NR₅R_(5′), haloalkyl, haloalkoxy, —SR5, —S(O)R₅ or —S(O)₂R₅; X is a bond, —C(O)O—, —C(O)NR₅, —C(O)—, —O— or —C(R₄R_(4′))—, R₂ is substituted or unsubstituted aryl, substituted or unsubstituted monocyclic heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl, heterocyclyl or cycloalkyl in R₂ if substituted (also in alkylaryl or alkylheterocyclyl) is substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R₅, —C(O)OR₅, —NR₅C(O)R₅, —C(O)NR₅R₅, —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR₅R_(5″), —S(O)?NR₅R₅, —NR₅S(O)₂NR₅R₅, haloalkyl, -haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅ R₃ and R_(3′) are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl and substituted or unsubstituted alkylycloalkyl; wherein the aryl, cycloalkyl and heterocyclyl as defined in R₃ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅ R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R₅, —NR₅COR₅, —NR5R5′″ or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, wherein the aryl, cycloalkyl and heterocyclyl as defined in R₄ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)R₅; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R₅ and R₅ are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R₅ is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc; R₆, R₆, R₇ and R₇ are Independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; and wherein the alkyl, alkenyl and alkynyl as defined in R₁, R₁, R₂, R₃, R_(3′), R₄, R₄, R₆, R_(6′), R₇, R_(7′), R₈, R₈ and R₉ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅, —S(O)₂R₅, C(O)OR₅ or C(O)NR₅R_(5′); optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In this EMBODIMENT DC the following proviso might apply:

the following compound being excluded from the general formula I

In another preferred embodiment of the compound according to the invention of general formula I is a compound wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉— m is 0 or 1 n is 1, 2 or 3 q is 1, 2, 3, 4, 5 or 6 R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyaryl, substituted or unsubstituted alkylheterocyclyl or —(CH2)_(r)—W—R_(1′); r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or C(CH₅)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl (−), substituted or unsubstituted cycloalkyl or R₅; with the proviso that when W is a bond, then R₁ cannot be H, alkyl, alkenyl, alkynyl or cycloalkyl; X is a bond; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocycyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₃ and R_(3′) are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄, R₄ is H, —OR₁, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R_(5′″) or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; R₅, R₅ and R₅ are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkyaryl; R₅ is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc R₆, R₆, R₇ and R₇ are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In one embodiment the following compounds are excluded:

In another preferred embodiment of the compound according to the invention of general formula I is a compound

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉—, m is 0 or 1 n is 1, 2 or 3, q is 1, 2, 3, 4, 5 or 6 R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R_(1′); r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl (−), substituted or unsubstituted cycloalkyl or R₅; with the proviso that when W is a bond, then R₁ cannot be H, alkyl alkenyl, alkynyl or cycloalkyl; X is —C(R₄R₄)—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₁₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄; R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR₅, —NR₅R_(5″) or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; R₄ is H, substituted or unsubstituted C₁₋₆ alkyl substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R₅ and R_(5′) are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl, R_(5′″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc R₆, R₆, R₇ and R₇ are Independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R₈ are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In one embodiment the following compounds are excluded:

In another embodiment of the compound according to the invention of general formula I is a compound

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₅—; m is 0 or 1; n is 1, 2 or 3; q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R_(1′); r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; with the proviso that when W is a bond, then R₁ cannot be H, alkyl, alkenyl, alkynyl or cycloalkyl;

X is —C(O)O—, —C(O)NR₅—, —C(O)— or —O—;

R₁ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄; R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR₅, —NR₅R_(5′″) or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R₅ and R_(5′) are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5′) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc R₆, R₆, R₇ and R₇ are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R₈ are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general formula I is a compound

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉—; m is 0 or 1; n is 1, 2 or 3; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocycly, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R₁; r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl (−), substituted or unsubstituted cycloalkyl or R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄; R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R_(5′″) or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; R_(4′) is H substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R₅ and R₅ are Independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5′″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C alkynyl or -Boc R₆, R₆, R₇ and R₇ are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl: R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In one embodiment the following compounds are excluded

In another preferred embodiment of the compound according to the invention of general formula I is a compound

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉—; m is 0 or 1 n is 1, 2 or 3; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)_(r)—W—R_(1′); r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—, R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R₅ or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R₅ and R_(5′) are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5′) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc R₆, R_(6′), R₇ and R_(7′) are Independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C a alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general formula I is a compound

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉—; m is 0 or 1, n is 1, 2 or 3; q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R_(1′), r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl (−), substituted or unsubstituted cycloalkyl or R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR₅, —NR₅R_(5″) or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R_(5′) and R_(5″) are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5′) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc R₇ and R_(7′) are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₆ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₄ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment the compound according to the invention according to general formula I is a compound of formula I′

wherein

Y is

q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R_(1′); r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl (−), substituted or unsubstituted cycloalkyl or R₅; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₁. R₅, R₅ and R₅ are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl. R_(5″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc R₆, R₆, R₇ and R₇ are Independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R₈ are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In one embodiment of the above embodiment of formula I′ the following compounds are excluded

In another preferred embodiment the compound according to the invention of general formula I is a compound of formula I″

wherein

Y is

q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R_(1′); r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl (−), substituted or unsubstituted cycloalkyl or R₅; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₃ and R_(3′) are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄; R₅, R₅ and R_(5′) are independently selected from H, unsubstituted C₁₋₅ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc R₆, R₆, R₇ and R₇ are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R₈ are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment the compound according to the invention of general formula I is a compound of formula I′″

wherein

Y is

q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R₁; r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl (−), substituted or unsubstituted cycloalkyl or R₅; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄; R₅, R₅ and R₅ are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₁₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc R₆, R₆, R₇ and R₇ are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R₈ are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

Y is

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

Y is

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

Y is

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

Y is

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocycly substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R₁; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R₄)—; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄: optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, and substituted or unsubstituted alkylcycloalkyl, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I the compound is a compound, wherein

R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R_(5′″) or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the Invention according to general formulas I, the compound is a compound, wherein

R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R_(5′″) or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I the compound is a compound, wherein

R₄ is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R₅, R₅ and R₅ are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl: optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R_(5′) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R₆, R₆, R₇ and R₇ are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R₈ and R₈ are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl: optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R₉ is H, substituted or unsubstituted C₁₋₆ alkyl substituted or unsubstituted Cu alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I the compound is a compound, wherein

Z is —CH₂—, —C(O)— or —CHR₉—; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

m is 0 or 1; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I the compound is a compound, wherein

n is 1, 2 or 3; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

q is 1, 2, 3, 4, 5 or 6; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

r is 0, 1 or 2; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R₁; wherein the aryl is selected from phenyl, naphtyl, or anthracene; preferably is napthyl and phenyl; more preferably is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, more preferably the heterocycle is pyridine, pyrazine, Indazole, benzodioxane, thiazole, benzothiazole, morpholine, tetrahydropyrane, pyrazole, imidazole, and/or the alkyl is C₁₋₆ alkyl like methyl, ethyl propyl, butyl, pentyl, hexyl more preferably the alkyl is methyl, and/or R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; wherein wherein the aryl is selected from phenyl, naphtyl, or anthracene; preferably is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from Imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, more preferably the heterocycle is morpholine or tetrahydropyrane, and/or the cycloalkyl is C₁ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C₃₋₇ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C₁ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl: and/or R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl is selected from phenyl, naphtyl, or anthracene; preferably is napthyl and phenyl; more preferably is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from Imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazote, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrazole, benzodioxolane, benzodioxane, carbazole and quinazoline, more preferably the heterocycle is pyridine, piperidine, thiazole, morpholine, tetrahydropyrane, pyrazole, thiophene, indole, benzimidazole, pyrrolo[2,3b]pyridine, benzoxazole, oxopyrrolidine, pyrimidine; and/or the C₁₋₆ alky is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C₁₋₆ alkyl is methyl, isopropyl; and/or the C₂₋₆-alkenyl is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆ alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or the cycloalkyl is C₃ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C₃₋₇ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C₃₋₆ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably the cycloalkyl is cyclopropyl; and/or R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄; wherein the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl hexyl isopropyl, or 2-methylpropyl, the C₁₋₆ alkyl is preferably methyl, ethyl isopropyl; and/or the C₂₋₆ alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆ alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or the cycloalkyl is C₃ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, preferably is C₃₋₇ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C₃₋₆ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or R₄ (for Formula I) is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R₅, —NR₅COR₅, —NR₅R₅ or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; wherein the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl isopropyl, or 2-methylpropyl, preferably the C₁₋₆ alkyl is methyl, and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or the cycloalkyl is C₃₋₈ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C₃₋₇ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C₃₋₆ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphtyl, or anthracene; preferably is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, preferably is tetrahydropyrane; and/or R_(4′) (for Formula I) is H or substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein wherein the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably the C₁₋₆ alkyl is methyl, and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or R₅, R₅ and R₅ are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; wherein the alkyl is C₁₋₆ alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, more preferably the alkyl is methyl or ethyl; and/or the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butylpentyl, hexyl isopropyl, or 2-methylpropyl, more preferably the C₁₋₆ alkyl is methyl, ethyl, or isopropyl; and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or the aryl is selected from phenyl, naphtyl, or anthracene; preferably is napthyl and phenyl; preferably phenyl and/or R_(5′) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc, wherein the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C₁₋₆ alkyl is methyl; and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or R₁, R₆, R₇ and R_(7′) are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; wherein the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl isopropyl, or 2-methylpropyl, more preferably the C₁₋₆ alkyl is methyl or ethyl, and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or the cycloalkyl is C₃₋₈ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C₃₋₇ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C₃₋₆ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphtyl, or anthracene; preferably is napthyl and phenyl; and/or the heterocycly is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, more preferably the heterocycle is tetrahydropyrane, and/or R₈ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl, wherein the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or R₉ is H or substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl); wherein wherein the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably the C₁₋₆ alkyl is methyl, and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or Z (for Formula I) is —CH₂—, —C(O)— or —CHR₉—; and/or m is 0 or 1, preferably m is 1; and/or n is 1, 2 or 3, preferably n is 2; and/or q is 1, 2, 3, 4, 5 or 6, preferably q is 1; and/or r is 0, 1 or 2; and/or W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; and/or X (for Formula I) is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; preferably X is a bond o —C(R₄R₄)—; and/or

Y is

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

in R₁ as defined in any of the above embodiments, the aryl is selected from phenyl, naphtyl, or anthracene; preferably is napthyl and phenyl; more preferably is phenyl; and/or the heterocycly is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, more preferably the heterocycle is pyridine, pyrazine, indazole, benzodioxane, thiazole, benzothiazole, morpholine, tetrahydropyrane, pyrazole, imidazole, and/or the alkyl is C₁₋₆ alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, more preferably the alkyl is methyl, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the Invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

in R₁ as defined in any of the above embodiments, the aryl is selected from phenyl, naphtyl, or anthracene; preferably is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from Imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, more preferably the heterocycle is morpholine or tetrahydropyrane, and/or the cycloalkyl is C₃ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C₃₋₇ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C₃₋₆cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

in R as defined in any of the above embodiments, the aryl is selected from phenyl, naphtyl or anthracene; preferably is napthyl and phenyl; more preferably is phenyl; and/or the heterocycly is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, more preferably the heterocycle is pyridine, piperidine, thiazole, morpholine, tetrahydropyrane, pyrazole, thiophene, indole, benzimidazole, pyrrolo[2,3b]pyridine, benzoxazole, oxopyrrolidine, pyrimidine; and/or the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C₁₋₆ alkyl is methyl, isopropyl; and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or the cycloalkyl is C₃ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C₃₋₇ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C₃₋₆ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably the cycloalkyl is cyclopropyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general formulas I, I′, I″ or I″ the compound is a compound, wherein

in R₃ or R₃ as defined in any of the above embodiments, the alkyl is C₁₋₆ alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl the alkyl is preferably methyl or ethyl; and/or the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butylpentyl, hexyl, isopropyl, or 2-methylpropyl, the C₁₋₆ alkyl is preferably methyl, ethyl, isopropyl; the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or the cycloalkyl is C₃ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C₃₋₇ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C₃₋₆ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphtyl, or anthracene; preferably is napthyl and phenyl; more preferably is phenyl; and/or the heterocycly is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazote, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general formulas I the compound is a compound, wherein

in R₄ as defined in any of the above embodiments, the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably the C₁₋₆ alkyl is methyl, and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or the cycloalkyl is C₃₋₈ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C₃₋₇ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C₃₋₆ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphtyl, or anthracene; preferably is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, preferably is tetrahydropyrane; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general formulas I the compound is a compound, wherein

in R₄ as defined in any of the above embodiments, the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl isopropyl, or 2-methylpropyl preferably the C₁₋₆ alkyl is methyl, and/or the C₂₋₆-alkenyl is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

in R₅ R₅ or R₅ as defined in any of the above embodiments, the alkyl is C₁₋₆ alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, more preferably the alkyl is methyl or ethyl; and/or the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl isopropyl, or 2-methylpropyl, more preferably the C₁₋₆ alkyl is methyl, ethyl, or isopropyl; and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or the aryl is selected from phenyl, naphtyl, or anthracene; preferably is napthyl and phenyl; preferably phenyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

in R_(5′) as defined in any of the above embodiments. the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C₁₋₆ alkyl is methyl. and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene: and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

in R₆, R₆, R₇ or R_(7′) as defined in any of the above embodiments. the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl or 2-methylpropyl, more preferably the C₁₋₆ alkyl is methyl or ethyl. and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene: and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; and/or the cycloalkyl is C₁ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C₃₋₇ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C₃₋₈ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphtyl or anthracene; preferably is napthyl and phenyl; and/or the heterocycly is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, more preferably the heterocycle is tetrahydropyrane. optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

in R₈ or R₈ as defined in any of the above embodiments, the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butylpentyl, hexyl, isopropyl, or 2-methylpropyl, and/or the C₂₋₆-alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general formulas I, I′, I″ or I′″ the compound is a compound, wherein

in R₉ as defined in any of the above embodiments. the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl preferably the C₁₋₆ alkyl is methyl, and/or the C₂₋₆-alkenyl is preferably selected from ethylene, propylene, butylene, pentylene or hexylene; and/or the C₂₋₆-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a preferred embodiment

R₁ is a substituted or unsubstituted group selected from phenyl, benzyl, pyridine, methylpyridine, pyrazine, indazole, benzodioxane, thiazole, methythiazole, benzothiazole, morpholine-2-oxoethyl, tetrahydro-2H-pyrane-2yl-oxyethyl, methyltetrahydropyrane, pyrazole, methylpyrazole, imidazole, methylimidazole, hydroxyethyl, methyl-3-propanoate, hydroxypropyl, N-methyl-3-propanamide, 3-methoxypropyl, 3-propanenitrile and N,N-dimethyl-3-propanamide.

In another preferred embodiment

R₁ is substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, substituted or unsubstituted pyridine or substituted or unsubstituted methylpyridine.

In a most preferred embodiment

R₁ is substituted or unsubstituted phenyl, substituted or unsubstituted benzyl or substituted or unsubstituted pyridine.

In a preferred embodiment

R₁ is preferably H, —CN, substituted or unsubstituted heterocyclyl, or R⁵.

In another preferred embodiment

R_(1′) is H, —CN, substituted or unsubstituted morpholine, substituted or unsubstituted tetrahydropyrane, or unsubstituted methyl.

In a preferred embodiment

R₇ is substituted or unsubstituted phenyl, substituted or unsubstituted pyridine, substituted or unsubstituted thiazole, substituted or unsubstituted methyl, substituted or unsubstituted isopropyl, substituted or unsubstituted O-isopropyl, substituted or unsubstituted morpholine, substituted or unsubstituted piperidine;

In a preferred embodiment

R₂ is substituted or unsubstituted phenyl, substituted or unsubstituted pyridine, substituted or unsubstituted thiazole, unsubstituted methyl, unsubstituted isopropyl, unsubstituted O-isopropyl, substituted or unsubstituted morpholine, substituted or unsubstituted piperidine;

In another preferred embodiment

R₂ is substituted or unsubstituted phenyl or substituted or unsubstituted pyridine.

In a preferred embodiment

R₁ is preferably H, substituted or unsubstituted methyl substituted or unsubstituted ethyl, substituted or unsubstituted isopropyl, substituted or unsubstituted methoxymethyl, methylacetate, ethanol, —CH₂COOH, N,N-dimethylacetamide, benzyloxymethyl, —CH₂OH, substituted or unsubstituted methyltetrahydropyrane, 4-methoxypropyl or hydroxypropyl.

In a preferred embodiment

R₃ is preferably H, unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl, unsubstituted methoxymethyl, methylacetate, ethanol, —CH₂COOH, N,N-dimethylacetamide, benzyloxymethyl, —CH₂OH, substituted or unsubstituted methyltetrahydropyrane, 4-methoxypropyl or hydroxypropyl.

In another preferred embodiment

R₃ is preferably H or substituted or unsubstituted methyl preferably unsubstituted methyl.

In particular preferred embodiment

R₃ is H or methyl, while R_(3′) is H or substituted or unsubstituted methyl, preferably unsubstituted methyl.

In another particular preferred embodiment

R₃ is substituted or unsubstituted methyl while R₃ is hydrogen, preferably R is unsubstituted methyl while R₃ is hydrogen.

In a most preferred embodiment

R₃ and R_(3′) are both hydrogen.

In a preferred embodiment

R₄ is hydroxyl, substituted or unsubstituted methyl, substituted or unsubstituted tetrahydropyrane. R₄ is preferably hydroxyl or unsubstituted methyl.

In another preferred embodiment

R_(4′) is hydrogen or substituted or unsubstituted methyl, preferably hydrogen or unsubstituted methyl.

In particular preferred embodiment

R_(4′) is hydrogen;

In another particular preferred embodiment

R₄ is hydroxyl, while R₄ is hydrogen;

In a most preferred embodiment

R₄ and R₄ are both hydrogen.

In a preferred embodiment

R₁ is H, unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl or unsubstituted phenyl.

In another preferred embodiment

R_(5′) is H or unsubstituted methyl.

In a preferred embodiment

R₆, R_(6′), R₇ and R_(7′) are independently selected from H, substituted or unsubstituted C₁ ₆ alkyl or unsubstituted heterocyclyl.

In another preferred embodiment

R₆ is H, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, or unsubstituted tetrahydropyrane, while R_(6′) is hydrogen or substituted or unsubstituted methyl. In particularly preferred embodiment R₆ and R₆ are both hydrogen

In another particularly preferred embodiment

R₆ and R₆ are both substituted or unsubstituted methyl

In still another particularly preferred embodiment

R₆ is substituted or unsubstituted ethyl and R_(6′) is hydrogen.

In a preferred embodiment

R₇ and R_(7′) are both hydrogen.

In a preferred embodiment

R₈ and R₈ are preferably both hydrogen.

In another preferred embodiment

R₉ is substituted or unsubstituted methyl.

In a preferred embodiment

Y is

In another preferred embodiment

m is 1.

In an particular embodiment

n is 2.

In a preferred embodiment

q is 1.

In another preferred embodiment

X is a bond.

In an particular embodiment

x is —C(R₄R_(4′))—.

In an particular embodiment

the halogen is fluorine, chlorine, iodine or bromine,

In an particular embodiment

the halogen is fluorine or chlorine.

In an particular embodiment

Z is —CH₂—.

In an particular embodiment

Z is —CHR₉—.

In an particular embodiment

Z is —CH(CH₃)—.

In an particular embodiment

Z is —C(O)—.

In a preferred further embodiment, the compounds of the general formula I are selected from

EX Chemical name  1 4-(4-methoxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  2 9-benzyl-4-(2-methoxyphenyl)-l-oxa-4,9-diazaspiro[5.5]undecan-3-one  3 9-benzyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  4 4-(2-methoxyphenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  5 9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  6 9-benzyl-4-(3-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  7 2-benzyl-9-phenyl-6-oxa-2.9-diazaspira[4.5]decan-8-one  8 4-(3-methoxyphenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  9 2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  10a (R)-2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  10b (S)-2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  11 2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  12a (S)-2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  12b (R)-2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  13 2-ethyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  14 methyl 2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2- yl)acetate  15 4-(3-methoxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  16 9-benzyl-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  17 2-isopropyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspira[5.5]undecan-3-one  18 2,2-dimethyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  19 2-(benzyloxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  20 2-methyl-4-(1-methyl-1H-pyrazol-3-yl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  21 2-methylene-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  22 4-(2-fluorophenyl)-2-methylene-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  23 2-methyl-9-(2-(5-nitropyridin-2-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  24 4-(2-fluorophenyl)-2-methyl-9-(2-(5-nitropyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  25 4-(2-fluorophenyl)-2-methyl-9-(2-(3-nitropyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  26 2-methyl-4-phenyl-9-(2-(pyrinidin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  27 2-methyl-9-(2-(2-nitropyridin-3-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  28 2-methyl-4-phenyl-9-(2-(4-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  29 9-(2-(6-aminopyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  30 9-(2-(4-aminopyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  31 4-(2-fluorophenyl)-2-methyl-9-(2-(6-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa- 4,9-diazaspiro[5.51undecan-3-one  32 9-(2-(2-aminopyridin-4-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  33 2-methyl-4-phenyl-9-(2-(3-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  34 2-methyl-4-phenyl-9-(2-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  35 9-(2-(4-methoxypyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  36 6-(2-(2-methyl-3-oxa-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)nicotinonitrile  37 9-(2-(3-chloropyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  38 9-(2-(5-chloropyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  39 4-(2-fluorophenyl)-2-isopropyl-9-(2-(2-nitropyridin-3-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  40 2-methyl-4-phenyl-9-(2-(2-(trifluoromethyl)pyridin-4-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  41 2-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)isonicotinonitrile  42 9-(2-(6-aminopyridin-2-yl)ethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  43 2-methyl-9-(2-(2-nitropyridin-3-yl)ethyl)-4-(4-(trifluoromethyl)pyridin-3-yl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  44 9-(2-(3-chloropyridin-2-yl)ethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  45 9-(2-(3-chloropyridin-2-yl)ethyl)-2-methyl-4-((5-(trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  46 9-(2-(3-chloropyridin-2-yl)ethyl)-4-((5-fluoropyridin-2-yl)methyl)-2-methyl-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  47 9-(2-(3-fluoropyridin-2-yl)ethyl)-4-((5-fluoropyridin-2-yl)methyl)-2-methyl-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  48 9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-4-(2-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  49 4-((5-fluoropyridin-2-yl)methyl)-2-methyl-9-(2-(6-(trifluoromethyl)pyridin-2- yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  50 9-(2-(3-chloropyridin-4-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  51 9-(2-fluorophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  52 9-(4-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  53 2-methyl-4-phenyl-9-(2-(thiophen-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  54 9-(3-fluorophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  55 9-(4-fluorophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  56 9-(2-(1H-pyrazol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  57 9-(2-methoxyphenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  58 2-methyl-4-phenyl-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  59 2-methyl-4-phenyl-9-((tetrahydro-2H-pyran-4-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  60 2-methyl-4-phenyl-9-(3-phenylpropyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  61 2-methyl-9-(2-(4-methylthiazol-5-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  62 9-(2-(1H-indol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  63 9-(2-(1H-benzo[d]imidazol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  64 methyl 3-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)propanoate  65 2-methyl-9-(2-morpholinoethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  66 2-methyl-9-(4-nitrophenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  67 2-methyl-9-(3-nitrophenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5-5]undecan-3- one  68 2-methyl-9-(2-nitrophenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  69 9-(2-(1H-pyrrolo[2,3-b]pyridin-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  70 methyl 4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzoate  71 2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)-N- phenylacetamide  72 2-methyl-9-(2-phenoxyethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  73 2-methyl-4-phenyl-9-(2-(pyridin-3-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  74 3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzo[d]oxazol-2(3H)-one  75 3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzonitrile  76 4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzonitrile  77 9-(2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  78 2-methyl-9-(2-morpholino-2-oxoethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  79 9-(2-methoxyphenethyl)-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  80 (Z)-(2-fluorophenyl)-9-phenethyl-2-((tetrahydro-2H-pyran-4-yl)methylene)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  81 4-(2-fluorophenyl)-9-isopentyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  82 9-(cyclopropylmethyl)-4-(2-fluorophenyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  83 4-(2-fluorophenyl)-9-(3-methoxyphenethyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  84 9-(2-(pyridin-2-yl)ethyl)-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  85 4-(2-fluorophenyl)-9-phenethyl-2-(propan-2-ylidene)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  86 9-phenethyl-4-(pyridin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  87 4-benzyl-9-(2-methoxyphenethyl)-1-oxa-4,9-diazaspiro[5.5]undecane  88 2-methyl-9-phenethyl-4-(thiazol-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  89 4-(2-fluorophenyl)-9-(2-(6-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  90 12-phenyl-8-[2-(pyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 13-one  91 4-(2-fluorophenyl)-2-methyl-9-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one  92 8-(3-nitrophenethyl)-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3)tridecan-13- one  93 N-methyl-3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzenesulfonamide  94 9-(2-(5-fluoropyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  95 2-methyl-4-phenyl-9-(2-(thiazol-2-yl)ethyl)-1-oxa-4,9-diazaspiro|5.5]undecan- 3-one  96 9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  97 8-(2-oxo-2-phenylethyl)-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 13-one  98 9-(2-(pyridin-2-yl)ethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  99 9-(2-oxo-2-phenylethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 100 N-methyl-3-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]unclecan-9-yl)- N-phenylpropanamide 101 2-methyl-9-(2-(pyridin-2-yl)ethyl)-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 102 9-(2-(6-methoxypyridin-2-yl)ethyl)-2-rnethyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 103 9-(3-nitrophenethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 104 4-((6-aminopyridin-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 105 4-((5-chloropyridin-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 106 tert-butyl (4-(2-(3-oxo-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)thiazol-2-yl)carbamate 107 N-methyl-4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzenesulfonamide 108 4-(2-(2-methyl-3-oxa-4-phenyl-1-oxo-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzenesulfonamide 109 12-(4-methoxybenzyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1 5.3]tridecan- 13-one hydrochloride 110 2-methyl-9-(2-(3-nitro-1H-pyrazol-1-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 111 9-(2-(6-methoxypyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 112 2-methyl-4-phenyl-9-(2-(5-(trifluoromethyl)pyridin-3-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 113 9-(2-(6-chloropyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 114 9-(2-(5-fluoropyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 115 9-(2-(5-chloropyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 116 tert-butyl (1-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)-1H-pyrazol-5-yl)carbamate 117 tert-butyl (4-(2-(4-(2-fluorophenyl)-2-isopropyl-3-oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)thiazol-2-yl)carbamate 118 tert-butyl (4-(2-(13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8- yl)ethyl)thiazol-2-yl)carbamate 119 8-(3-nitrophenethyl)-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 120 tert-butyl (4-(2-(13-oxo-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-8-yl)ethyl)thiazol-2-yl)carbamate 121 tert-butyl (4-(2-(2-methyl-3-oxo-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)thiazol-2-yl)carbamate 122 9-(2-isopropoxyethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 123 6-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)picolinonitrile 124 2-methyl-9-(2-morpholino-2-oxoethyl)-4-((5-(trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 125 9-(2-isopropoxyethyl)-2-methyl-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one 126 9-(2-fluorophenethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 127a (S)-9-(2-fluorophenethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one hydrochloride 127b (R)-9-(2-fluorophenethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one hydrochloride 128 2-methyl-9-(2-oxo-2-(piperidin-1-yl)ethyl)-4-((5-(trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 129 2-methyl-9-(2-oxo-2-(piperidin-1-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 130 9-(2-fluorophenethyl)-2-methyl-4-(2-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 131 2-methyl-4-phenyl-9-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 132 9-(3-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 133 2-methyl-4-phenyl-9-(2-(pyridin-4-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 134 4-(2-fluorophenyl)-2-(methoxymethyl)-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 135 4-(2-fluorophenyl)-2-(methoxymethyl)-9-(2-methoxyphenethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 136 9-(2-fluorophenethyl)-4-(2-fluorophenyl)-2-(methoxymethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 137 4-(2-fluorophenyl)-2-isopropyl-9-(2-methoxyphenethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 138 4-benzyl-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecane 139 4-(2-fluorophenyl)-2-(propan-2-ylidene)-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 140 tert-butyl (4-(2-(4-(2-fluorophenyl)-2-methyl-3-oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)thiazol-2-yl)carbamate 141 4-(2-fluorophenyl)-9-(2-(4-methylthiazol-5-yl)ethyl)-2-(propan-2-ylidene)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one 142 (Z)-4-(2-fluorophenyl)-2-(3-methoxypropylidene)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 143 ethyl 3-(2-(4-(2-fluorophenyl)-2-methyl-3-oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)benzoate 144 3-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)-N- phenylpropanamide 145 2-methyl-4-phenyl-9-(2-(pyridin-3-yloxy)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 146 2-methyl-9-(2-(2-oxopyrrolidin-1-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 147 9-(2-(1H-pyrazol-4-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 148 8-(2-fluorophenethyl)-12-(4-methoxybenzyl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 149 2-phenethyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one 150 9-(2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 151a (R)-9-((R)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 151b (R)-9-((S)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 151c (S)-9-((S)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 151d (S)-9-((R)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 152 4-benzyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 153 4-benzyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 154 4-(2-fluorobenzyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 155 4-(3-fluorobenzyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 156 2-methyl-4,9-diphenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 157 2-methyl-9-phenethyl-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 158 4-(4-fluorobenzyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 159 2-methyl-9-phenethyl-4-(pyridin-3-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 160 2-methyl-9-phenethyl-4-(thiazol-2-yl methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 161 2-methyl-9-phenethyl-4-(thiazol-5-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 162 2-methyl-9-phenethyl-4-(pyridin-4-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 163 2-methyl-9-phenethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 164 2-methyl-9-phenethyl-4-(thiazol-4-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 165 9-phenethyl-4-(pyridin-4-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 166 4-(3-methoxybenzyl)-9-phenethyl-1-oxa-4,9-diazaspira[5.5]undecan-3-one 167 9-phenethyl-4-(thiazol-4-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 168 4-((1-benzyl-1H-imidazol-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 169 9-phenethyl-4-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 170 2-methyl-4-(2-morpholino-2-oxoethyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 171 2-methyl-((1-methyl-1H-pyrazol-3-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 172 2-methyl-4-((1-methyl-1H-imidazol-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 173 4-((3-fluoropyridin-2-yl)methyl)-2-methyl-9-phenethyl -1-oxa-4,9- diazaspiro[5.5]undecan-3-one 174 2-methyl-9-phenethyl-4-((6-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 175 2-methyl-9-phenethyl-4-(2-(pyridin-3-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 176 4-((5-fluoropyridin-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 177 9-phenethyl-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 178 9-phenethyl-4-(2-(pyridin-4-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 179 4-(3-nitrobenzyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 180 12-(3-methoxypropyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 13-one 181 3-[13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-12- yl]propanenitrile 182 N,N-dimethyl-3-[13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 12-yl]propanamide 183 4-(2-hydroxy-2-methylpropyl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 184 12-(2-methoxyethyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13- one 185 12-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-8-phenethyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 186 methyl 3-(13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-12- yl)propanoate 187 8-phenethyl-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 188 9-benzyl-4-(4-fluorophenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 189 4-(2-fluorophenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5lundecan-3-one 190 4-(4-fluorophenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 191 4-(3-fluorophenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 192 4-(2-fluorophenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 193 4-(2-chlorophenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 194 2-methyl-9-phenethyl-4-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 195 2-methyl-9-phenethyl-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 196 2-methyl-9-phenethyl-4-(pyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 197 ethyl 3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4- yl)benzoate 198 3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4- yl)benzonitrile 199 2-methyl-4-(3-nitrophenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 200 2-methyl-4-(1-methyl-1H-indazol-3-yl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 201 2-methyl-4-(1-methyl-1H-indazol-6-yl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 202 4-(benzo[d][1,3]dioxol-5-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 203 4-(benzo[d]thiazol-6-yl)-2-methyl-9-phenethyl-oxa-4,9- diazaspiro[5.5]undecan-3-one 204 4-(benzo[d)thiazol-2-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 205 2-methyl-9-phenethyl-4-(pyridin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 206 4-(2-methoxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 207 2-methyl-9-phenethyl-4-(6-(trifluoromethyl)pyridin-2-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 208 4-(3-fluoropyridin-2-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 209 2-methyl-9-phenethyl-4-(thiazol-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 210 2-methyl-4-(1-methyl-1H-pyrazol-4-yl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 211 4-(6-methoxypyridin-2-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 212 2-methyl-9-phenethyl-4-(6-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 213 4-(2-fluoropyridin-3-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 214 2-methyl-9-phenethyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 215 2-methyl-9-phenethyl-4-(2-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 216 4-(5-fluoropyridin-3-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 217 2-methyl-9-phenethyl-4-(5-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 218 2-methyl-9-phenethyl-4-(3-(trifluoromethyl)pyridin-2-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 219 8-(2-fluorophenethyl)-12-(2-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 220 8-(2-fluorophenethyl)-12-(3-(trifluoromethyl)pyridin-2-yl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one hydrochloride 221 9-(2-fluorophenethyl)-2-methyl-4-(3-(trifluoromethyl)pyridin-2-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 222a (R)-9-(2-fluorophenethyl)-2-methyl-4-(3-(trifluoromethyl)pyridin-2-yl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one hydrochloride 222b (S)-9-(2-fluorophenethyl)-2-methyl-4-(3-(trifluoromethyl)pyridin-2-yl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one hydrochloride 223 8-(2-fluorophenethyl)-12-(4-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one hydrochloride 224 12-(2-Fluorophenyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13- one 225 8-phenethyl-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one 226 9-(3-aminophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 227 4-(3-aminophenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 228 9-(4-aminophenetnyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 229 9-(2-aminophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 230 9-(2-(5-aminopyridin-2-yl)ethyl)-4-(2-fluorophenyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 231 8-(3-aminophenethyl)-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13- one 232 9-(2-(3-aminopyridin-2-yl)ethyl)-4-(2-fluorophenyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 233 4-(3-aminobenzyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 234 9-(2-(2-aminopyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 235 9-(3-aminophenethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 236 9-(2-(5-aminopyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 237 9-(2-(3-amino-1H-pyrazol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 238 9-(2-(2-aminopyridin-3-yl)ethyl)-4-(2-fluorophenyl)-2-isopropyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 239 8-(3-aminophenethyl)-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 240 9-(2-(2-aminopyridin-3-yl)ethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one 241 N-(4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 242 N-(3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4- yl)phenyl)acetamide 243 N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 244a (S)-N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 244b (R)-N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)pheny)acetamide 245 N-(2-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 246 N-[3-(2-(13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8- yl)ethyl)phenyl]acetamide 247 N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)isobutyramide 248 1,1-dimethyl-3-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)urea 249 N-(3-((3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4- yl)methyl)phenyl)acetamide 250 N-(2-(2-(4-(2-fluorophenyl)-2-methyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan- 9-yl)ethyl)pyridin-3-yl)acetamide 251 N-(3-(2-(3-oxo-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide 252 N-(6-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro(5.5]undecan-9- yl)ethyl)pyridin-3-yl)acetamide 253 N-(2-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-4-yl)acetamide 254 N-(6-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-2-yl)acetamide 255 N-(4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-2-yl)acetamide 256 N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)methanesulfonamide 257 N-(2-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)methanesulfonamide 258 N-(4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)methanesulfonamlde 259 N-(3-((3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4- yl)methyl)phenyl)methanesulfonamide 260 N-[3-(2-(13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8- yl)ethyl)phenyl]methanesulfonamide 261 N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)propane-2-sulfonamide 262 1-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)urea 263 {3-{2-(13-oxo-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8.12- diazadispiro[2.1.5.3]tridecan-8-yl)ethyl]phenyl}urea 264 1-(6-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-2-yl)urea 265 N-[3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl]aminosulfonamide 266 3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethy)benzamide 267 4-(2-(2-methyl-3-oxo-4-phenyl-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl}benzoic acid 268 3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)benzoic acid 269 3-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)prapanoic acid 270 2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)acetic acid 271 N,N-dimethyl-3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-4-yl)benzamide 272 N,N-dimethyl-2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9- diazaspiro{5.5]undecan-2-yl)acetamide 273 N,N-dimethyl-4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)benzamide 274 N-methyl-4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzamide 275 N-methyl-3-[13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-12-yl]propanamid 276 3-(2-(4-(2-fluorophenyl)-2-methyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecar-9- yl)ethyl)-N-methylbenzamide 277 8-(2-hydroxy-2-phenylethyl)-12-phenyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 278 9-(2-hydroxy-2-phenylethyl)-4-((5-trifluoromethyl)pyridin-2-yl)methyl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one 279 12-(3-hydroxypropyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 13-one 280 9-(2-(6-aminopyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 281 4-(2-fluorophenyl)-9-(2-(2-hydroxyethoxy)phenethyl)-2-isopropyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 282 4-(2-fluorophenyl)-9-(3-(2-hydroxyethoxy)phenethyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 283 2-(hydroxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 284 4-((1H-imidazol-2-yl)methyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 285 9-benzyl-4-(2-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 286 4-(2-hydroxyphenyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 287 9-benzyl-4-(3-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 288 4-(3-hydroxyphenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 289 9-(2-hydroxyphenethyt)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 290 9-(4-hydroxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 291 9-(3-hydroxyphenethyl)-4-phenyt-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 292 4-(2-(4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol 293 4-(4-hydroxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 294 4-(3-hydroxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 295 9-(2-hydroxyphenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 296 4-(2-hydroxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 297 4-(2-fluorophenyl)-9-(2-hydroxyphenethyl)-2-isopropy|-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 298 4-(2-fluorophenyl)-9-(3-hydroxyphenethyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 299 2-(2-(4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol 300 9-(2-hydroxyphenethyl)-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 301 4-(2-fluorophenyl)-2-(hydroxymethyl)-9-(2-hydroxyphenethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 302 4-(2-fluorophenyl)-2-(3-hydroxypropyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 303 9-(2-(2-aminothiazol-4-yl)ethyl)-4-(2-fluorophenyl)-2-methy|-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 304 9-(2-(2-aminothiazol-4-yl)ethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one 305 9-(2-(5-amino-1H-pyrazol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 306 9-(2-(2-aminothiazol-4-yl)ethyl)-4-(2-fluorophenyl)-2-isopropyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 307 8-[2-(2-aminothiazol-4-yl)ethyl]-12-phenyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 308 8-[2-(2-aminothiazol-4-yl)ethyl]-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4- oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one 309 9-(2-(2-aminothiazol-4-yl)ethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one 310 12-(2-hydroxyethyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13- one 311 4-(2-fluorophenyl)-9-phenethyl-2-((tetrahydro-2H-pyran-4-yl)methyl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one 312 4-(2-fluorophenyl)-2-isopropyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 313 4-(2-fluorophenyl)-2-isopropyl-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 314 4-(2-fluorophenyl)-2-(3-methoxypropyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 315 N-methyl-2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)- N-phenylacetamide 316 3-(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)phenol 317 9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 318 3-(9-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)phenol 319 2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 320 9-(3-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 321 2-(2-(4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol 322 3-(2-(4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol 323 2-(9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)ethanol 324 4-benzyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane 325 9-phenethy-4-(thiazol-4-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecane 326 9-(2-methoxyphenethyl)-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecane 327 2-methyl-4-((1-methyl-1 H-imidazol-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecane 328 2-methyl-4-((1-methyl-1H-pyrazol-3-yl)methyl)-9-phenethy-1-oxa-4,9- diazaspiro[5.5[undecane 329 2-(2-(4-pyridrin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenol 330 2-methyl-9-phenethyl-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecane 331 2-methyl-9-phenethyl-4-(2-(pyridin-3-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecane 332 9-(4-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 333 4-(3-methoxyphenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane 334 9-(2-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 335 4-benzyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane 336 9-phenethyl-4-(pyridin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecane 337 4,9-diphenethyl-1-oxa-4,9-diazaspiro[5.5]undecane 338 3-(2-(4-benzyl-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)aniline 339 N-(3-(2-(4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 340 3-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a further preferred further embodiment, the compounds of the general formula I are selected from

EX Chemical name  1 4-(4-methoxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  2 9-benzyl-4-(2-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  3 9-benzyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  4 4-(2-methoxyphenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  5 9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  6 9-benzyl-4-(3-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  7 2-benzyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one  8 4-(3-methoxyphenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5] undecan-3-one  9 2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  10a (R)-2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  10b (S)-2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  11 2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  12a (S)-2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  12b (R)-2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  13 2-ethyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  14 methyl 2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2- yl)acetate  15 4-(3-methoxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  16 9-benzyl-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  17 2-isopropyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  18 2,2-dimethyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  19 2-(benzyloxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  20 2-methyl-4-(1-methyl-1H-pyrazol-3-yl)-9-phenethyl-oxa-4,9- diazaspiro[5.5]undecan-3-one  21 2-methylene-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  22 4-(2-fluorophenyl)-2-methylene-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  23 2-methyl-9-(2-(5-nitropyridin-2-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  24 4-(2-fluorophenyl)-2-methyl-9-(2-(5-nitropyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  25 4-(2-fluorophenyl)-2-methyl-9-(2-(3-nitropyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  26 2-methyl-4-phenyl-9-(2-(pyrimidin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  27 2-methyl-9-(2-(2-nitropyridin-3-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  28 2-methyl-4-phenyl-9-(2-(4-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  29 9-(2-(6-aminopyridin-2-yl)ethyl)-2-nnethyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  30 9-(2-(4-aminopyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  31 4-(2-fluorophenyl)-2-methyl-9-(2-(6-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one  32 9-(2-(2-aminopyridin-4-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  33 2-methyl-4-phenyl-9-(2-(3-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  34 2-methyl-4-phenyl-9-(2-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  35 9-(2-(4-methoxypyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  36 6-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)nicotinonitrile  37 9-(2-(3-chloropyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  38 9-(2-(5-chloropyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  39 4-(2-fluorophenyl)-2-isopropyl-9-(2-(2-nitropyridin-3-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  40 2-methyl-4-phenyl-9-(2-(2-(trifluoromethyl)pyridin-4-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  41 2-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)isonicotinonitrile  42 9-(2-(6-aminopyridin-2-yl)ethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  43 2-methyl-9-(2-(2-nitropyridin-3-yl)ethyl)-4-(4-(trifluoromethyl)pyridln-3-yl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  44 9-(2-(3-chlonopyridin-2-yl)ethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  45 9-(2-(3-chloropyridin-2-yl)ethyl)-2-methyl-4-((5-(trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  46 9-(2-(3-chloropyridin-2-yl)ethyl)-4-((5-fluoropyridin-2-yl)methyl)-2-methyl-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  47 9-(2-(3-fluoropyridin-2-yl)ethyl)-4-((5-fluoropyridin-2-yl)methyl)-2-methyl-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  48 9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-4-(2-(trifluoromethyl)pyridin-3-yl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  49 4-((5-fluoropyridin-2-yl)methyl)-2-methyl-9-(2-(6-(trifluoromethyl)pyridin-2- yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  50 9-(2-(3-chloropyridin-4-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  51 9-(2-fluorophenethyl)-2-methyl-4-phenyl-oxa-4,9-diazaspiro[5.5]undecan-3- one  52 9-(4-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  53 2-methyl-4-phenyl-9-(2-(thiophen-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  54 9-(3-fluorophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  55 9-(4-fluorophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  56 9-(2-(1H-pyrazol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  57 9-(2-methoxyphenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  58 2-methyl-4-phenyl-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  59 2-methyl-4-phenyl-9-((tetrahydro-2H-pyran-4-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  60 2-methyl-4-phenyl-9-(3-phenylpropyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  61 2-methyl-9-(2-(4-methylthiazol-5-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  62 9-(2-(1H-indol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  63 9-(2-(1H-benzo[d]imidazol-1-yl)ethyl)-2-methyl-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  64 methyl 3-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)propanoate  65 2-methyl-9-(2-morpholinoethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  66 2-methyl-9-(4-nitrophenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  67 2-methyl-9-(3-nitrophenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  68 2-methyl-9-(2-nitrophenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  69 9-(2-(1H-pyrrolo[2,3-b]pyridin-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  70 methyl 4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzoate  71 2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)-N- phenylacetamide  72 2-methyl-9-(2-phenoxyethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  73 2-methyl-4-phenyl-9-(2-(pyridin-3-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  74 3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzo[d]oxazol-2(3H)-one  75 3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzonitrile  76 4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzonitrile  77 9-(2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  78 2-methyl-9-(2-morpholino-2-oxoethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  79 9-(2-methoxyphenethyl)-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  80 (Z)-4-(2-fluorophenyl)-9-phenethyl-2-((tetrahydro-2H-pyran-4-yl)methylene)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one  81 4-(2-fluorophenyl)-9-isopentyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one  82 9-(cyclopropylmethyl)-4-(2-fluorophenyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  83 4-(2-fluorophenyl)-9-(3-methoxyphenethyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  84 9-(2-(pyridin-2-yl)ethyl)-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  85 4-(2-fluorophenyl)-9-phenethyl-2-(propan-2-ylidene)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  86 9-phenethyl-4-(pyridin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  87 4-benzyl-9-(2-methoxyphenethyl)-1-oxa-4,9-diazaspiro[5.5]undecane  88 2-methyl-9-phenethyl-4-(thiazol-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one  89 4-(2-fluorophenyl)9-(2-(6-fluoropyridin-2-yl)ethyl)-2-methyl-oxa-4,9- diazaspiro[5.5]undecan-3-one  90 12-phenyl-8-[2-(pyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 13-one  91 4-(2-fluorophenyl)-2-methyl-9-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one  92 8-(3-nitrophenethyl)-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13- one  93 N-methyl-3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzenesulfonamide  94 9-(2-(5-fluoropyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  95 2-methyl-4-phenyl-9-(2-(thiazol-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one  96 9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  97 8-(2-oxo-2-phenylethyl)-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 13-one  98 9-(2-(pyridin-2-yl)ethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one  99 9-(2-oxo-2-phenylethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 100 N-methyl-3-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)- N-phenylpropanamide 101 2-methyl-9-(2-(pyridin-2-yl)ethyl)-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 102 9-(2-(6-methoxypyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 103 9-(3-nitrophenethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 104 4-((6-aminopyridin-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 105 4-((5-chloropyridin-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 106 tert-butyl (4-(2-(3-oxo-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)thiazol-2-yl)carbamate 107 N-methyl-4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzenesulfonamide 108 4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzenesulfonamide 109 12-(4-methoxybenzyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 13-one hydrochloride 110 2-methyl-9-(2-(3-nitro-1H-pyrazol-1-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 111 9-(2-(6-methoxypyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 112 2-methyl-4-phenyl-9-(2-(5-(trifluoromethyl)pyridin-3-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 113 9-(2-(6-chloropyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 114 9-(2-(5-fluoropyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 115 9-(2-(5-chloropyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 116 tert-butyl (1-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)-1H-pyrazol-5-yl)carbamate 117 tert-butyl (4-(2-(4-(2-fluorophenyl)-2-isopropyl-3-oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)thiazol-2-yl)carbamate 118 tert-butyl (4-(2-(13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8- yl)ethyl)thiazol-2-yl)carbamate 119 8-(3-nitrophenethyl)-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 120 tert-butyl (4-(2-(13-oxo-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12- diazadispiro[2.1 5.3]tridecan-8-yl)ethyl)thiazol-2-yl)carbamate 121 tert-butyl (4-(2-(2-methyl-3-oxo-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)thiazol-2-yl)carbamate 122 9-(2-isopropoxyethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 123 6-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)picolinonitrile 124 2-methyl-9-(2-morpholino-2-oxoethyl)-4-((5-(trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 125 9-(2-isopropoxyethyl)-2-methyl-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one 126 9-(2-fluorophenethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 127a (S)-9-(2-fluorophenethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one hydrochloride 127b (R)-9-(2-fluorophenethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl]-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one hydrochloride 128 2-methyl-9-(2-oxo-2-(piperidin-1-yl)ethyl)-4-((5-(trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 129 2-methyl-9-(2-oxo-2-(piperidin-1-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 130 9-(2-fluorophenethyl)-2-methyl-4-(2-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 131 2-methyl-4-phenyl-9-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 132 9-(3-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 133 2-methyl-4-phenyl-9-(2-(pyridin-4-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 134 4-(2-fluorophenyl)-2-(methoxymethyl)-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 135 4-(2-fluorophenyl)-2-(methoxymethyl)-9-(2-methoxyphenethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 136 9-(2-fluorophenethyl)-4-(2-fluorophenyl)-2-(methoxymethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 137 4-(2-fluorophenyl)-2-isopropyl-9-(2-methoxyphenethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 138 4-benzyl-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecane 139 4-(2-fluorophenyl)-2-(propan-2-ylidene)-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 140 tert-butyl (4-(2-(4-(2-fluorophenyl)-2-methyl-3-oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)thiazol-2-yl)carbamate 141 4-(2-fluorophenyl)-9-(2-(4-methylthiazol-5-yl)ethyl)-2-(propan-2-ylidene)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one 142 (Z)-4-(2-fluorophenyl)-2-(3-methoxypropylidene)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 143 ethyl 3-(2-(4-(2-fluorophenyl)-2-methyl-3-oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)benzoate 144 3-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)-N- phenylpropanamide 145 2-methyl-4-phenyl-9-(2-(pyridin-3-yloxy)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 146 2-methyl-9-(2-(2-oxopyrrolidin-1-yl)ethyl)-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 147 9-(2-(1H-pyrazol-4-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 148 8-(2-fluorophenethyl)-12-(4-methoxybenzyl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 149 2-phenethyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one 150 9-(2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 151a ((R)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 151b (R)-9-((S)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 151c (S)-9-((S)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 151d (S)-9-((R)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 152 4-benzyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 153 4-benzyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 154 4-(2-fluorobenzyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 155 4-(3-fluorobenzyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 156 2-methyl-4,9-diphenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 157 2-methyl-9-phenethyl-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 158 4-(4-fluorobenzyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 159 2-methyl-9-phenethyl-4-(pyridin-3-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 160 2-methyl-9-phenethyl-4-(thiazol-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 161 2-methyl-9-phenethyl-4-(thiazol-5-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 162 2-methyl-9-phenethyl-4-(pyridin-4-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 163 2-methyl-9-phenethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 164 2-methyl-9-phenethyl-4-(thiazol-4-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 165 9-phenethyl-4-(pyridin-4-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 166 4-(3-methoxybenzyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 167 9-phenethyl-4-(thiazol-4-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 168 4-((1-benzyl-1H-imidazol-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 169 9-phenethyl-4-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 170 2-methyl-4-(2-morpholino-2-oxoethyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 171 2-methyl-4-((1-methyl-1H-pyrazol-3-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 172 2-methyl-4-((1-methyl-1H-imidazol-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 173 4-((3-fluoropyridin-2-yl)methyl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 174 2-methyl-9-phenethyl-4-((6-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 175 2-methyl-9-phenethyl-4-(2-(pyridin-3-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 176 4-((5-fluoropyridin-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 177 9-phenethyl-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 178 9-phenethyl-4-(2-(pyridin-4-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 179 4-(3-nitrobenzyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 180 12-(3-methoxypropyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 13-one 181 3-[13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-12- yl]propanenitrile 182 N,N-dimethyl-3-[13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 12-yl]propanamide 183 4-(2-hydroxy-2-methylpropyl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 184 12-(2-methoxyethyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13- one 185 12-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-8-phenethyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 186 methyl 3-(13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-12- yl)propanoate 187 8-phenethyl-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 188 9-benzyl-4-(4-fluorophenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 189 4-(2-fluorophenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 190 4-(4-fluorophenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 191 4-(3-fluorophenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 192 4-(2-fluorophenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 193 4-(2-chlorophenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 194 2-methyl-9-phenethyl-4-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 195 2-methyl-9-phenethyl-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 196 2-methyl-9-phenethyl-4-(pyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 197 ethyl 3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4- yl)benzoate 198 3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4- yl)benzonitrile 199 2-methyl-4-(3-nitrophenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 200 2-methyl-4-(1-methyl-1H-indazol-3-yl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 201 2-methyl-4-(1-methyl-1H-indazol-6-yl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 202 4-(benzo[d][1,3]dioxol-5-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 203 4-(benzo[d]thiazol-6-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 204 4-(benzo[d]thiazol-2-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 205 2-methyl-9-phenethyl-4-(pyridin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 206 4-(2-methoxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 207 2-methyl-9-phenethyl-4-(6-(trifluoromethyl)pyridin-2-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 208 4-(3-fluoropyridin-2-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 209 2-methyl-9-phenethyl-4-(thiazol-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 210 2-methyl-4-(1-methyl-1H-pyrazol-4-yl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 211 4-(6-methoxypyridin-2-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 212 2-methyl-9-phenethyl-4-(6-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 213 4-(2-fluoropyridin-3-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 214 2-methyl-9-phenethyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 215 2-methyl-9-phenethyl-4-(2-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 216 4-(5-fluoropyridin-3-yl)-2-methyl-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 217 2-methyl-9-phenethyl-4-(5-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 218 2-methyl-9-phenethyl-4-(3-(trifluoromethyl)pyridin-2-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 219 8-(2-fluorophenethyl)-12-(2-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 220 8-(2-fluorophenethyl)-12-(3-(trifluoromethyl)pyridin-2-yl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one hydrochloride 221 9-(2-fluorophenethyl)-2-methyl-4-(3-(trifluoromethyl)pyridin-2-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 222a (R)-9-(2-fluorophenethyl)-2-methyl-4-(3-(trifluoromethyl)pyridin-2-yl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one hydrochloride 222b (S)-9-(2-fluorophenethyl)-2-methyl-4-(3-(trifluoromethyl)pyridin-2-yl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one hydrochloride 223 8-(2-fluorophenethyl)-12-(4-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one hydrochloride 224 12-(2-Fluorophenyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13- one 225 8-phenethyl-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one 226 9-(3-aminophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 227 4-(3-aminophenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 228 9-(4-aminophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 229 9-(2-aminophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 230 9-(2-(5-aminopyridin-2-yl)ethyl)-4-(2-fluorophenyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 231 8-(3-aminophenethyl)-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13- one 232 9-(2-(3-aminopyridin-2-yl)ethyl)-4-(2-fluorophenyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 233 4-(3-aminobenzyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 234 9-(2-(2-aminopyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 235 9-(3-aminophenethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 236 9-(2-(5-aminopyridin-2-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 237 9-(2-(3-amino-1H-pyrazol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 238 9-(2-(2-aminopyridin-3-yl)ethyl)-4-(2-fluorophenyl)-2-isopropyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 239 8-(3-aminophenethyl)-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 240 9-(2-(2-aminopyridin-3-yl)ethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one 241 N-(4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 242 N-(3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4- yl)phenyl)acetamide 243 N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 244a (S)-N-(3-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 244b (R)-N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazapiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 245 N-(2-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 246 N-[3-(2-{13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3] tridecan-8- yl}ethyl)phenyl]acetamide 247 N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)isobutyramide 248 1,1-dimethyl-3-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)urea 249 N-(3-((3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4- yl)methyl)phenyl)acetamide 250 N-(2-(2-(4-(2-fluorophenyl)-2-methyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan- 9-yl)ethyl)pyridin-3-yl)acetamide 251 N-(3-(2-(3-oxo-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide 252 N-(6-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-3-yl)acetamide 253 N-(2-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-4-yl)acetamide 254 N-(6-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-2-yl)acetamide 255 N-(4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-2-yl)acetamide 256 N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)methanesulfonamide 257 N-(2-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)methanesulfonamide 258 N-(4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)methanesulfonamide 259 N-(3-((3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4- yl)methyl)phenyl)methanesulfonamide 260 N-[3-(2-{13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8- yl}ethyl)phenyl)methanesulfonamide 261 N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)propane-2-sulfonamide 262 1-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)urea 263 {3-[2-(13-oxo-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-8-yl)ethyl]phenyl)urea 264 1-(6-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-2-yl)urea 265 N-[3-(2-{2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl}ethyl)phenyl]aminosulfonamide 266 3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzamide 267 4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzoic acid 268 3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)benzoic acid 269 3-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)propanoic acid 270 2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)acetic acid 271 N,N-dimethyl-3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-4-yl)benzamide 272 N,N-dimethyl-2-(3-oxo-9-phenethyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-2-yl)acetamide 273 N,N-dimethyl-4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)ethyl)benzamide 274 N-methyl-4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)benzamide 275 N-methyl-3-[13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1 5.3]tridecan-12- yl)propanamide 276 3-(2-(4-(2-fluorophenyl)-2-methyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)-N-methylbenzamide 277 8-(2-hydroxy-2-phenylethyl)-12-phenyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 278 9-(2-hydroxy-2-phenylethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one 279 12-(3-hydroxypropyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan- 13-one 280 9-(2-(6-aminopyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 281 4-(2-fluorophenyl)-9-(2-(2-hydroxyethoxy)phenethyl)-2-isopropyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 282 4-(2-fluorophenyl)-9-(3-(2-hydroxyethoxy)phenethyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 283 2-(hydroxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3- one 284 4-((1H-imidazol-2-yl)methyl)-9-phenethyl-oxa-4,9-diazaspiro[5.5]undecan-3- one 285 9-benzyl-4-(2-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 286 4-(2-hydroxyphenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 287 9-benzyl-4-(3-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 288 4-(3-hydroxyphenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 289 9-(2-hydroxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 290 9-(4-hydroxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 291 9-(3-hydroxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 292 4-(2-(4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol 293 4-(4-hydroxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 294 4-(3-hydroxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 295 9-(2-hydroxyphenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 296 4-(2-hydroxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 297 4-(2-fluorophenyl)-9-(2-hydroxyphenethyl)-2-isopropyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 298 4-(2-fluorophenyl)-9-(3-hydroxyphenethyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 299 2-(2-(4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol 300 9-(2-hydroxyphenethyl)-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 301 4-(2-fluorophenyl)-2-(hydroxymethyl)-9-(2-hydroxyphenethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 302 4-(2-fluorophenyl)-2-(3-hydroxypropyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 303 9-(2-(2-aminothiazol-4-yl)ethyl)-4-(2-fluorophenyl)-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 304 9-(2-(2-aminothiazol-4-yl)ethyl)-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one 305 9-(2-(5-amino-1H-pyrazol-1-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 306 9-(2-(2-aminothiazol-4-yl)ethyl)-4-(2-fluorophenyl)-2-isopropyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 307 8-[2-(2-aminothiazol-4-yl)ethyl]-12-phenyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 308 8-[2-(2-aminothiazol-4-yl)ethyl]-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4- oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one 309 9-(2-(2-aminothiazol-4-yl)ethyl)-2-methyl-4-(4-(trifluoromethyl)pyridin-3-yl)-1- oxa-4,9-diazaspiro[5.5]undecan-3-one 310 12-(2-hydroxyethyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13- one 311 4-(2-fluorophenyl)-9-phenethyl-2-((tetrahydro-2H-pyran-4-yl)methyl)-1-oxa- 4,9-diazaspiro[5.5]undecan-3-one 312 4-(2-fluorophenyl)-2-isopropyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan- 3-one 313 4-(2-fluorophenyl)-2-isopropyl-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 314 4-(2-fluorophenyl)-2-(3-methoxypropyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3-one 315 N-methyl-2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)- N-phenylacetamide 316 3-(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-y|)phenol 317 9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 318 3-(9-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)phenol 319 2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 320 9-(3-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 321 2-(2-(4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol 322 3-(2-(4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol 323 2-(9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)ethanol 324 4-benzyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane 325 9-phenethyl-4-(thiazol-4-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecane 326 9-(2-methoxyphenethyl)-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecane 327 2-methyl-4-((1-methyl-1H-imidazol-2-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecane 328 2-methyl-4-((1-methyl-1H-pyrazol-3-yl)methyl)-9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecane 329 2-(2-(4-(pyridin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenol 330 2-methyl-9-phenethyl-4-(pyridin-2-ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecane 331 2-methyl-9-phenethyl-4-(2-(pyridin-3-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecane 332 9-(4-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 333 4-(3-methoxyphenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane 334 9-(2-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 335 4-benzyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane 336 9-phenethyl-4-(pyridrin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecane 337 4,9-diphenethyl-1-oxa-4,9-diazaspiro[5.5]undecane 338 3-(2-(4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)aniline 339 N-(3-(2-(4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 340 3-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane 341 8-(2,5-difluorophenethyl)-12-(2-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 342 8-(2,5-difluorophenethyl)-12-(4-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan-13-one 343 8-(2,5-difluorophenethyl)-12-(3-(trifluoromethyl)pyridin-2-yl)-4-oxa-8,12- diazadispiro[2.1 5.3]tridecan-13-one 344 12-benzyl-8-(2-(3-fluoropyridin-2-yl)ethyl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecane 345 8-(2-(3-fluoropyridin-2-yl)ethyl)-12-(3-methylpyridin-2-yl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecane 346 methyl 3-(12-benzyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8- yl)propanoate 347 methyl 3-(12-benzyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)propanoate 348 methyl 3-(13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8- yl)propanoate 349 (R)-2-benzyl-9-phenyl-6-oxa-2.9-diazaspiro[4.5]decan-8-one 350 (S)-2-benzyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another very preferred embodiment of the compound according to the invention according to general formula I′ the compound is selected from examples 1, 4, 5, 8 to 15, 17 to 70, 73 to 77, 79 to 81, 83 to 86, 88 to 96, 98, 101 to 121, 123, 126 to 127b, 130 to 137, 139 to 143, 146 to 149, 152 to 187, 189 to 268, 270 to 276, 279 to 284, 286, 288 to 298 and 300 to 314, and 315;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another very preferred embodiment of the compound according to the invention according to general formula I′ the compound is selected from examples 1, 4, 5, 8 to 15, 17 to 70, 73 to 77, 79 to 81, 83 to 86, 88 to 96, 98, 101 to 121, 123, 126 to 127b, 130 to 137, 139 to 143, 146 to 149, 152 to 187, 189 to 268, 270 to 276, 279 to 284, 286, 288 to 298, 300 to 315, 341 to 343, 346 and 348;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another preferred embodiment of the compound according to the invention according to general formula I″ the compound is selected from examples 87, 138, 299, 316, 317, and 319 to 339;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another preferred embodiment of the compound according to the invention according to general formula I″ the compound is selected from examples 87, 138, 299, 316, 317, 319 to 339, 344, 345 and 347;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another preferred embodiment of the compound according to the invention according to general formula I′″ the compound is the compound of example 340, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a preferred embodiment of the compound according to the invention according to general formula I, I′, I″ or I′″ wherein

R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R₁, wherein the aryl, heterocyclyl or cycloalkyl in R₁ or R₁ if substituted (also in alkylaryl or alkylheterocyclyl) are substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′), —C(O)OR₅, NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR₅R₅, —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another embodiment of the invention the compound of general formulas I, I′, I″ and I′″

R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; wherein the aryl, heterocyclyl or cycloalkyl in R_(1′) if substituted are substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, NR₅C(O)R₅, —C(O)NR₅R_(5′), —NR₅S(O)₂R₅, ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another embodiment of the invention the compound of general formulas I, I′, I″ and I′″,

R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl, heterocyclyl or cycloalkyl in R2 if substituted is substituted with substituents selected from —R₅, —OR₅ halogen, —CN, —NO₂, —NR₅R_(5′), —C(O)OR₅, —NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R₅, ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O) NR₂R_(5′)R_(5″), haloalkyl, -haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another embodiment of the invention in the compound according to general formulas I, I′, I″ and I′″ wherein

R₃ and R_(3′) are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl and —CH₂R₄; wherein the cycloalkyl as defined in R₃ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another embodiment of the invention in the compound according to general formulas I, I′, I″ and I′″ wherein

R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkyheterocyclyl, wherein the aryl, cycloalkyl and heterocyclyl as defined in R₁ if substituted (also in alkylaryl or alkylheterocyclyl) are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅ optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another embodiment of the invention in the compound according to general formulas I wherein

R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R₅, —NR₅COR₅, —NR₅R_(5″) or unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted cycloalkyl; wherein the aryl, cycloalkyl and heterocyclyl as defined in Rd if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅.

In another embodiment of the invention in the compound according to general formulas I wherein

R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R₅, —NR₅COR_(5′), —NR5R5′″ or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl wherein the aryl, cycloalkyl and heterocyclyl as defined in R₄ if substituted are substituted with substituents selected from —OR₅ halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅.

In an embodiment of the Invention in the compound of general formulas I, I′, I″ and I′″ the alkyl, alkenyl and alkynyl as defined in R₁, R₁, R₂, R₃, R_(3′), R₄, R₁, R₆, R_(6′), R₇, R_(7′), R₈, R₈ and R₉ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅, —S(O)₂R₅, C(O)OR₅ or C(O)NR₅R_(5′);

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In an embodiment of the invention in the compound of general formulas I, I′, I″ and I′″

the halogen is fluorine, chlorine, iodine or bromine; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a most preferred embodiment of the invention in the compound according to general formulas I, I′, I″ and I′″

the halogen ° s fluorine or chlorine optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In an embodiment of the invention in the compound of general formulas I, I′, I″ and I′″ the haloalkyl is —CF₃,

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In another embodiment of the invention in the compound of general formulas I, I′, I″ and I′″

the haloalkoxy is —OCF3; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In an embodiment of the invention in the compound of general formula I

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉—; m is 0 or 1; n is 1, 2 or 3; q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R_(1′); r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; wherein the aryl, heterocyclyl or cycloalkyl in R₁ or R_(1′) (also in alkylaryl or alkylheterocyclyl) if substituted are substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, haloalkoxy, —SR5, —S(O)R₅ or —S(O)₂R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl, heterocyclyl or cycloalkyl in R2 if substituted is substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′), —C(O)OR₅, —NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5′), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR₅R_(5′), haloalkyl, -haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅; R₃ and R₃ are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, substituted or unsubstituted alkylcycloalkyl, wherein the aryl, cycloalkyl and heterocyclyl as defined in R₃ if substituted (also in alkylaryl alkylcycloalkyl or alkylheterocyclyl) are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅, R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R₅, —NR₅COR₅, —NR5R5′″ or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl wherein the aryl, cycloalkyl and heterocyclyl as defined in R₄ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅, R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R₅ and R₅ are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5″) is H, unsubstituted C₁₋₆ alkyl unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc R₆, R₆, R₇ and R₇ are independently selected from H, halogen —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocycyl, unsubstituted aryl and unsubstituted cycloalkyl; R₁ and R₁ are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; and/or wherein the alkyl, alkenyl and alkynyl as defined in R₁, R_(1′), R₂, R₃, R_(3′), R₄, R_(4′), R₆, R_(6′), R₇, R_(7′), R₈, R₈ and R₈ if substituted are substituted with substituents selected from —ORS, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅, —S(O)₂R₅, C(O)OR₅ or C(O)NR₅R_(5′); optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof, with the proviso that when W is a bond, then R₁ cannot be H, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl or substituted or unsubstituted cycloalkyl; with the following compounds being excluded from the general formula I:

In an embodiment of the invention in the compound of general formula I

wherein

Y is

Z is —CH₂—, —C(O)— or —CHR₉—; m is 0 or 1; n is 1, 2 or 3; q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)₁—W—R_(1′); r is 0, 1 or 2 W is a bond, —CH₂O—, —CH₂C(O)NR₅—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl (−), substituted or unsubstituted cycloalkyl or R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₃ and R_(3′) are Independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, substituted or unsubstituted alkylcycloalkyl, R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R₅, —NR₅COR₅, —NR5R5′″ or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl R₄ is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R₅ and R₅ are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkyaryl; R_(5′) is H unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc R₆, R₆, R₇ and R₇ are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and Re are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₁ is selected from H, substituted or unsubstituted C₁₋₆ alky, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof, with the proviso that when W is a bond, then R₁ cannot be H, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl or substituted or unsubstituted cycloalkyl; with the following compounds being excluded from the general formula I

In addition to the two embodiments above, also the following compound may be excluded:

As this invention is aimed at providing a compound or a chemically related series of compounds which act as dual ligands of the σ₁ receptor and the μ-opiod receptor it is a very preferred embodiment in which the compounds are selected which act as dual ligands of the σ₁ receptor and the μ-opiod receptor and especially compounds which have a binding expressed as K₁ which is preferably <1000 nM for both receptors, more preferably <500 nM, even more preferably <100 nM.

In the following the phrase “compound of the invention” is used. This is to be understood as any compound according to the invention as described above according to general formulas I, I′, I″ or I′″.

The compounds of the invention represented by the above described formula (I) may include enantiomers depending on the presence of chiral centres or isomers depending on the presence of multiple bonds (e.g. Z, E). The single isomers, enantiomers or diastereoisomers and mixtures thereof fall within the scope of the present invention.

In general the processes are described below in the experimental part. The starting materials are commercially available or can be prepared by conventional methods.

A preferred aspect of the invention is also a process for the production of a compound according to formula I,

wherein R₁, R₂, R₈, R_(8′), X, Y, Z, m and n are as already defined above in the description, wherein a compound of formula (VIIIH′) or its suitable salt like the hydrochloride

wherein R₁, R₁₃, R₅, Y, Z and m are already defined in above in the description, is reacted with a compound according to formula IX, X or XI.

wherein R₂, X and n are as already defined in above in the description, and wherein LG is a leaving group, leading to a compound according to formula (I)

A particular embodiment is a process for the preparation of a compound of general formula Ia

wherein R₁, R₂, R₃, R₃, R₆, R₈, X, m, n and Z are as already defined above in the description; which comprises the steps of

-   -   (a) reacting a compound of formula Va

with a compound of formula VI

wherein LG is a leaving group, R₃, R₃ and Z are as already defined above in the description; to obtain a compound of formula VIIa

and

-   -   (b) carrying out a cyclisation of the resulting compound in a         suitable solvent, in the presence of a strong base and at a         temperature comprised between −78° C. and the reflux         temperature;         wherein the hydrogen, the blocking agent or the —(CH₂)n-X—R₂         group defined as A in the above general Markush formulae Iax′,         Vax′ and VIIax′ may be introduced in any step during the         process.

Another particular embodiment of the invention is a process for the preparation of a compound of general formula Icx

wherein R₁, R₂, R₆, R_(6′), R₈, R_(8′), X, m, n and Z are as defined in the preceeding claims; which comprises the dehydration of a compound of formula XIXx

A further embodiment of the invention is a process for the preparation of a compound of general formula Ifx

wherein R₁, R₂, R₈, R₈, m, n, X and Z are already defined above in the description, and R₇ and R_(7′) are hydrogen; which comprises the cyclopropanation of a compound of formula Icx

wherein R₁, R₂, R₈, R₈, m, n, X and Z are already defined above in the description; R₆ and R_(6′) are hydrogen;

A further embodiment of the invention is a process for the preparation of a compound of general formula Iox

wherein R₁, R₂, R₈, R₈, m, n, q, X and Z are already defined above in the description; which comprises reacting a compound of formula Ikx

wherein R₁, R₂, R₈, R₈, m, n, X and Z are already defined above in the description: with a compound of formula XXXIV

wherein R₇, R_(7′) and q are already defined above in the description, X′ and X″ independently represent a leaving group:

Preparation of the hydrochloride salt: To a solution of the free base in a suitable solvent, preferably in anhydrous diethyl ether, HCl is added and the mixture is stirred, preferably at r.t. and preferably for 1 h. The solids are filtered and dried, preferably under vacuum, to give the corresponding HCl salt.

The obtained reaction products may, if desired, be purified by conventional methods, such as crystallisation and chromatography. Where the above described processes for the preparation of compounds of the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. If there are chiral centers the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.

One preferred pharmaceutically acceptable form of a compound of the invention is the crystalline form, including such form in pharmaceutical composition. In the case of salts and also solvates of the compounds of the invention the additional ionic and solvent moieties must also be non-toxic. The compounds of the invention may present different polymorphic forms, it is intended that the invention encompasses all such forms.

Another aspect of the invention refers to a pharmaceutical composition which comprises a compound according to the invention as described above according to general formulas I, I′, I″ or I′″ or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. The present invention thus provides pharmaceutical compositions comprising a compound of this invention, or a pharmaceutically acceptable salt or stereoisomers thereof together with a pharmaceutically acceptable carrier, adjuvant, or vehicle, for administration to a patient.

Examples of pharmaceutical compositions include any solid (tablets, pills, capsules, granules etc.) or liquid (solutions, suspensions or emulsions) composition for oral, topical or parenteral administration.

In a preferred embodiment the pharmaceutical compositions are in oral form, either solid or liquid. Suitable dose forms for oral administration may be tablets, capsules, syrops or solutions and may contain conventional excipients known in the art such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone: fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulfate.

The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art. The tablets may for example be prepared by wet or dry granulation and optionally coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

The pharmaceutical compositions may also be adapted for parenteral administration, such as sterile solutions, suspensions or lyophilized products in the appropriate unit dosage form. Adequate excipients can be used, such as bulking agents, buffering agents or surfactants.

The mentioned formulations will be prepared using standard methods such as those described or referred to in the Spanish and US Pharmacopoeias and similar reference texts.

Administration of the compounds or compositions of the present invention may be by any suitable method, such as intravenous infusion, oral preparations, and intraperitoneal and intravenous administration Oral administration is preferred because of the convenience for the patient and the chronic character of the diseases to be treated

Generally an effective administered amount of a compound of the Invention will depend on the relative efficacy of the compound chosen, the severity of the disorder being treated and the weight of the sufferer. However, active compounds will typically be administered once or more times a day for example 1, 2, 3 or 4 times daily, with typical total daily doses in the range of from 0.1 to 1000 mg/kg/day.

The compounds and compositions of this invention may be used with other drugs to provide a combination therapy. The other drugs may form part of the same composition, or be provided as a separate composition for administration at the same time or at different time.

Another aspect of the invention refers to the use of a compound of the invention or a pharmaceutically acceptable salt or isomer thereof in the manufacture of a medicament.

Another aspect of the Invention refers to a compound of the invention according as described above according to general formulas I, I′, I″ or I′″ or a pharmaceutically acceptable salt or isomer thereof, for use as a medicament for the treatment of pain. Preferably the pain is medium to severe pain, visceral pain, chronic pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia. This may include mechanical allodynia or thermal hyperalgesia.

Another aspect of the invention refers to the use of a compound of the invention in the manufacture of a medicament for the treatment or prophylaxis of pain.

In a preferred embodiment the pain is selected from medium to severe pain, visceral pain, chronic pain, chronic pain, cancer pain, migraine, Inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia, also preferably including mechanical allodynia or thermal hyperalgesia.

Another aspect of this Invention relates to a method of treating or preventing pain which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound as above defined or a pharmaceutical composition thereof. Among the pain syndromes that can be treated are medium to severe pain, visceral pain, chronic pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia, whereas this could also include mechanical allodynia or thermal hyperalgesia.

The present invention is illustrated below with the aid of examples. These illustrations are given solely by way of example and do not limit the general spirit of the present invention.

EXAMPLES General Experimental Part (Methods and Equipment of the Synthesis and Analysis) Scheme 1:

A 4-step process is described for the preparation of compounds of general formula (I) wherein Y is CR₃R₃ (compounds of formula Ia) starting from a ketone of formula II, as shown in the following scheme:

wherein R₁, R₂, R₃, R₈, R₈, X, Z, m and n have the meanings as defined above for a compound of formula (I), p represents 0, 1 or 2, LG represents a leaving group such as halogen, mesylate, tosylate or triflate, with the proviso that when Z=CO it can only be chloro or bromo, V represents an aldehyde or another leaving group (such as halogen, mesylate, tosylate or triflate), P represents a suitable protecting group (preferably Boc) and R_(1a) represents a R₁ group that can be used as a protecting group (preferably 4-methoxybenzyl or benzyl).

The 4 step-process is carried out as described below:

Step1: When R₆=H, a compound of formula III is prepared by treating a compound of formula II with a suitable methyl-transfer reagent such as trimethysulfoxonium iodide or trimethylsulfonium iodide, in a suitable aprotic solvent such as dimethylsulfoxide, and in the presence of a strong base such as sodium hydride or potassium tert-butoxide, at a suitable temperature, preferably comprised between room temperature and 60° C. The compounds of formula III wherein R₈≠H can be prepared from compounds of formula I in a two-step process, comprising an olefination under typical Wittig reaction conditions followed by an epoxidation using a suitable oxidizing agent such as a peracid (as for example m-chloroperbenzoic acid), or hydrogen peroxide (optionally in the presence of a metal catalyst)

Step2: A compound of formula Va is prepared by reacting a compound of formula III with an amine of formula IVa, in a suitable solvent such as an alcohol, preferably ethanol-water mixtures, at a suitable temperature comprised between room temperature and the reflux temperature.

Step3: A compound of formula Vila is prepared by reacting a compound of formula Va with a compound of formula VI. Depending on the meaning of Z, the compound of formula VI can be of different nature and different reaction conditions will apply:

-   -   a) When Z represents CO, VI is an acylating agent. The acylation         reaction is carried out in a suitable solvent, such as         dichloromethane or ethyl acetate-water mixtures: in the presence         of an organic base such as triethylamine or         diisopropylethylamine or an Inorganic base such as K₂CO₃; and at         a suitable temperature, preferably comprised between −78° C. and         room temperature.     -   b) When Z represents CH₂ or CHR₉, VI is an alkylating agent. The         alkylation react on may be carried out in a suitable solvent,         such as acetonitrile, dichloromethane, tetrahydrofuran,         1,4-dioxane or dimethylformamide; in the presence of an         inorganic base such as K₂CO₃, Cs₂CO₃ or NaH, or an organic base         such as triethylamine or diisopropylethylamine, at a suitable         temperature comprised between room temperature and the reflux         temperature. The OH group present may need protection previous         to the alkylation reaction.

Step4: The intramolecular cyclization of a compound of formula Vila renders a compound of formula Ia. The cyclization reaction is cared out in a suitable solvent, such as tetrahydrofuran; in the presence of a strong base such as potassium tert-butoxide or sodium hydride; and at a suitable temperature, comprised between −78° C. and the reflux temperature, preferably cooling.

Alternatively, the group (CH)_(n)XR₂ can be incorporated in the last step of the synthesis by reaction of a compound of formula VIIIH with a compound of formula IX, X or XI, as shown in Scheme 1. A compound of formula VIIIH is obtained by deprotection of a compound of formula VIIIP, wherein P represents a suitable protecting group, preferably Boc (tert-butoxycarbonyl). When the protecting group is Boc, the deprotection can be conducted by adding a solution of a strong acid such as HCl, in a suitable solvent such as diethyl ether, 1,4-dioxane or methanol, or with trifluoroacetic acid in dichloromethane. A compound of formula VIIIP is prepared from a compound of formula IIP following the same sequence described for the synthesis of compounds of formula Ia.

The alkylation reaction between a compound of formula VIIH (or a suitable salt such as trifluoroacetate or hydrochloride) and a compound of formula IX is carried out in a suitable solvent, such as acetonitrile, dichloromethane, 1,4-dioxane or dimethylformamide, preferably in acetonitrile; in the presence of an inorganic base such as K₂CO₃ or Cs₂CO₃, or an organic base such as triethylamine or diisopropylethylamine, preferably K₂CO₃, at a suitable temperature comprised between room temperature and the reflux temperature, preferably heating, or alternatively, the reactions can be carried out in a microwave reactor. Additionally, an activating agent such as NaI can be used.

The reductive amination reaction between a compound of formula VIIIH and a compound of formula X is carried out in the presence of a reductive reagent, preferably sodium triacetoxyborohydride, in an aprotic solvent, preferably tetrahydrofuran or dichloroethane, optionally in the presence of an acid, preferably acetic acid.

The condensation reaction between a compound of general formula VIIIH and a compound of formula XI is preferably carried out in a suitable solvent, such as isopropanol, n-butanol or 2-methoxyethanol, optionally in the presence of an organic base such as triethylamine or diisopropylethylamine, at a suitable temperature comprised between room temperature and the reflux temperature, preferably heating, or alternatively, the reactions can be carried out in a microwave reactor.

In another alternative approach, the R₁ substituent can be incorporated later in the sequence by the reaction of a compound of formula XIV with a compound of formula XV. Depending on the meaning of R₁ and Z, V can be of different nature and different reaction conditions will apply:

-   -   a) When Z is CH₂ and R₁ is not aryl or heterocyclyl, compound XV         is an alkylating agent and V represents a leaving group such as         halogen, mesylate, tosylate or triflate. The alkylation reaction         is carried out under the same react on conditions described         above for the reaction of a compound of formula VIIH and a         compound of formula IX.         -   Alternatively, when Z is CH; compound XV can be an aldehyde             wherein V represents a C(O)—H group. The reductive amination             reaction is carried out under the same reaction conditions             described above for the reaction of a compound of formula             VIIIH and a compound of formula X.     -   b) When Z is C(O) and R₁ is not aryl or heterocyclyl, compound         XV is an alkylating agent and V represents a leaving group such         as halogen, mesylate, tosylate or triflate. This alkylation         reaction is carried out in an aprotic solvent, preferably         dimethylformamide, in the presence of an inorganic base such as         NaH, at a suitable temperature, preferably between room         temperature and 60° C.     -   c) When R₁ is aryl or heterocyclyl, compound XV is an arylating         agent and V represents halogen (preferably bromo or iodo) or         triflate. This arylation react on is carried out under catalytic         conditions using a palladium or copper catalyst, in the presence         of a suitable ligand and a suitable base, in a suitable solvent,         and at a suitable temperature, preferably heating at the reflux         temperature or in a microwave reactor. When using copper         catalysts such as copper(I) iodide, trans-1,2-cyclohexanediamine         is the preferred ligand, potassium phosphate is used preferably         as the base and 1,4-dioxane is the solvent of choice. When using         palladium catalysts such as tris(d         benzylideneacetone)dipalladium(0) or palladium diacetate,         4,5-bis(diphenylphosphino)-9,9-dimethyxanthene (Xantphos) or         BINAP are the preferred ligands, cessium carbonate or sodium         tert-butoxide are used preferably as the base and 1,4-dioxane or         toluene are the solvents of choice.

A compound of formula XIV is synthesized following an analogous sequence as described for the synthesis of compounds of formula Ia, but effecting step 2 using ammonia instead of an amine. Alternatively, a compound of formula XIV can be prepared by reaction of a compound of formula XIVH (prepared from a compound of formula XIVP, wherein P represents a suitable protecting group) with a compound of formula IX, X or XI, as described above.

Additionally, a compound of formula XIV can be prepared from a compound of formula Ib, wherein R_(1a) represents a R₁ group that can be used as a protecting group. When Z is C(O), R₁₋₁ is preferably a 4-methoxybenzyl group and the deprotection reaction is carried out with cerium ammonium nitrate in a suitable solvent such as mixtures of acetonitrile-water or by heating in trifluoroacetic acid or hydrochloric acid. When Z is —CH2- or CHR9-, R₁₋₁ is preferably a 4-methoxybenzyl or a benzyl group, and the deprotection reaction is preferably carried out by hydrogenation under hydrogen atmosphere and metal catalysis, preferably by the use of palladium over charcoal as catalyst in a suitable solvent such as methanol or ethanol, optionally in the presence of an acid such as acetic acid or hydrochloric acid.

A compound of formula Ib is synthesized from a compound of formula II following an analogous sequence as described for the synthesis of compounds of formula Ia. Alternatively, a compound of formula Ib can be prepared by reaction of a compound of formula XVIH (prepared from a compound of formula XVIP, wherein P represents a suitable protecting group) with a compound of formula IX, X or XI, as described above.

The compounds of general formula II, IIP, IVa, IVb, VI, IX, X, XI and XV wherein R₁, R₁, R₂, R₃, R₃, R₆, LG, P, V, X, Z, m, n and p have the meanings as defined above, are commercially available or can be prepared by conventional methods described in the bibliography.

Scheme 2

The preparation of compounds of general formula (I) wherein Y is

is described in the following scheme:

wherein R₁, R₂, R₆, R₆, R₇, R₇, R₈, R₈, X, m, n and q have the meanings as defined above for a compound of formula (I), p represents 0, 1 or 2, LG represents a leaving group such as halogen, mesylate, tosylate or triflate, V represents an aldehyde or another leaving group (such as halogen, mesylate, tosylate or triflate), P represents a suitable protecting group (preferably Boc), R_(1a) represents a R₁ group that can be used as a protecting group (preferably 4-methoxybenzyl), T represents chloro, bromo or iodo and Q represents methyl or benzyl.

Compounds of formula Ic can be prepared in a 3-step process starting from a compound of formula Va:

Step1; A compound of formula XVII is prepared by treating a compound of formula Va with oxalyl chloride, in a suitable solvent such as dichloromethane, in the presence of a base such as triethylamine, at a suitable temperature, preferably comprised between 0° C. and room temperature. Additionally, an activating agent such as 4-dimethylaminopyridine can be used.

Step2: A compound of formula XIX is prepared by reacting a compound of formula XVII with a Grignard reagent of formula XVIII, in an aprotic solvent such as tetrahydrofuran, at a suitable temperature, preferably at room temperature.

Step3: A compound of formula Ic is prepared by reacting a compound of formula XIX with a dehydrating agent such as boron trifluoride diethyl etherate, in a suitable solvent such as dichloromethane, at a suitable temperature, preferably at room temperature.

Alternatively, a compound of formula Ic wherein R₆=R₆=H can be prepared from a compound of formula Id wherein Q represents methyl or benzyl. The elimination reaction is carried out in the presence of a base, such as potassium tert-butoxide, in a suitable solvent, such as tetrahydrofuran.

Compounds of formula Ie can be prepared from compounds of formula Ic. The reduction reaction is preferably carried out by hydrogenation under hydrogen atmosphere and metal catalysis, preferably by the use of palladium over charcoal as catalyst in a suitable solvent such as methanol or ethanol, optionally in the presence of an acid such as acetic acid or hydrochloric acid.

Compounds of formula If can be prepared from compounds of formula Ic wherein R₆=R₆H. The cyclopropanation reaction is carried out using a suitable methyl-transfer reagent such as trimethylsulfoxonium iodide or trimethylsulfonium iodide, in a suitable aprotic solvent such as dimethylsufoxide, and in the presence of a strong base such as sodium hydride or potassium ter-butoxide, at a suitable temperature, preferably comprised between room temperature and 60° C. Alternatively, typical Simmons-Smith reaction conditions could be used, comprising the treatment of a compound of formula Ic with diiodomethane, a zinc source such as zinc-copper, zinc iodide or diethylzinc, in a suitable aprotic solvent, such as diethyl ether.

Alternatively, a compound of formula If can be prepared from a compound of formula Ig wherein R₇=R₇=H and q=1 by treatment with a strong base such as lithium diisopropylamide or potassium tert-butoxide, in an aprotic solvent such as tetrahydrofuran, at a suitable temperature, preferably cooling at 0° C. And analogously, compounds of formula Ih can be prepared from compounds of formula Ig under the same reaction conditions.

In another alternative approach, the R₁ substituent can be incorporated later in the synthesis. Thus, compounds of formula If and Ih can be prepared from compounds of formula Ii and Ij, respectively, following the reaction conditions described in Scheme 1 for the preparation of compounds of formula Ia from compounds of formula Ib.

In addition, the group (CH₂)_(n)XR₂ can be incorporated in the last step of the synthesis to prepare compounds of formula Ic, Id, Ie, If, Ih, Ii and Ij from suitable protected precursors, by deprotection followed by reaction with a compound of formula IX. X or XI, as described in Scheme 1 for the preparation of compounds of formula Ia.

The compounds of general formula Id and Ig can be prepared by the procedures described in Scheme 1 using suitable starting materials. The compounds of general formula Ii and I can be prepared from a compound of formula Vb following the procedures described in Schemes 1 and 2.

The compounds of general formula IX, X, XI XV and XVIII wherein R₁, R₂, R₆, R_(6′), LG, T, V, X, n and p have the meanings as defined above, are commercially available or can be prepared by conventional methods described in the bibliography.

Scheme 3 and Scheme 4

Compounds of formula (I) can also be prepared starting from other compounds of formula (I), as described in Schemes 3 and 4 below.

Compounds of formula Im, In and to can be prepared from a compound of formula Ik as shown in Scheme 3:

wherein R₁, R₂, R₃, R₃, R₇, R₇, R₈, R₈, X, m, n and q have the meanings as defined above for a compound of formula (I), p represents 0, 1 or 2, LG, X′ and X″ independently represent a leaving group such as halogen, mesylate, tosylate or triflate, and P represents a suitable protecting group (preferably Boc).

A compound of formula Im can be prepared by treating a compound of formula Ik with an alkylating agent of formula XXXIa in the presence of a strong base such as lithium diisopropylamide or potassium tert-butoxide, in an aprotic solvent such as tetrahydrofuran, at a suitable temperature, preferably comprised between −78° C. and room temperature. A second alkylation can be performed under the same reaction conditions to prepare a compound of formula In. An analogous double-alkylation process can be used for the preparation of compounds of formula to, by reacting a compound of formula Ik with an alkylating agent of formula XXXV.

In addition, the group (CH₂)_(n)XR₂ can be incorporated in the last step of the synthesis to prepare compounds of formula Im, In and to from suitable protected precursors, by deprotection followed by reaction with a compound of formula IX, X or XI, under the reaction conditions described in Scheme 1 for the preparation of compounds of formula Ia.

The compounds of general formula Ik and Im can be prepared by the procedures described in Scheme 1 using suitable starting materials.

Scheme 4 shows the preparation of compounds of formula (l) wherein Z is CH₂ from the corresponding compounds of formula (I) wherein Z is C(O):

wherein R₁, R₂, R₈, R₈, X, Y, m and n have the meanings as defined above for a compound of formula (I). p represents 0, 1 or 2, LG represents a leaving group such as halogen, mesylate, tosylate or triflate, V represents an aldehyde or another leaving group (such as halogen, mesylate, tosylate or triflate), P represents a suitable protecting group (preferably Boc) and R represents a R, group that can be used as a protecting group (preferably 4-methoxybenzyl or benzyl).

The reduction reaction of a compound of formula Ir to yield a compound of formula Is can be performed using a suitable reducing agent such as lithium aluminium hydride, borane-tetrahydrofuran complex or borane-dimethyl sulphide complex, in a suitable solvent such as tetrahydrofuran, at a suitable temperature comprised between room temperature and the reflux temperature, preferably heating.

The compounds of general formula Ir can be prepared by the procedures described in Scheme 1 and Scheme 2 using suitable starting materials, or they can be prepared from a compound of formula Ip or XXXVII. The deprotection of a compound of formula Ip to give a compound of formula XXXVII and the subsequent reaction with a compound of formula XV to yield a compound of formula Ir are performed following the procedures described in Scheme 1.

The compounds of general formula Ip and XXXVII can be prepared according to the procedures described in Scheme 1 using suitable starting materials.

The reduction reaction can also be performed on a suitable precursor (compounds of formula Ip or XXXVII) or a protected derivative wherein A=P. When P represents Boc, borane is the preferred reducing agent. Accordingly, the compounds of general formula Is may be prepared from a compound of formula Iq or XL following an analogous procedure to the one described above.

In addition, the group (CH)_(n)XR₂ may be incorporated at different stages of the synthesis to prepare compounds of formula Is from suitable precursors and compounds of formula IX, X and XI, following similar reaction conditions as described in Scheme 1 for the preparation of compounds of formula Ia

The compounds of general formula IX, X, XI, XV, XXXIa, XXXIb and XXXIV wherein R₁, R₂, R₃, R₃, R₇, R₇, LG, X, X′, X″, n, p and q have the meanings as defined above, are commercially available or can be prepared by conventional methods described in the bibliography.

Moreover, certain compounds of the present invention can also be obtained starting from other compounds of formula (I) by appropriate conversion reactions of functional groups, in one or several steps, using well-known reactions in organic chemistry under standard experimental conditions. As a way of example, some of these conversions include the demethylation of a methoxy group to yield an hydroxy group, the reduction of a nitro group to yield an amino group, the acylation or sulfonylation of an amino group to yield an acylamino or sulfonylamino group, the conversion of an amino group into an ureido or sulfamido group, the hydrolysis of an ester to yield a carboxylic acid, the conversion of an acid or an ester to an amide, and the reduction of a ketone or an ester to yield the corresponding hydroxyl compound.

In addition, a compound of formula I that shows chirality can also be obtained by resolution of a racemic compound of formula I either by chiral preparative HPLC or by crystallization of a diastereomeric salt or co-crystal. Alternatively, the resolution step can be carried out at a previous stage, using any suitable intermediate.

EXAMPLES

All solvents used for synthesis were p. a. quality.

The following abbreviations are used in the examples:

ACN: acetonitrile AcOH: acetic acid Boc: tert-butoxycarbonyl CAN: cerium ammonium nitrate DCM: dichloromethane DEA: diethylamine DIPEA: diisopropylethylamine DMF: dimethytformamide DMSO: dimethysulfoxide Eq: equivalent EtOH: ethanol EX: example h: hour/s HPLC: high performance liquid chromatography IPA: isopropano INT: intermediate LDA: lithium diisopropylamide MeOH: methanol MS: mass spectrometry Min.: minutes Quant: quantitative Ret.: retention r.t.: room temperature Sat: saturated s.m.: starting material TFA: trifluoroacetic acid THF: tetrahydrofuran Wt: weight

The following method was used to determine the HPLC-MS spectrums:

Column: Xbridge C₁₈ XP 30×4.6 mm. 2.5 um Temperature: 40′C

Flow: 2.0 mL/min Gradient: NH₄HCO₃ pH 8: ACN (95.5)—0.5 min—(95:5)—6.5 min—(0:100)—1 min—(0:100) Sample dissolved aprox. 1 mg mL n NH₄HCO₃ pH 8/ACN

Alternatively, methods B or C were used in some cases:

Method B Column: Xbridge C₁₈ XP 30×46 mm. 2.5 um Temperature: 25° C.

Flow: 2.0 mL/min Gradient: NH₄HCO₃ pH 8 ACN (95:5)—7 min—(0:100)—3 min—(0:100) Sample dissolved aprox 1 mg/mL in MeOH

Method C: Column: Gemini-NX 30×4.6 mm, 3 um Temperature: 40° C.

Flow: 2.0 mL/min Gradient: NH₄HCO₃ pH 8 ACN (95:5)—0.5 min—(95:5)—6.5 min—(0:100)—1 min—(0.100) Sample dissolved aprox 1 mg/mL in NH₄HCO₃ pH 8/ACN

Synthesis of Intermediates Intermediate 1A: tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate

To a suspension of trimethylsulfoxonium iodide (24.3 g. 110 mmol) and NaH (4.4 g, 60 wt % in mineral oil, 110 mmol) in DMSO (140 mL), a solution of tert-butyl 4-oxopiperidine-1-carboxylate (20.0 g, 100 mmol) in DMSO (140 mL) was added dropwise. The reaction mixture was stirred at r.t. for 30 min, then heated at 50° C. for 1 h. After cooling to r.t., ice was slowly added, and the reaction mixture was extracted three times with ethyl acetate. The organic phases were combined, washed with water, dried over MgSO₄ and concentrated under vacuum to give the title compound (17.6 g, 82% yield) as a white solid. HPLC retention time: 3.31 min: MS: 158 (M+H-56).

This method was used for the preparation of intermediates 1B-1D using suitable starting materials:

Ret time MS INT Structure Chemical name (min) (M + H) 1B

6-phenethyl-1-oxa-6- azaspiro[2.5]octane 3.36 218 1C

6-benzyl-1-oxa-6- azaspiro[2.5]octane 3.21 (method B) 204 1D

5-benzyl-1-oxa-5- azaspiro[2.4]heptane 2.94 190

Intermediate 2A: tert-butyl 4-hydroxy-4-((phenylamino)methyl)piperidine-1-carboxylate

To a solution of intermediate 1A (5.0 g, 23.4 mmol) in a mixture of ethanol-water 9:1 (103 mL), aniline (2.14 mL, 23.4 mmol) was added. The reaction mixture was heated to 100° C. overnight in an autoclave reactor. The solvent was removed under vacuum and the residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (4.90 g. 68% yield) as an oil. HPLC retention time: 4.14 min; MS: 251 (M+H-56).

This method was used for the preparation of intermediates 2B-2L using suitable starting materials:

Ret time MS INT Structure Chemical name s.m. (min) (M + H) 2B

1-phenethyl-4- ((phenylamino)methyl) piperidin-4-ol 1B 3.64 311 2C

4-(((2- methoxyphenyl)amino) methyl)-1- phenethylpiperidin-4- ol 1B 4.00 (method B) 341 2D

4-(((3- methoxyphenyl)amino) methyl)-1- phenethylpiperidin-4- ol 1B 3.63 341 2E

4-(((4- methoxyphenyl)amino) methyl)-1- phenethylpiperidin-4- ol 1B 3.49 341 2F

4-(((2- fluorophenyl)amino) methyl)-1- phenethylpiperidin-4- ol 1B 4.01 329 2G

tert-butyl 4-(((2- fluorophenyl)amino) methyl)-4- hydroxypiperidine-1- carboxylate 1A 4.37 269 (M + H − 56) 2H

1-benzyl-4-(((2- methoxyphenyl)amino) mothyl)piperidin-4-ol 1C 4.11 (method B) 327 2I

1-benzyl-4- ((phenylamino)methyl) piperidin-4-ol 1C 3.85 (method B) 297 2J

1-benzyl-4-(((3- methoxyphenyl)amino) methyl)piperidin-4-ol 1C 3.82 (method B) 327 2K

1-benzyl-3- ((phenylamino)methyl) pyrrolidin-3-ol 1D ¹H-RMN (300 MHz) (1*) 2L

4-(((1-methyl-1H- pyrazol-3- yl)amino)methyl)-1- phenethylpiperidin-4- ol 1B 2.75 315 (1*) ¹H-RMN (300 MHz, CDCl₃) δ : 7.32 (d, 4H), 7.27 (m, 1H), 7.17 (m, 2H), 6.71 (m, 1H), 6.64 (m, 2H), 4.14 (broad s, 1H), 3.64 (m, 2H), 3.23 (s, 2H), 2.90 (m, 1H), 2.76 (m, 1H), 2.42-2.51 (m, 2H), 1.88-2.06 (m, 2H)

Intermediate 2M: tert-butyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate

A mixture of intermediate 1A (10.0 g. 46.9 mmol) and ammonia solution (201 mL, 7 M solution in methanol, 1.4 mol) was stirred at r.t. overnight. The solvent was removed under vacuum and the residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (7.4 g, 69% yield) as a white solid. HPLC retention time: 2.15 min; MS: 131 (M+H-100).

This method was used for the preparation of intermediates 2N-2O using suitable starting materials:

Ret MS time (M + INT Structure Chemical name s.m. (min) H) 2N

4- (aminomethyl)- 1- phenethyl- piperidin- 4-ol 1B 2.19 235 2O

4- (aminomethyl)- 1- benzylpiperidin- 4-ol 1C 1.77 221

Intermediate 2P:tert-butyl 4-hydroxy-4-(((4-methoxybenzyl)amino)methyl) piperidine-1-carboxylate

To a solution of intermediate 1A (9.1 g, 42.5 mmol) in a mixture of ethanol-water 9:1 (205 mL), 4-methoxybenzylamine (5.8 g. 42.5 mmol) was added. The reaction mixture was heated at 100° C. overnight in a sealed tube. The solvent was removed under vacuum and the residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (9.3 g, 63% yield). HPLC retention time: 3.80 min; MS: 351 (M+H).

This method was used for the preparation of intermediates 2Q-2R using suitable starting materials:

Ret time MS INT Structure Chemical name s.m. (min) (M + H) 2Q

tert-butyl 4-hydroxy- 4-(((pyridin-2- ylmethyl)amino) methyl)piperidine-1- carboxylate 1A 3.14 322 2R

tert-butyl 4- ((benzylamino) methyl)-4- hydroxypiperidine-1- carboxylate 1A 3.90 321

Intermediate 3A:tert-butyl 2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate

Step 1. tert-Butyl 4-((2-chloro-N-phenylpropanamido)methyl)-4-hydroxypiperidine-1-carboxylate: To a solution of intermediate 2A (4.90 g, 16.0 mmol) and triethylamine (5.3 mL. 38.4 mmol) in dichloromethane (180 mL), 2-chloropropionyl chloride (2.3 mL, 24.0 mmol) was added dropwise at 0° C. The reaction mixture was stirred at r.t. for 1 h. Dichloromethane was then added, and the organic phase was washed with NaHCO₃ sat solution, dried over MgSO₄, filtered and concentrated to dryness to give the title compound (6.6 g). HPLC retention time: 4.37 min: MS: 297 (M+H-100).

Step 2. Title compound: A solution of the crude product obtained in step 1 in THF (280 mL) was cooled to −78° C. using a dry ice/acetone bath. After addition of potassium tert-butoxide solution (25 mL, 1M in THF. 25 mmol), the reaction mixture was stirred at −78° C. for 30 min and then 4 h at −30° C. NaHCO₃ sat solution was then added and the aqueous phase was extracted with dichloromethane. The organic phases were combined, dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (4.56 g, 79% yield for the 2 steps). HPLC retention time: 4.23 min: MS: 361 (M+H).

This method was used for the preparation of intermediates 3B-3F using suitable starting materials:

Ret time MS INT Structure Chemical name s.m. (min) (M + H) 3B

tert-butyl 3-oxo-1- phenyl-1-oxa-4,9- diazaspiro[5.5] undecane-9- carboxylate 2A 3.85 347   3C

tert-butyl 2- ((benzyloxy)methyl)-3- oxo-4-phenyl-1-oxa- 4,9- diazaspiro[5.5] undecane-9- carboxylate 2A 4.96 467   3D

tert-butyl 4-(2- fluorophenyl)-2- (methoxymethyl)-3- oxo-1-oxa-4,9- diazaspiro[5.5] undecane-9- carboxylate 2G 4.14 409   3E

tert-butyl 4-(2- fluorophenyl)-2- isopropyl-3-oxo-1-oxa- 4,9- diazaspiro[5.5] undecane-9- carboxylate 2G 5.13 407   3F

tert-butyl 4-(2- fluorophenyl)-2- methyl-3-oxo-1-oxa- 4,9- diazaspiro[5.5] undecane-9- carboxylate 2G 4.39 379.1

Intermediate 3G:tert-butyl 3-oxo-1-oxa-4.9-diazaspiro[5.5]undecane-9-carboxylate carboxylate

Step 1. tert-Butyl 4-((2-chloroacetamido)methyl)-4-hydroxypiperidine-1-carboxylate: To a solution of intermediate 2M (1.0 g, 4.34 mmol) in ethyl acetate (9 mL), a solution of K₂CO₃ (67 g, 12.11 mmol) in water (7 mL) was added. After cooling to 0° C., chloroacetyl chloride (0.47 mL, 5.91 mmol) was added dropwise. The reaction mixture was stirred at 0° C. for 30 min, the layers were separated and the aqueous phase was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness to give the title compound (11 g). HPLC retention time: 2.90 min; MS: 207 (M+H-100).

Step 2. Title compound: To a solution of potassium tert-butoxide (7.16 mL. 1M in THF, 7.16 mmol) in a mixture of THF:tert-butanol 2.3:1 (25 mL) heated at reflux, a solution of the crude product obtained in step 1 in THF (20 mL) was added dropwise over 1 h. The reaction mixture was cooled to r.t. and stirred overnight. The solvent was removed under vacuum, water was added to the residue and the mixture thus obtained was extracted with ethyl acetate. The organic phase was dried over MgSO₄, filtered and concentrated under vacuum to give the title compound (0.87 g. 74% yield for the 2 steps). HPLC retention time: 2.88 min; MS: 215 (M+H-56).

This method was used for the preparation of intermediates 3H-3K using suitable starting materials:

Ret time MS INT Structure Chemical name s.m. (min) (M + H) 3H

tert-butyl 2-methyl-3- oxo-1-oxa-4,9- diazaspiro[5.5] undecane-9- carboxylate 2M 3.16 229 3I

9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 2N 2.80 275 3J

2-methyl-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one 2N 3.13 289 3K

9-benzyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 2O 2.58 261

Intermediate 3L:tert-butyl 3-oxo-4-(pyridin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate undecane-9-carboxylate

To a solution of intermediate 2Q (0.5 g, 1.56 mmol) and triethylamine (0.65 mL, 4.67 mmol) in dichloromethane (44 mL), a solution of chloroacetyl chloride (0.19 g, 1.71 mmol) in dichloromethane (9 mL) was added dropwise at 0° C. and the reaction mixture was stirred at that temperature for 2 h. NaHCO₃ sat solution was added and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was dissolved in tert-butanol (24 mL) and heated to 50° C. Powdered KOH (3.02 g, 34.7 mmol) was added and the mixture was stirred at 50° C. overnight. The solvent was evaporated and the residue was taken into water and ethyl acetate. The aqueous phase was back extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (306 mg, 52% yield) HPLC retention time: 3.43 min: MS: 362 (M+H).

Intermediate 3M: tert-butyl 3-oxo-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate

To a solution of intermediate 3G (0.97 g, 3.59 mmol) in dry DMF (5 mL), NaH (362 mg, 60 wt % in mineral oil, 8.98 mmol) was added. The mixture was stirred at r.t. for 30 min, then a solution of 2-(chloromethyl)-5-(trifluoromethyl)pyridine hydrochloride (0.92 g. 3.95 mmol) in DMF (5 mL) was added and the resulting mixture was stirred at r.t. overnight. Water was then added to the reaction mixture and it was extracted with ethyl acetate. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (561 mg, 36% yield). HPLC retention time: 4.22 min; MS: 374 (M+H-56).

This method was used for the preparation of intermediates 3N-3O using suitable starting materials:

Ret time MS INT Structure Chemical name s.m. (min) (M + H) 3N

tert-butyl 4-((5- chloropyridin-2-yl)methyl)- 3-oxo-1-oxa-4,9- diazaspiro[5.5]undecane-9- carboxylate 3G 3.91 396 3O

tert-butyl 4-((5-fluoropyridin- 2-yl)methyl)-2-methyl-3- oxo-1-oxa-4,9- diazaspiro[5.5]undecane-9- carboxylate 3H 3.98 394 3P

tert-butyl 2-methyl-3-oxo-4- ((5-(trifluoromethyl)pyridin- 2-yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecane-9- carboxylate 3H 4.41 388 (M + H − 56) 3Q

tert-butyl 4-((6-(di(tert- butoxycarbonyl)amino) pyridin-2-yl)methyl)-3- oxo-1-oxa-4,9- diazaspiro[5.5]undecane-9- carboxylate 3G 4.90 477 (M + H − 100)

Intermediate 3R:tert-butyl 2-methyl-3-oxo-4-(thiazol-4-yl)-1-oxa-4,9-diazaspiro [5.5]undecane-9-cxrboxylate

A mixture of intermediate 3H (500 mg, 1.76 mmol), K₃PO₄ (747 mg, 3-52 mmol), Cut (33 mg, 0.176 mmol), trans-1,2-cyclohexanediamine (0.042 mL, 0.352 mmol) and 4-bromothiazole (0.19 mL, 2.11 mmol) in dry 1,4-dioxane (5 mL) was heated under an argon atmosphere at 110° C. overnight. The reaction crude was cooled and ethyl acetate and water were added. The phases were separated and the aqueous phase was back extracted with ethyl acetate. The combined organic phases were dried over MgSO₄ and concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (270 mg, 41% yield). HPLC retention time: 4.16 min; MS: 312 (M+H-56).

Intermediate 3S: tert-butyl 2-methyl-3-oxo-4-(4-(trifluoromethyl)pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate

A mixture of intermediate 3H (1.00 g, 3.52 mmol), Cs₂CO₃ (1.49 g, 7.74 mmol), tris(dibenzylideneacetone)dipalladium(0) (161 mg, 0,176 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (173 mg, 0.299 mmol) and 3-bromo-4-(trifluoromethyl)pyridine (0.954 g, 4.22 mmol) in dry 1,4-dioxane (28 mL) was heated under an argon atmosphere at 110° C. overnight. After cooling the solids were filtered off and the reaction mixture was concentrated to dryness. Additional Cs₂CO₃ (1.49 g, 7.74 mmol), tris(dibenzylideneacetone)dipalladium(0) (161 mg, 0.176 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (173 mg, 0.299 mmol). 3-bromo-4-(trifluoromethyl)pyridine (0.397 g, 1.76 mmol) and dry 1,4-dioxane (28 mL) were added, After stirring an additional day at 110° C. under an argon atmosphere, the solids were filtered off and the solvent evaporated to dryness. Again, additional Cs₂CO₃ (1.49 g, 7.74 mmol), tris(dibenzylideneacetone)dipalladium(0) (161 mg, 0.176 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (173 mg, 0.299 mmol), 3-bromo-4-(trifluoromethyl)pyridine (0.410 g, 1.81 mmol) and dry 1,4-dioxane (28 mL) were added. The mixture was stirred at 110° C. overnight. The solids were filtered off, and the reaction mixture concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (627 mg, 41% yield). HPLC retention time: 4.25 min; MS: 374 (M+H-56).

This method was used for the preparation of intermediate 3T using suitable starting materials:

Ret time MS INT Structure Chemical name s.m. (min) (M + H) 3T

tert-butyl 2-methyl-3-oxo- 4-(2- (trifluoromethyl)pyridin-3- yl)-1-oxa-4,9- diazaspiro[5.5]undecane- 9-carboxylate 3H 4.3 374 (M + H − 56)

Intermediate 3U:9-(2-fluorophenethyl)-2-methyl-1-oxa-4.9-diazaspiro[5.5]undecan-3-one

Step 1: 2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one trifluoroacetate. To a solution of intermediate 3H (0.80 g, 2.8 mmol) in dichloromethane (8 mL), trifluoroacetic acid (2.2 mL, 280 mmol) was added, and the reaction mixture was stirred at r.t for 3 h. The solvent was evaporated to dryness to give the title compound as a crude product (1.54 g, 54 wt %, quant yield), that was used in the following step without further purification. HPLC retention time: 0.30 min; MS: 185 (M+H).

Step 2: A mixture of the crude product obtained in step 1 (1.54 g, 54 wt %, 2.78 mmol). 2-fluorophenethyl methanesulfonate (prepared as described in WO2008105497 Ex88-step1) (1.03 g, 4.74 mmol) and K₂CO₃ (1.93 g, 13.9 mmol) in acetonitrile (23 mL) was heated at 80° C. in a sealed tube overnight. Water was added, and the reaction mixture was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (513 mg, 60% yield). HPLC retention time: 3.22 min; MS: 307 (M+H).

Intermediate 4: tert-butyl 4-(2-fluorophenyl)-2,3-dioxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate

To a solution of intermediate 2G (2.0 g, 6.16 mmol) and 4-dimethylaminopyridine (0.038 g, 0.308 mmol) in dichloromethane (200 mL) at 0° C., triethylamine (3.18 mL, 22.8 mmol) was added. After stirring for 10 min at 0° C., a solution of oxalyl chloride (0.783 mL. 9.25 mmol) in dichloromethane (100 mL) was added dropwise over 3 h. The reaction mixture was stirred at 0° C. for 2 hours, and then ice was added. The organic layer was separated and washed with water, dried over MgSO₄, filtered and concentrated to dryness, to give the title compound as a crude product (2.5 g, quant. yield), that was used in the following step without further purification. HPLC retention time: 3.94 min: MS: 323 (M+H-56).

Intermediate 5A: 4-(2-fluorophenyl)-2-(propan-2-ylidene)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

Step 1. 4-(2-fluorophenyl)-2-hydroxy-2-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one: To a solution of intermediate 4 (1.0 g. 2.64 mmol) in dry tetrahydrofuran (10 mL), isopropylmagnesium chloride solution (2.1 mL, 2M in THF, 4.2 mmol) was added dropwise. The reaction mixture was stirred at r.t. for 40 min, then NH₄Cl sat solution was added and the aqueous phase was extracted with ethyl acetate. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness to give the title compound (0.918 g, 82% yield), that was used in the next step without further purification. HPLC retention time: 4.62 min; MS: 405 (M+H—OH).

Step 2. Title compound: To a solution of the crude product obtained in step 1 in DCM (18 mL), boron trifluoride diethyl etherate (2.40 mL, 22.7 mmol) was added at 0° C. The reaction mixture was stirred at r.t, overnight. Ice was added and the resulting mixture was basified to pH 9 with 1 M NaOH aqueous solution and extracted with dichloromethane. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated to dryness to give the title compound as a crude product (0.666 g, quant. yield), that was used in the next step without further purification. HPLC retention time: 2.69 min; MS: 305 (M+H).

This method was used for the preparation of intermediates 5B-5C using suitable starting materials:

Intermediate 6:4-(2-fluorophenyl)-2-isopropyl-1-oxa-4.9-diazaspiro[5.5]undecan-3-one acetate

Ret time MS INT Structure Chemical name s.m. (min) (M + H) 5B

4-(2-fluorophenyl)-2-(3- methoxypropylidene)- 1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 4 2.48 335 5C

4-(2-fluorophenyl)-2- ((tetrahydro-2H-pyran- 4-yl)methylene)-1-oxa- 4,9 diazaspiro[5.5]undecan- 3-one 4 2.61 361

A mixture of intermediate 5A (0.350 g, 1.15 mmol), AcOH (0.13 mL, 2.30 mmol) and palladium (55 mg, 10% wt on charcoal) in methanol (11.5 mL) was heated at 50° C. under 4 bars of H: for 3 days. Then, additional palladium (100 mg, 10% wt on charcoal) was added, and the reaction mixture was heated at 60° C. under 4.5 bars of H₂. After 2 days, the solids were filtered off and the solvent was removed under vacuum, to give the title compound as a crude product (0.438 g, quant. yield), that was used in the next step without further purification. HPLC retention time: 2.79 min; MS: 307 (M+H).

Intermediate 7: tert-butyl 2-methylene-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate

A solution of intermediate 3C (1.278 g. 2.74 mmol) in THF (46 mL) was cooled to −78° C. using a dry ice/acetone bath. After addition of potassium tert-butoxide solution (3.0 mL, 1M in THF. 3.0 mmol), the reaction mixture was stirred at −30° C. for 30 min. NH₄Cl sat solution was added and the aqueous phase was extracted with ethyl acetate. The organic phase was dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (0,577 g. 59% yield). HPLC retention time: 4.41 min; MS: 359 (M+H).

Intermediate 8A: tert-butyl 13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane-8-carboxylate

To a suspension of trimethylsulfoxonium iodide (0.645 g, 2.93 mmol) and NaH (0.117 g. 60 wt % in mineral oil, 2.93 mmol) in DMSO (3 mL), a solution of intermediate 7 (0.700 g, 1.95 mmol) in DMSO (3 mL) was added dropwise. The reaction mixture was stirred at r.t. for 30 min, then heated at 50° C. for 2 h. After cooling to r.t., ice was slowly added, and the reaction mixture was extracted three times with ethyl acetate. The organic phases were combined, washed with water, dried over MgSO₄ and concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (0,191 g, 26% yield). HPLC retention time: 4.39 min; MS: 373 (M+H).

Alternative Method for the Preparation of Intermediate 8A:

A mixture of intermediate 8E (200 mg, 0.67 mmol), K₃P04 (286 mg, 1.35 mmol), Cut (33 mg, 0.67 mmol), trans-1,2-cyclohexanediamine (0.081 mL, 0.67 mmol) and iodobenzene (0.09 mL, 0.81 mmol) in dry 1,4-dioxane (4 mL) was heated under an argon atmosphere at 110° C. overnight. The reaction crude was cooled and ethyl acetate and water were added. The phases were separated and the aqueous phase was back extracted with ethyl acetate. The combined organic phases were dried over MgSO₄, and concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (185 mg, 73% yield). HPLC retention time: 4.42 min; MS: 373 (M+H).

Intermediate 8B: tert-butyl 12-(4-methoxybenzyl)-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane-8-carboxylate

Step 1. tert-butyl 4-((2-bromo-4-chloro-N-(4-methoxybenzyl)butanamido)methyl)-4-hydroxypiperidine-1-carboxylate: To a solution of intermediate 2P (9.94 g. 28.4 mmol) and triethylamine (9.5 mL, 68.1 mmol) in dichloromethane (500 mL), a solution of 2-bromo-4-chlorobutanoyl chloride (prepared as described in U.S. Pat. No. 6,114,541A1(2000) Ex1) (9.35 g, 20.2 mmol) in dichloromethane (200 mL) was added dropwise at 0° C. The reaction mixture was stirred at 0° C. for 3 h. Dichloromethane and NaHCO₃ aqueous sat solution were added and the phases were separated. The aqueous phase was back extracted with dichloromethane. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness to give the title compound (17.6 g, crude product). HPLC retention time: 4.82 min; MS: 435 (M+H-100).

Step 2. Title compound: A solution of the crude product obtained in step 1 (14.8 g, 27.7 mmol) in THF (185 mL) was cooled under nitrogen to 0° C. After addition of potassium tert-butoxide solution (111 mL, 1M in THF, 111 mmol), the reaction mixture was stirred at 0° C. for 2 h. NH₄Cl sat solution was then added, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (5.51 g. 48% yield for the 2 steps). HPLC retention time: 4.46 min; MS: 417 (M+H).

Intermediate 8C: 8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one

A mixture of example 109 (free base) (0.170 g. 0.404 mmol) and CAN (0.568 g, 1.21 mmol) in a mixture of acetonitrile-water 1:1 (5 mL) was stirred at r.t. for 7 h. Na₂CO₃ sat solution was added to the reaction mixture and it was extracted with ethyl acetate. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by eluting through an acidic ion exchange resin cartridge (SCX), to give the title compound (106 mg, 88% yield). HPLC retention time: 3.31 min; MS: 301 (M+H).

This method was used for the preparation of intermediate 8D using suitable starting materials:

Ret time MS INT Structure Chemical name s.m. (min) (M + H) 8D

8-(2-fluorophenethyl)- 4-oxa-8,12- diazadispiro[2.1.5.3] tridecan-13-one Ex 149 3.41 319

Intermediate 8E:tert-butyl 13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane-8-carboxylate

Step 1. 4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one trifluoroacetate: A solution of intermediate 8B (1.78 g, 4.26 mmol) in TFA (20 mL) was stirred in a sealed tube at 80° C. for 4 days. The reaction mixture was concentrated to dryness and water was added to the residue. The acidic aqueous phase was washed with ethyl ether, which was discarded. The aqueous layer was evaporated to dryness to give the title compound (1.17 g, 88% yield). HPLC retention time: 0.33 min; MS: 197 (M+H), Step 2. Title compound: A solution of the crude product obtained in step 1 and di-tert-butyl dicarbonate (1.40 g, 6.40 mmol) in a mixture of 1,4-dioxane (40 mL) and 1M NaOH aqueous solution (10 mL) was stirred at r.t. overnight. Water was added and the resulting mixture was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (0.872 g, 78% yield). HPLC retention time: 3.29 min; MS: 297 (M+H).

Intermediate 8F: tert-butyl 13-oxo-12-((5-(trifluoromethyl)pyridin-2-yl)methyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane-8-carboxylate

To a solution of intermediate 8E (0.400 g, 1.35 mmol) in dry DMF (3 mL), NaH (135 mg, 60 wt % in mineral oil, 3.37 mmol) was added at r.t. The reaction mixture was stirred at r.t. for 30 min, then a solution of 2-(chloromethyl)-5-(trifluoromethyl)pyridine hydrochloride (0.344 g, 1.485 mmol) in DMF (3 mL) was dropwise added and the resulting mixture was stirred at r.t. overnight. Additional NaH and alkylating agent were added and the reaction was stirred at r.t. overnight to get the reaction to completion. Water was added to the reaction mixture and it was extracted with ethyl acetate. The organic phases were combined, washed with brine, dried over MgSO₄ filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient cyclohexane to ethyl acetate cyclohexane (1:1) to give the title compound (290 mg, 47% yield). HPLC retention time: 4.66 min; MS: 456 (M+H).

Intermediate 8G: 8-(2,5-difluorophenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one

Intermediate 8G was prepared according to the procedure described for Intermediate 3U, using Intermediate 8E as starting material HPLC retention time: 4.51 min; MS, 337 (M+H).

Intermediate 8H: tert-butyl 12-(benzyl)-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane-8-carboxylate

Intermediate 8H was prepared according to the procedure described for Intermediate 8B, using Intermediate 2R as starting material. HPLC retention time: 4.69 min; MS: 387 (M+H).

Intermediate 9A: tert-butyl 1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate

To a solution of intermediate 3G (1.50 g, 5.55 mmol) in THF (19 mL), borane-dimethyl sulfide complex (1.67 mL, 16.6 mmol) was added dropwise at r.t. The reaction mixture was stirred at 55° C. for 2 h, then it was cooled to r.t. MeOH was added dropwise and the solvent was concentrated under vacuum. The obtained residue was dissolved in methanol (20 mL), N,N-dimethylethylenediamine (3.0 mL, 28.3 mmol) was added and the mixture was stirred under reflux overnight After cooling to r.t., the volatiles were removed under vacuum, and the residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (0.928 g, 65% yield). HPLC retention time: 2.91 min; MS: 257 (M+H).

Intermediate 9B: 9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane

To a solution of intermediate 31 (1.25 g. 4.56 mmol) in THF (25 mL), lithium aluminium hydride solution (18.2 mL, 1M in THF, 18.2 mmol) was added dropwise and the reaction mixture was stirred at 50° C. overnight. Then. 1M NaOH aqueous solution was added, and the aqueous phase was extracted with dichloromethane. The organic phases were combined, dried over MgSO₄, filtered and concentrated under vacuum to give the title compound (1.10 g, 84% yield). HPLC retention time: 2.67 min; MS: 261 (M+H).

This method was used for the preparation of intermediate 9C using suitable starting materials:

Ret time MS INT Structure Chemical name s.m. (min) (M + H) 9C

2-methyl-9-phenethyl- 1-oxa-4,9- diazaspiro[5.5]undecane 3J 3.00 275

Intermediate 9D:tert-butyl 12-benzyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane-8-carboxylate

Intermediate 90 was prepared according to the procedure described for Intermediate 9A, using Intermediate 8H as starting material. HPLC retention time: 5.80 min; MS: 373 (M+H).

Intermediate 10: tert-butyl 4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate

To a solution of intermediate 9A (0.311 g. 1.21 mmol) and benzaldehyde (0.15 mL, 1.45 mmol) in THF (8 mL), acetic acid (0.15 mL, 2.67 mmol) was added. The reaction mixture was stirred at r.t. for 15 min. and sodium triacetoxyborohydride (0.77 g, 3.63 mmol) was added in 3 portions during a period of 30 min. The resulting mixture was stirred at r.t. overnight. Water was added, the pH of the mixture was adjusted to 9 by addition of concentrated NH and it was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄ filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol/dichloromethane (1:4) to give the title compound (350 mg, 83% yield) HPLC retention time: 5.36 min: MS: 347 (M+H).

Intermediate 11: tert-butyl 3-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate

Step 1. tert-butyl 3-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undec-2-ene-9-carboxylate: To a solution of intermediate 3B (0.150 g, 0.43 mmol) in dry tetrahydrofuran (2.5 mL) cooled at −10° C., zirconium tetrachloride (0.100 g. 0.43 mmol) was added. The mixture was stirred at −10° C. for 30 min under a N₂ atmosphere. Then, methylmagnesium bromide solution (0.72 mL, 3M in diethyl ether, 2.16 mmol) was added dropwise. The reaction mixture was stirred at r.t. for 6 h, then 2M NaOH aqueous solution was added and the mixture was filtered through a pad of celite. The aqueous phase was extracted with ethyl acetate. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness to give the title compound (0.107 g. 72% yield), used in the next step without further purification. HPLC retention time: 5.58 min: MS: 345 (M+H).

Step 2. Title compound: A mixture of the crude product obtained in step 1 (0.107 g, 0.31 mmol) and palladium (11 mg, 10% wt on charcoal) in ethanol (2 mL) was stirred at r.t. under 3 bars of H overnight. Additional palladium (11 mg, 10% wt on charcoal) was added and the reaction mixture was again stirred at r.t. under 3 bars of H overnight. The solids were filtered off and the solvent was removed under vacuum, to give the title compound as a crude product (78 mg, 72% yield), that was used in the next step without further purification. HPLC retention time: 5.30 min; MS: 347 (M+H).

SYNTHESIS OF EXAMPLES Example 1: 4-(4-methoxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5,5]undecan-3-one hydrochloride

Step 1. 2-chloro-N-((4-hydroxy-1-phenethylpiperidin-4-yl)methyl)-N-(4-methoxyphenyl) propanamide: To a solution of intermediate 2E (0.266 g, 0.78 mmol) and triethylamine (0.26 mL, 1.88 mmol) in dichloromethane (10 mL). 2-chloropropionyl chloride (0.11 mL, 1.17 mmol) was added dropwise at 0° C. Then, the reaction mixture was stirred at 0° C. for 2 h. NaHCO₃ sat solution was then added and the aqueous phase extracted with dichlorometane. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness to give the title compound (0.296 g, 88% yield). HPLC retention time: 4.05 min; MS: 431.1 (M+H).

Step 2, Title compound: A solution of the crude product obtained in step 1 (296 mg, 0.69 mmol) in THF (12 mL) was cooled to −78° C. using a dry ice/acetone bath. After addition of potassium tert-butoxide solution (1.03 mL, 1M in THF, 1.03 mmol), the reaction mixture was stirred at −30° C. for 2 h. Water was then added, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄, filtered and concentrated under vacuum to give the title compound (251 mg, 93% yield). HPLC retention time: 4.10 min; MS: 395.2 (M+H).

Step 3. Preparation of the hydrochloride salt: To a solution of the free base (50 mg, 0.13 mmol) in anhydrous diethyl ether (1 mL), HCl (2M solution in diethyl ether, 0.063 mL, 0.13 mmol) was added and the mixture was stirred at r.t. for 1 h. The solids were filtered and dried under vacuum to give the corresponding HCl salt (37 mg, 68% yield), HPLC retention time: 4.08 min; MS: 395.2 (M+H).

This method was used for the preparation of examples 2-22 using suitable starting materials:

Ret time MS EX Structure Chemical name (min) (M + H)  2

9-benzyl-4-(2- methoxyphenyl)-1-oxa- 4,9-diazaspiro[5.5] undecan-3-one 3.90 (method B) 367.1  3

9-benzyl-4-phenyl-1-oxa- 4,9- diazaspiro[5.5]undecan- 3-one hydrochloride 3.86 (method B) 337.1  4

4-(2-methoxyphenyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.91 (method B) 381.2  5

9-phenethyl-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.88 (method B) 351.2  6

9-benzyl-4-(3- methoxyphenyl)-1-oxa- 4,9- diazaspiro[5.5]undecan- 3-one 4.01 (method B) 367.2  7

2-benzyl-9-phenyl-6-oxa- 2,9-diazaspiro[4.5]decan- 8-one 3.77 323.1  8

4-(3-methoxyphenyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.86 381.2  9

2-methyl-9-phenethyl-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 4.10 365.2 10a

(R)-2-methyl-9-phenethyl- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one (1*) 4.10 365.2 10b

(S)-2-methyl-9-phenethyl- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one (1*) 4.10 365.2 11

2-(methoxymethyl)-9- phenethyl-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.85 395.2 12a

(S)-2-(methoxymethyl)-9- phenethyl-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one (2*) 3.85 395.2 12b

(R)-2-(methoxymethyl)-9- phenethyl-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one (2*) 3.85 395.2 13

2-ethyl-9-phenethyl-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 4.45 379.2 14

methyl 2-(3-oxo-9- phenethyl-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan- 2-yl)acetate hydrochloride 4.08 423.2 15

4-(3-methoxyphenyl)-2- methyl-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one hydrochloride 4.16 395.2 16

9-benzyl-2-methyl-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one hydrochloride 4.09 351.2 17

2-isopropyl-9-phenethyl- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one hydrochloride 4.96 393.2 18

2 2-dimethyl-3-phenethyl- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 5.03 379.2 19

2-((benzyloxy)methyl)-9- phenethyl-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one hydrochloride 4.95 471.2 20

2-methyl-4-(1-methyl-1H- pyrazol-3-yl)-9-phenethyl- 1-oxa-4,9- diazaspiro[5.5]undecan- 3-one hydrochloride 3.74 369.2 21

2-methylene-9-phenethyl- 4-phenyl-1-oxo-4,9- diazaspiro[5.5]undecan- 3-one (3*) 4.46 363.1 22

4-(2-fluorophenyl)-2- methylene-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one (3*) 4.53 381.1 Where indicated, the hydrochloride salts were prepared as described in example 1 1* Obtained by chiral preparative HPLC from previous example Column: Chiralpak IA: Temperature: ambient; Flow: 0.9 mL/min; Mobile phase: n-Heptane (IPA + 2% DEA) 95/5 v/v 2* Obtained by chiral preparative HPLC from previous example Column: Chiralpak ASH. Temperature: ambient; Flow: 0.8 mL/min; Mobile phase: n-Heptane/EtOH 90/10 v/v 3* Obtained as by-product under the reaction conditions when preparing the corresponding 2-methoxymethyl derivatives

Example 23: 2-methyl-9-(2-(5-nitropyridin-2-yl)ethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

Step 1: 2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one trifluoroacetate. To a solution of intermediate 3A (3.57 g, 9.90 mmol) in dichloromethane (35 mL), trifluoroacetic acid (7.8 mL, 99.0 mmol) was added, and the reaction mixture was refluxed for 5 h. The solvent was evaporated to dryness to give the title compound as a crude product (7.1 g, 53 wt %, quant yield), that was used in the following step without further purification. HPLC retention time: 1.94 min; MS: 26′ (M+H).

Step 2: 2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one. The crude product obtained in step 1 (0,519 g, 53 wt %. 0.72 mmol) was dissolved in dichloromethane and it was washed three times with 1M NaOH aqueous solution. The combined aqueous phases were back extracted with dichloromethane. The organic phases were combined, washed with water, dried over MgSO₄, filtered and concentrated under vacuum to give the title compound as a crude product (0.207 g, quant yield). HPLC retention time: 1.91 min; MS: 261 (M+H).

Step 3: Title compound: A solution of the compound obtained in step 2 (0.095 g, 0.365 mmol) and 3-nitro-6-vinylpyridine (prepared similarly as described in WO2009/32667 Ex 40.C) (0.071 g, 0.474 mmol) in isopropanol (1 mL) was heated at 140° C. under microwave irradiation for 15 min. The reaction mixture was allowed to cool to r.t. and the solvent was evaporated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (90 mg, 60% yield). HPLC retention time: 3.51 min; MS: 411.2 (M+H).

This method was used for the preparation of examples 24-32 using suitable starting materials

Ret time MS EX Structure Chemical name (min) (M + H) 24

4-(2-fluorophenyl)-2-methyl- 9-(2-(5-nitropyridin-2- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.61 429.2 25

4-(2-fluorophenyl)-2-methyl- 9-(2-(3-nitropyridin-2- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.62 429.2 26

2-methyl-4-phenyl-9-(2- (pyrimidin-2-yl)ethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 3.75 367.1 27

2-methyl-9-(2-(2- nitropyridin-3-yl)ethyl)-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.59 411.2 28

2-methyl-4-phenyl-9-(2-(4- (trifluoromethyl)pyridin-2- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.99 434.1 29

9-(2-(6-aminopyridin-2- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.04 381.2 30

9-(2-(4-aminopyridin-2- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspira[5.5]undecan-3- one hydrochloride 2.57 381.2 31

4-(2-fluorophenyl)-2-methyl- 9-(2-(6- (trifluoromethyl)pyridin-2- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride (*1) 4.22 452.2 32

9-(2-(2-aminopyridin-4- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one (*1) 2.92 381.1 Where indicated, the hydrochloride salts were prepared as described in example 1 *1 The reaction was carried out in butanol at 180° C.

Example 33: 2-methyl-4-phenyl-9-(2-(3-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[0.5]undecan-3-one hydrochloride

A solution of the crude product obtained in step 2 of example 23 (0.060 g, 0.231 mmol) and 3-trifluoromethyl-2-vinylpyridine (prepared similarly as described in Angewandte Chemie—International Edition, 2013, vol. 52, nb 37 p. 9755) (0.068 g. 0.393 mmol) in 2-methoxyethanol (1.1 mL) was heated at 120° C. in a sealed tube under argon for 1 day. The reaction mixture was allowed to cool to r.t. and the solvent was evaporated. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound as its free base (41 mg, 41% yield),

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 3.92 min; MS: 434.0 (M+H).

This method was used for the preparation of examples 34-50 using suitable starting materials:

Ret time MS EX Structure Chemical name (min) (M + H) 34

2-methyl-4-phenyl-9-(2-(5- (trifluoromethyl)pyridin-2- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.98 434.0 35

9-(2-(4-methoxypyridin-2- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.27 396.1 36

6-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)nicotinonitrile hydrochloride 3.30 391.0 37

9-(2-(3-chloropyridin-2- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.68 400.1 38

9-(2-(5-chloropyridin-2- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.72 400.1 39

4-(2-fluorophenyl)-2- isopropyl-9-(2-(2- nitropyridin-3-yl)ethyl)-1- oxa-4,9- diazaspiro[5.5]undecan-3- one 4.49 457.2 40

2-methyl-4-phenyl-9-(2-(2- (trifluoromethyl)pyridin-4- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.05 434.2 41

2-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)isonicotinonitrile 3.25 391.2 42

9-(2-(6-aminopyridin-2- yl)ethyl)-2-methyl-4-(4- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.05 450.2 43

2-methyl-9-(2-(2- nitropyridin-3-yl)ethyl)-4-(4- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.69 480.2 44

9-(2-(3-chloropyridin-2- yl)ethyl)-2-methyl-4-(4- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.76 469.1 45

9-(2-(3-chloropyridin-2- yl)ethyl)-2-methyl-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.99 483.2 46

9-(2-(3-chloropyridin-2- yl)ethyl)-4-((5-fluoropyridin- 2-yl)methyl)-2-methyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 3.46 433.1 47

9-(2-(3-fluoropyridin-2- yl)ethyl)-4-((5-fluoropyridin- 2-yl)methyl)-2-methyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 3.24 417.2 48

9-(2-(3-fluoropyridin-2- yl)ethyl)-2-methyl-4-(2- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.53 453.2 49

4-((5-fluoropyridin-2- yl)methyl)-2-methyl-9-(2-(6- (trifluoromethyl)pyridin-2- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.92 467.2 50

9-(2-(3-chloropyridin-4- yl)ethyl)-2-methyl-1-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.58 400.1 Where indicated, the hydrochloride salts were prepared as described in example 1

Example 51: 9-(2-fluorophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride

A mixture of the crude product obtained in step 1 of example 23 (0.326 g. 61 wt %, 0.534 mmol), 1-(2-bromoethyl)-2-fluorobenzene (0.075 mL, 0.534 mmol), sodium iodide (0.048 g, 0.321 mmol) and K₂CO₃ (0.369 g. 2.671 mmol) in acetonitrile (4 mL) was heated at 80° C. in a sealed tube overnight. Water was added, and the reaction mixture was extracted with ethyl acetate. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:9) to give the title compound as its free base (148 mg, 72% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 4.32 min: MS: 383.2 (M+H).

This method was used for the preparation of examples 52-148 using suitable starting materials:

Ret time MS EX Structure Chemical name (min) (M + H)  52

9-(4-methoxyphenethyl)-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.65 381.2  53

2-methyl-4-phenyl-9-(2- (thiophen-2-yl)ethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one 4.19 371.1  54

9-(3-fluorophenethyl)-2- methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.31 383.2  55

9-(4-fluorophenethyl)-2- methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.26 383.1  56

9-(2-(1H-pyrazol-1-yl)ethyl)- 2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.06 355.2  57

9-(2-methoxyphenethyl)-2- methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.18 395.2  58

2-methyl-4-phenyl-9-(2- (pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.12 366.2  59

2-methyl-4-phenyl-9- (tetrahydro-2H-pyran-4- yl)methyl)-4-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.21 359.2  60

2-methyl-4-phenyl-9-(3- phenylpropyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.29 379.2  61

2-methyl-9-(2-(4 methylthiazol-5-yl)ethyl-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.41 386.1  62

9-(2-(1H-indol-1-yl)ethyl)-2- methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.54 404.2  63

9-(2-(1H-benzo[d]imidazol-1- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.48 405.2  64

methyl 3-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)propanoate 3.11 347.1  65

2-methyl-9-(2- morpholinoethyl)-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one 2.74 374.2  66

2-methyl-9-(4- nitrophenethyl)-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one 4.26 410.2  67

2-methyl-9-(3- nitrophenethyl)-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one 4.20 410.2  68

2-methyl-9-(2- nitrophenethyl)-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one 4.18 410.1  69

9-(2-(1H-pyrrolo[2.3- b]pyridin-1-yl)ethyl)-2- methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.89 405.2  70

methyl 4-(2-(2-methyl-3-oxo- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)benzoate hydrochloride 4.12 423.2  71

2-(2-methyl-3-oxo-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)- N-phenylacetamide 3.88 394.2  72

2-methyl-9-(2-phenoxyethyl)- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.15 381.2  73

2-methyl-4-phenyl-9-(2- (pyridin-3-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.13 366.2  74

3-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)benzo[d]oxazol- 2(3H)-one hydrochloride 3.88 422.1  75

3-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)benzonitrile hydrochloride 3.95 390.2  76

4-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)benzonitrile hydrochloride 3.91 390.2  77

9-(2-(3,5-dimethyl-1H- pyrazol-1-yl)ethyl)-2-methyl- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.47 383.2  78

2-methyl-9-(2-morpholino-2- oxoethyl)-4-phenyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 2.8  388.2  79

9-(2-methoxyphenethyl)-4- (pyridin-2-ylmethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one 3.43 396.2  80

4-(2-fluorophenyl)-9- phenethyl-2-((tetrahydro-2H- pyran-4-yl)methylene)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one 4.62 465.2  81

4-(2-fluorophenyl)-9- isopentyl-2-methyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 4.00 349.2  82

9-(cyclopropylmethyl)-4-(2- fluorophenyl)-2-methyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.18 333.2  83

4-(2-fluorophenyl)-9-(3- methoxyphenethyl)-2-methyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.21 413.2  84

9-(2-(pyridin-2-yl)ethyl)-4- (pyridin-2-ylmethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one 2.54 367.2  85

4-(2-fluorophenyl)-9- phenethyl-2-(propan-2- ylidene)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 5.11 409.2  86

9-phenethyl-4-(pyridin-2- ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.37 366.2  87

4-benzyl-9-(2- methoxyphenethyl)-1-oxa- 4,9-diazaspiro[5.5]undecane dihydrochloride 4.80 381.2  88

2-methyl-9-phenethyl-4- (thiazol-4-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.04 372.1  89

4-(2-fluorophenyl)-9-(2-(6- fluoropyridin-2-yl)ethyl)-2- methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.60 402.2  90

12-phenyl-8-[2-(pyridin-2- yl)ethyl]-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 3.29 378.2  91

4-(2-fluorophenyl)-2-methyl- 9-(2-(6- (trifluoromethyl)pyridin-3- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one dihydrochloride 4.18 452.2  92

8-(3-nitrophenethyl)-12- phenyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 4.36 422.2  93

N-methyl-3-(2-(2-methyl-3- oxo-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)benzanesulfonamide 3.46 458.2  94

9-(2-(5-fluoropyridin-2- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.29 384.1  95

2-methyl-4-phenyl-9-(2- (thiazol-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.32 372.1  96

9-(2-(3-fluoropyridin-2- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.42 384.2  97

8-(2-oxo-2-phenylethyl)-12- phenyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 3.91 391.1  98

9-(2-(pyridin-2-yl)ethyl)-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.19 435.1  99

9-(2-oxo-2-phenylethyl)-4- ((5-(trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.87 448.1 100

N-methyl-3-(2-methyl-3-oxo- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)- N-phenylpropanamide hydrochloride 3.47 422.2 101

2-methyl-9-(2-(pyridin-2- yl)ethyl)-4-(4- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.22 435.2 102

9-(2-(6-methoxypyridin-2- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.77 396.2 103

9-(3-nitrophenethyl)-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 4.19 479.1 104

4-((6-aminopyridin-2- yl)methyl)-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one 3.27 381.2 105

4-((5-chloropyridin-2- yl)methyl)-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.93 400.1 106

tert-butyl (4-(2-(3-oxo-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)thiazol-2- yl)carbamate 4.100 556.2 107

N-methyl-4-(2-(2-methyl-3- oxo-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)benzenesulfonamide 3.39 458.0 108

4-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)benzenesulfonamide 3.17 444 109

12-(4-methoxybenzyl)-8- phenethyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one hydrochloride 4.55 421.1 110

2-methyl-9-(2-(3-nitro-1H- pyrazol-1-yl)ethyl)-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.49 400 111

9-(2-(6-methoxypyridin-3- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.64 396.2 112

2-methyl-4-phenyl-9-(2-(5- (trifluoromethyl)pyridin-3- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.01 434.2 113

9-(2-(6-chloropyridin-3- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.72 400.1 114

9-(2-(5-fluoropyridin-3- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.42 384.2 115

9-(2-(5-chloropyridin-3- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.27 400.2 116

tert-butyl (1-(2-(2-methyl-3- oxo-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)-1H-pyrazol-5- yl)carbamate 4.63 470.1 117

tert-butyl (4-(2-(4-(2- fluorophenyl)-2-isopropyl-3- oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)thiazol-2- yl)carbamate 4.86 533.3 118

tert-butyl (4-(2-(13-oxo-12- phenyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 8-yl)ethyl)thiazol-2- yl)carbamate 4.30 499.2 119

8-(3-nitrophenethyl)-12-{[5- (trifluoromethyl)pyridin-2- yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 4.59 505.2 120

tert-butyl (4-(2-(13-oxo-12- {[5-(trifluoromethyl)pyridin-2- yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 8-yl)ethyl)thiazol-2- yl)carbamate 4.51 582.2 121

tert-butyl (4-(2-(2-methyl-3- oxo-4-(4- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)thiazol-2- yl)carbamate 4.19 556.2 122

9-(2-isopropoxyethyl)-2- methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.47 347.2 123

6-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)picolinonitrile hydrochloride 3.47 391.1 124

2-methyl-9-(2-morpholino-2- oxoethyl)-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.17 471.2 125

9-(2-isopropoxyethyl)-2- methyl-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.81 430.2 126

9-(2-fluorophenethyl)-2- methyl-4-(4- trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride (5*) 4.35 452.2 127a

(S)-9-(2-fluorophenethyl)-2- methyl-4-(4- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride (6*) 4.22 452.2 127b

(R)-9-(2-fluorophenethyl)-2- methyl-4-(4- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride (6*) 4.22 452.2 128

2-methyl-9-(2-oxo-2- (piperidin-1-yl)ethyl)-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.79 469.2 129

2-methyl-9-(2-oxo-2- (piperidin-1-yl)ethyl)-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.49 386.2 130

9-(2-fluorophenethyl)-2- methyl-4-(2- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one dihydrochloride 4.41 452.2 131

2-methyl-4-phenyl-9-(2- (tetrahydro-2H-pyran-4- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride (1*) 3.17 373.2 132

9-(3-methoxyphenethyl)-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one (2*) 3.75 381.2 133

2-methyl-4-phenyl-9-(2- (pyridin-4-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride (2*) 3.10 366.1 134

4-(2-fluorophenyl)-2- (methoxymethyl)-9-(2- (pyridin-2-yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride (3*) 3.09 414.2 135

4-(2-fluorophenyl)-2- (methoxymethyl)-9-(2- methoxyphenethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one (3*) 4.09 443.2 136

9-(2-fluorophenethyl)-4-(2- fluorophenyl)-2- (methoxymethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride (3*) 4.17 431.2 137

4-(2-fluorophenyl)-2- isopropyl-9-(2- methoxyphenethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride (3*) 5.04 441.2 138

4-benzyl-9-(2-(pyridin-2- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecano hydrochloride (3*) 3.78 352.2 139

4-(2-fluorophenyl)-2-(propan- 2-ylidene)-9-(2-(pyridin-2- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one (3*) 3.99 410.1 140

tert-butyl (4-(2-(4-(2- fluorophenyl)-2-methyl-3- oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)thiazol-2- yl)carbamate (3*) 4.22 505.2 141

4-(2-fluorophenyl)-9-(2-(4- methylthiazol-5-yl)ethyl)-2- (propan-2-ylidene)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride (3*) 4.30 430.2 142

4-(2-fluorophenyl)-2-(3- methoxypropylidene)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one (3*) 4.53 439.2 143

ethyl 3-(2-(4-(2- fluorophenyl)-2-methyl-3- oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)benzoate (3*) 4.53 455.2 144

3-(2-methyl-3-oxo-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-9-yl)- N-phenylpropanamide hydrochloride (3*) (4*) 3.57 408.2 145

2-methyl-4-phenyl-9-(2- (pyridin-3-yloxy)ethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride (3*) (4*) 3.18 382.2 146

2-methyl-9-(2-(2- oxopyrrolidin-1-yl)ethyl)-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one (3*) (4*) 2.79 372.2 147

9-(2-(1H-pyrazol-4-yl)ethyl)- 2-methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one (3*) (4*) 2.74 355.2 148

8-(2-fluorophenethyl-12-(4- methoxybenzyl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 4.64 439.2 Where indicated, the hydrochloride salts were prepared as described in example 1 1* Dioxane was used instead of ACN 2* DMF was used instead of ACN 3* DIPEA was used instead of triethylamine 4* Dichloromethane was used instead of ACN 5* Alternatively obtained following the method described in Example 218 6* Obtained by chiral preparative HPLC from previous example Column Chiralpak ASH; Temperature ambient; Flow: 0.8 mL/min; Mobile phase: n-Heptane/(EtOH + 0.33% DEA) 85/15 v/v

Example 149: 2-phenethyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one hydrochloride

Step 1: 9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one: A mixture of example 7 (0.124 g, 0.385 mmol) and palladium (12 mg, 10% wt on charcoal) in methanol (10 mL) was stirred at r.t. under 3 bars of H₂ for 3 days. The solids were filtered off and the solvent was removed under vacuum. The residue was submitted to a second hydrogenation cycle, using fresh catalyst and a drop of AcOH, stirring the mixture at r.t. under 3 bars of H₂ overnight. The solids were filtered off and the solvent was removed under vacuum, to give the title compound as a crude product that was used without further purification (96 mg). HPLC retention time: 1.16 min: MS: 233.2 (M+H).

Step 2: Title compound: A mixture of the crude product obtained in step 1 (95 mg, 0.385 mmol). (2-bromoethyl)benzene (0.056 mL, 0.41 mmol), and DIPEA (0.184 mL, 1.06 mmol) in 1,4-dioxane (3 mL) was heated at 95° C. in a sealed tube overnight. Water was added, and the reaction mixture was extracted with ethyl acetate. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound as its free base (23 mg, 18% yield for the 2 steps).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 3.90 min: MS: 337.1 (M+H).

Example 150: 9-(2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro [5.5]undecan-3-one

A mixture of the crude product obtained in step 2 of example 23 (0.200 g, 0.768 mmol), 2-phenyloxirane (0.088 mL, 0.768 mmol) and montmorillonite K (0.020 g) was stirred at r.t. for 1 h. Ethyl ether (0.4 mL) was added and the mixture was stirred at r.t. overnight. Additional diethyl ether was added, and the solids were filtered off and washed with dichloromethane. The filtrate was dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (75 mg, 25% yield) as a mixture of 4 diastereomers. HPLC retention time: 3.73 min: MS: 381.2 (M+H).

Examples 151a, 151b, 151c, 151d

Example 150 was purified by chiral preparative HPLC and the four diastereomers were separated, yielding (R)-9-((R)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (Example 151a), (R)-9-((S)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (Example 151b), (S)-9-((S)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5] undecan-3-one (Example 151c) and (S)-9-((R)-2-hydroxy-2-phenylethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (Example 151d).

Conditions of Chiral HPLC: Column: Chiralcel ODH

Temperature: ambient Flow: 0.4 mL/min Mobile phase: n-Heptane/IPA 5050 v/v

Example 152: 4-benzyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride

To a solution of intermediate 3J (0.250 g, 0.867 mmol) in dry DMF (6 mL), NaH (69 mg, 60 wt % in mineral oil, 1.734 mmol) was added. The reaction mixture was stirred at r.t. for 30 min, then benzyl bromide (0.103 mL, 0.867 mmol) was added and the resulting mixture was stirred at r.t. for 4 h. and finally 5 h at 50° C. Water was added to the reaction mixture and it was extracted with ethyl acetate. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:9) to give the title compound as its free base (186 mg, 56% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 4.33 min; MS: 379.2 (M+H).

This method was used for the preparation of examples 153-187 using suitable starting materials:

Ret time MS EX Structure Chemical name (min) (M + H) 153

4-benzyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 3.99 365.2 154

4-(2-fluorobenzyl)-2-methyl- 9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.43 397.2 155

4-(3-fluorobenzyl)-2-methyl- 9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.45 397.2 156

2-methyl-4,9-diphenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one 4.41 393.2 157

2-methyl-9-phenethyl-4- (pyridin-2-ylmethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 3.58 380.2 158

4-(4-fluorobenzyl)-2-methyl- 9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.39 397.2 159

2-methyl-9-phenethyl-4- (pyridin-3-ylmethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 3.48 380.2 160

2-methyl-9-phenethyl-4- (thiazol-2-ylmethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 3.76 386.2 161

2-methyl-9-phenethyl-4- (thiazol-5-ylmethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 3.62 386.1 162

2-methyl-9-phenethyl-4- (pyridin-4-ylmethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one 3.51 380.2 163

2-methyl-9-phenethyl-4- ((tetrahydro-2H-pyran-4- yl)methyl)-1-oxa-4- diazaspiro[5.5]undecan-3- one hydrochloride 3.64 387.2 164

2-methyl-9-phenethyl-4- (thiazol-4-ylmethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one 3.57 386.1 165

9-phenethyl-4-(pyridin-4- ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.23 366.2 166

4-(3-methoxybenzyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.09 395.2 167

9-phenethyl-4-(thiazol-4- ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.35 372.1 168

4-((1-benzyl-1H-imidazol-2- yl)methyl)-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.91 445.2 169

9-phenethyl-4-(2-(pyridin-2- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.37 380.2 170

2-methyl-4-(2-morpholino-2- oxoethyl)-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.21 416.2 171

2-methyl-4-((1-methyl-1H- pyrazol-3-yl)methyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.51 383.2 172

2-methyl-4-((1-methyl-1H- imidazol-2-yl)methyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.39 383.2 173

4-((3-fluoropyridin-2- yl)methyl)-2-methyl-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.82 398.2 174

2-methyl-9-phenethyl-4-((6- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,3- diazaspiro[5.5]undecan-3- one hydrochloride 4.53 440.2 175

2-methyl-9-phenethyl-4-(2- (pyridin-3-yl)ethyl)-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one dihydrochloride 3.58 394.2 176

4-((5-fluoropyridin-2- yl)methyl)-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.61 384.2 177

9-phenethyl-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.18 434.2 178

9-phenethyl-4-(2-(pyridin-4- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.30 380.2 179

4-(3-nitrobenzyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 4.02 410.1 180

12-(3-methoxypropyl)-8- phenethyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one hydrochloride 3.82 373.2 181

3-[13-oxo-8-phenethyl-4- oxa-8,12- diazadispiro[2.1.5.3]tridecan- 12-yl]propanenitrile hydrochloride 3.68 354.2 182

N,N-dimethyl-3-[13-oxo-8- phenethyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 12-yl]propanamide hydrochloride 3.50 400.2 183

4-(7-hydroxy-2- methylpropyl)-2-methyl-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.43 361.2 184

12-(2-methoxyethyl)-8- phenethyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one hydrochloride 3.72 359.1 185

12-(2-((tetrahydro-2H- pyran-2-yl)oxy)ethyl)-8- phenethyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 4.28 429.2 186

methyl 3-(13-oxo-8- phenethyl-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 12-yl)propanoate 3.84 387.2 187

8-phenethyl-12-{[5- (trifluoromethyl)pyridin-2- yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one dihydrochloride 4.56 460.2 Where indicated, the hydrochloride salt ere prepared as described in example 1.

Example 188: 9-benzyl-4-(4-fluorophenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride

A mixture of intermediate 3K (112 mg, 0.430 mmol). K₃PO₄ (152 mg, 0.717 mmol), CuI (0-7 mg, 0.004 mmol), trans-1,2-cyclohexanediamine (0.004 mL, 0.036 mmol) and 1-fluoro-4-iodobenzene (0.41 mL, 0.359 mmol) in dry 1,4-dioxane (1 mL) was heated under an argon atmosphere at 110° C. overnight. The reaction mixture was allowed to cool to r.t., and dichloromethane and 1M NaOH aqueous solution were added. The phases were separated and the aqueous phase was back extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO₄ and concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound as its free base (68 mg, 53% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 3.82 min; MS: 355.1 (M+H).

This method was used for the preparation of examples 189-217 using suitable starting materials:

Ret time MS EX Structure Chemical name (min) (M + H) 189

4-(2-fluorophenyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.88 369.1 190

4-(4-fluorophenyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.85 369.1 191

4-(3-fluorophenyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.95 369.1 192

4-(2-fluorophenyl)-2-methyl- 9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.28 383.2 193

4-(2-chlorophenyl)-2- methyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 4.43 399.1 194

2-methyl-9-phenethyl-4- (pyridin-3-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.52 366.2 195

2-methyl-9-phenethyl-4- (pyrazin-2-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.86 367.1 196

2-methyl-9-phenethyl-4- pyridin-2-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.96 366.2 197

ethyl 3-(2-methyl-3-oxo-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-4- yl)benzoate hydrochloride 4.56 437.2 198

3-(2-methyl-3-oxo-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-4- yl)benzonitrile hydrochloride 4.18 390.2 199

2-methyl-4-(3-nitrophenyl)- 9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 4.39 410.2 200

2-methyl-4-(1-methyl-1H- indazol-3-yl)-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.40 419.2 201

2-methyl-4-(1-methyl-1H- indazol-6-yl)-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.00 419.2 202

4-(benzo[d][1.3]dioxol-5-yl)- 2-methyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 4.18 409.2 203

4-(benzo[d]thiazol-6-yl)-2- methyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one 4.05 422.2 204

4-(benzo[d]thiazol-2-yl)-2- methyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 5.27 422.1 205

2-methyl-9-phenethyl-4- (pyridin-4-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.69 366.2 206

4-(2-methoxyphenyl)-2- methyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 4.17 395.2 207

2-methyl-9-phenethyl-4-(6- (trifluoromethyl)pyridin-2-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 5.10 434.2 208

4-(3-fluoropyridin-2-yl)-2- methyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one 3.92 384.2 209

2-methyl-9-phenethyl-4- (thiazol-2-yl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.43 372.1 210

2-methyl-4-(1-methyl-1H- pyrazol-4-yl)-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one 3.61 369.2 211

4-(6-methoxypyridin-2-yl)-2- methyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 4.62 396.2 212

2-methyl-9-phenethyl-4-(6- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.52 434.2 213

4-(2-fluoropyridin-3-yl)-2- methyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one 3.90 384.2 214

2-methyl-9-phenethyl-4-(4 (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.23 434.2 215

2-methyl-9-phenethyl-4-(2- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.27 434.2 216

4-(5-fluoropyridin-3-yl)-2- methyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one hydrochloride 3.85 384.2 217

2-methyl-9-phenethyl-4-(5- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.38 434.2 Where indicated, the hydrochloride salts were prepared as described in example 1

Example 218:2-methyl-9-phenethyl-4-(3-(trifluoromethyl)pyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

A mixture of intermediate 3J (0.070 g, 0.243 mmol), CS₂CO₃ (0.103 g, 0.534 mmol), tris(dibenzylideneacetone)dipalladium(0) (11 mg, 0.012 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (12 mg, 0.021 mmol) and 2-bromo-3-(trifluoromethyl)pyridine (0.066 g, 0.291 mmol) in dry 1,4-dioxane (4 mL) was heated under an argon atmosphere at 110° C. overnight. The reaction mixture was allowed to cool to r.t. the solids were filtered off and it was concentrated to dryness. Additional reagents and solvent were added and the reaction cycle was repeated to get the reaction to completion. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (33 mg, 33% yield). HPLC retention time: 4.19 mm; MS: 434.2 (M+H),

This method was used for the preparation of examples 219-223 using suitable starting materials:

Ret time MS EX Structure Chemical name (min) (M + H) 219

8-(2-fluorophenethyl)-12-(2- (trifluoromethyl)pyridin-3-yl)- 4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 4.46 464.2 220

8-(2-fluorophenethyl)-12-(3- (trifluoromethyl)pyridin-2-yl)- 4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one hydrochloride 4.49 464.2 221

9-(2-fluorophenethyl)-2- methyl-4-(3- (trifluoromethyl)pyridin-2-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 4.36 452.2 222a

(R)-9-(2-fluorophenethyl)-2- methyl-4-(3- (trifluoromethyl)pyridin-2-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one (1*) 4.33 452.2 222b

(S)-9-(2-fluorophenethyl)-2- methyl-4-(3- (trifluoromethyl)pyridin-2-yl)- oxa-4,9- diazaspiro[5.5]undecan-3- one (1*) 4.33 452.2 223

8-(2-fluorophenethyl)-12-(4- (trifluoromethyl)pyridin-3-yl)- 4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one hydrochloride 4.43 464.2 Where indicated, the hydrochloride salts were prepared as described in example 1 1* Obtained by chiral preparative HPLC from previous example: Column: Chiralpax ASH, Temperature: ambient; Flow: 0.8 mL/min; Mobile phase: n-Heptane/(EtOH+ 0.33% DEA) 85/15 v/v

Example 224: 12-(2-fluorophenyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one

To a suspension of trimethylsulfoxonium iodide (0,054 g, 0.426 mmol) and NaH (0.017 g, 60 wt % in mineral oil, 0.426 mmol) in DMSO (1 mL), a solution of example 22 (0,054 g. 0.142 mmol) in DMSO (1 mL) was added dropwise. The reaction mixture was stirred at r.t. for 30 min and heated at 50° C. for 2 h. After cooling to r.t., ice was slowly added, and the reaction mixture was extracted three times with ethyl acetate. The organic phases were combined, washed with water, dried over MgSO₄ and concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (0,021 g, 37% yield). HPLC retention time: 4.47 min; MS: 395.2 (M+H).

This method was used for the preparation of example 225 using suitable starting materials:

Ret time MS EX Structure Chemical name (min) (M + H) 225

8-phenethyl-12-phenyl-4- oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 4.35 377.2

Example 226: 9-(3-aminophenethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

A mixture of example 67 (0.248 g, 0.606 mmol) and palladium (26 mg, 10% wt on charcoal) in methanol (5 mL) was stirred at r.t. under 4 bars of H₂ overnight. Then, the solids were filtered off, and the solvent was removed under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (0.160 g, 70% yield). HPLC retention time: 3.33 min; MS: 380.2 (M+H),

This method was used for the preparation of examples 227-240 starting from the corresponding examples described above:

Ret time MS EX Structure Chemical name (min) (M + H) 227

4-(3-aminophenyl)-2- methyl-9-phenethyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 3-one 3.66 380.2 228

9-(4-aminophenethyl)-2- methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.18 380.2 229

9-(2-aminophenethyl)-2- methyl-4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.60 380.2 230

9-(2-(5-aminopyridin-2- yl)ethyl)-4-(2-fluorophenyl)- 2-methyl-4-oxa-4,9- diazaspiro[5.5]undecan-3- one 2.83 399.2 231

8-(3-aminophenethyl)-12- phenyl-4-oxa-8,12- diazadispiro[5.5]tridecan- 13-one 3.51 392.2 232

9-(2-(3-aminopyridin-2- yl)ethyl)-4-(2-fluorophenyl)- 2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 2.82 399.2 233

4-(3-aminobenzyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.42 380.2 234

9-(2-(2-aminopyridin-3- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.19 381.2 235

9-(3-aminophenethyl)-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.37 449.2 236

9-)2-(5-aminopyridin-2- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 2.73 381.2 237

9-(2-(3-amino-1H-pyrazol-1- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 2.64 370.2 238

9-(2-(2-aminopyridin-3- yl)ethyl)-4-(2-fluorophenyl)- 2-isopropyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one dihydrochlonde 4.00 427.2 239

8-(3-aminophenethyl)-12- ([5-(trifluoromethyl)pyridin- 2-yl]methyl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 3.83 475.2 240

9-(2-(2-aminopyridin-3- yl)ethyl)-2-methyl-4-(4- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.15 450.2 Where indicated, the HCI salts were prepared as described in example 1

Example 241: N-(4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide hydrochloride

To a solution of example 228 (0-070 g 0.184 mmol) and triethylamine (0.039 mL, 0.277 mmol) in dichloromethane (1.5 mL), acetyl chloride (0.014 mL, 0,203 mmol) was added dropwise at r.t. The reaction mixture was stirred at r.t. overnight. NaHCO₃ sat solution was added and the aqueous phase was extracted with dichlorometane. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound as its free base (27 mg, 35% yield). HPLC retention time: 3.20 min; MS: 422.2 (M+H).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 3.82 min; MS: 355.1 (M+H).

This method was used for the preparation of examples 242-255 starting from the corresponding examples described above:

Ret time MS EX Structure Chemical name (min) (M + H) 242

N-(3-(2-methyl-3-oxo-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-4- yl)phenyl)acetamide 3.61 422.2 243

N-(3-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 3.30 422.2 244a

(S)-N-(3-(2-(2-methyl-3-oxo- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide hydrochloride (1*) 3.27 422.2 244b

(R)-N-(3-(2-(2-methyl-3-oxo- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide hydrochloride (1*) 3.29 422.2 245

N-(2-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 3.27 422.2 246

N-[3-(2-{13-oxo-12-phenyl- 4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 8- yl}ethyl)phenyl]acetamide 3.46 434.2 247

N-(3-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)phenyl) isobutyramide 3.81 450.2 248

1,1-dimethyl-3-(3-(2-(2- methyl-3-oxo-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)urea (2*) 3.29 451.2 249

N-(3-((3-oxo-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-4 yl)methyl)phenyl)acetamide hydrochloride 3.48 422.2 250

N-(2-(2-(4-(2-fluorophenyl)- 2-methyl-3-oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-3- yl)acetamide 2.70 441.2 251

N-(3-(2-(3-oxo-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide hydrochloride 3.34 491.2 252

N-(6-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-3- yl)acetamide 2.86 423.2 253

N-(2-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-4- yl)acetamide hydrochloride 2.83 423.1 264

N-(6-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-2- yl)acetamide hydrochloride 3.11 423 265

N-(4-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)pyridin-2- yl)acetamide hydrochloride 3.07 423 Where indicated, the HCI salts were prepared as described in example 1 1* Obtained by chiral preparative HPLC from previous example: Column: Chiralpak ASH, Temperature: ambient, Flow 0.6 mL/min Mobile phase: n-Heptane/EtOH 89/20 v/v 2* Dimethylcarbamic chloride was used instead of acetyl chloride

Example 256: N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)methanesulfonamide

To a solution of example 226 (0.091 g, 0.240 mmol) and triethylamine (0.050 mL, 0.360 mmol) in dichloromethane (2 mL), methanesulfonyl chloride (0.020 mL, 0.264 mmol) was added dropwise at r.t. The reaction mixture was stirred at r.t. overnight. NaHCO₃ aqueous sat. solution was added and the aqueous phase was extracted with dichlorometane. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (18 mg, 16% yield). HPLC retention time: 3.47 min; MS: 458.2 (M+H).

This method was used for the preparation of examples 257-260 starting from the corresponding examples described above:

Ret time MS EX Structure Chemical name (min) (M + H) 257

N-(2-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)methane- sulfonamide 4.05 458.2 258

N-(4-(2-(2-methyl-3-oxo-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)methane- sulfonamide 3.39 458.2 259

N-(3-((3-oxo-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-4- yl)methyl)phenyl)methane- sulfonamide hydrochloride 3.60 458.1 260

N-[3-(2-(13-oxo-12-phenyl- 4-oxa-8,12- diazadispiro[2.1.5.3] tridecan-8- yl)ethyl)phenyl]methane- sulfonamide hydrochloride 3.56 470.1 Where indicated, the hydrochlonde salts were prepared as described in example 1

Example 261: N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)propane-2-sulfonamide hydrochloride

To a solution of 2-propanesulfonyl chloride (0.024 mL, 0,217 mmol) in dichloromethane (0.15 mL), LiBr (19 mg, 0,217 mmol), pyridine (0.088 mL, 109 mmol) and example 226 (0.075 g, 0.198 mmol) were sequentially added and the reaction mixture was stirred at r.t. overnight. An additional load of reagents was added and the reaction mixture was again stirred at r.t. overnight to get the reaction to completion. It was then evaporated to dryness, water was added to the residue and it was extracted with dichloromethane. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound as its free base (21 mg, 22% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 3.81 min; MS: 486.2 (M+H).

Example 262: 1-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)urea

To a solution of example 226 (0.100 g, 0.263 mmol) in a mixture of acetic acid:water 1:1.5 (3 mL), potassium cyanate (0.032 g. 0.395 mmol) was added, and the reaction mixture was stirred at r.t, overnight. NaHCO₃ aqueous sat solution was added, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined, washed with water, dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (0.046 g. 53% yield). HPLC retention time: 3.08 min: MS: 423.2 (M+H).

This method was used for the preparation of example 263 starting from the corresponding example described above:

Ret time MS EX Structure Chemical name (min) (M + H) 263

(3-[2-(13-oxo-12-([5- trifluoromethyl)pyridin-2- yl]methyl)-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 8-yl)ethyl]phenyl)urea dihydrochloride 3.42 518.2 Where indicated, the hydrochloride salts were prepared as described in example 1

Example 264: 1-(6-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)pyridin-2-yl)urea

To a solution of example 29 (0.050 g. 0.131 mmol) in dichloromethane (1.1 mL), benzoyl isocyanate (0.290 g. 0.197 mmol) was added under nitrogen atmosphere and the reaction mixture was heated to reflux overnight. The mixture was concentrated to dryness and the residue was dissolved in ethanol (8.3 mL). K₂CO₃ (0.027 g, 0.197 mmol) was added and after stirring at 80° C. for 1 h the solvent was evaporated. Water was added to the residue, and the mixture was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, C₁₁, gradient aqueous NH₄HCO₃ pH 8 to acetonitrile, to give the title compound (22 mg, 40% yield). HPLC retention time: 2.96 min; MS 424.1 (M+H).

Example 265: N-[3-(2-{2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl}ethyl)phenyl]aminosulfonamide

To a solution of chlorosulfonyl isocyanate (0.22 mL, 1.48 mmol) in acetonitrile (15 mL) cooled at 0° C., water (0.042 mL, 2.32 mmol) was added and the mixture was stirred at r.t. for 3 h. 1.9 mL of the resulting solution were cooled to 0° C., then pyridine (0.034 mL, 0.422 mmol) and a solution of example 226 (0.080 g, 0.211 mmol) in acetonitrile (1.5 mL) were added. The reaction mixture was stirred at r.t. overnight. Water was then added and the mixture was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (9 mg, 9% yield) HPLC retention time: 3.23 min; MS: 459.0 (M+H).

Example 266: 3-(2-2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)benzamide

To a solution of example 75 (0.149 g, 0,383 mmol) in dichloromethane (0.5 mL) cooled with an ice/water bath, concentrated sulfuric acid (0.28 ml, 5.28 mmol) was added dropwise, maintaining the temperature below 20° C. The reaction mixture was then stirred at r.t. overnight, after which it was cooled to 0° C. Water was added dropwise, the mixture was diluted with dichloromethane and the phases were separated. The aqueous phase was washed with dichloromethane, basified with aqueous ammonia to pH 10 and extracted with dichloromethane. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (0.034 g. 22% yield), HPLC retention time: 3.07 min: MS; 4082 (M+H).

Example 267: 4-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)benzoic acid

To a solution of example 70 (0.066 g, 0.151 mmol) in a mixture of THF/methanol 1:1 (3.4 mL), 1M NaOH aqueous solution (0.33 mL, 0.33 mmol) was added. The reaction mixture was stirred at r.t. overnight. The solvent was removed under vacuum, the pH was adjusted to 5 by addition of 1M HCl aqueous solution and the mixture was extracted with dichloromethane. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness to give the title compound (0.048 g, 77% yield). HPLC retention time: 2.42 min; MS: 409.2 (M+H).

This method was used for the preparation of examples 268-270 starting from the corresponding examples described above:

Ret time MS EX Structure Chemical name (min) (M + H) 268

3-(2-methyl-3-oxo-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-4- yl)benzoic acid 2.91 409.2 269

3-(2-methyl-3-oxo-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)propanoic acid (*1) 1.81 333.1 270

2-(3-oxo-9-phenethyl-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecan-2- yl)acetic acid hydrochloride (*2) 2.72 409.2 Where indicated, the hydrochloride salts were prepared as described in example 1 *1. LiOH was used instead of NaOH *2. Potassium carbonate was used instead of NaOH

Example 271: N,N-dimethyl-3-(2-methyl-3-oxo-9-phenethyl-1-oxa-4,9-diazaspiro [5.5]undecan-4-yl)benzamide hydrochloride

To a solution of example 268 (0.047 g, 0,115 mmol) in dichloromethane (4 mL), dimethylamine solution (0.173 mL, 2M in THF, 0.345 mmol), 1-hydroxybenzotriazole (0.017 g, 0.127 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0,022 g, 0.115 mmol) and triethylamine (0.053, 0.380 mmol) were added. The reaction mixture was stirred at r.t. overnight, then additional dimethylamine solution (0.173 mL, 2M in THF, 0.345 mmol), 1-hydroxybenzotriazole (0.017 g. 0.127 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.022 g, 0.115 mmol) and triethylamine (0.053, 0.380 mmol) were added. The reaction mixture was stirred at r.t, for an additional day. Water was added to the reaction mixture and it was extracted with dichloromethane. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:9) to give the title compound as its free base (25 mg, 46% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 3.73 min; MS: 436.2 (M+H).

This method was used for the preparation of examples 272-274 starting from the corresponding examples described above:

Ret time MS EX Structure Chemical name (min) (M + H) 272

N,N-dimethyl-2-(3-oxo-9- phenethyl-4-phenyl-1-oxa- 4,9-diazaspiro[5.5]undecan- 2-yl)acetamide hydrochloride 3.68 436.2 273

N,N-dimethyl-4-(2-(2- methyl-3-oxo-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)benzamide hydrochloride 3.35 436.2 274

N-methyl-4-(2-(2-methyl-3- oxo-4-phenyl-1-oxa-4,9- diazospiro[5.5]undecan-9- yl)ethyl)benzamide hydrochloride 3.12 422.2

Example 275: N-methyl-3-[13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-12-yl]propanamide hydrochloride

To a solution of example 186 (0.052 g, 0.135 mmol) in methanol (13 mL), methylamine solution (0.33 mL, 33% in ethanol. 2.69 mmol) was added. The reaction mixture was stirred at 100° C. in a sealed tube overnight. The residue obtained after concentration to dryness, was purified by flash chromatography, silica gel gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound as its free base (0.040 g. 77% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 3.31 min: MS: 386.2 (M+H).

This method was used for the preparation of example 276 starting from the corresponding example described above:

Ret time MS EX Structure Chemical name (min) (M + H) 276

3-(2-(4-(2-fluorophenyl)-2- methyl-3-oxo-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)-N- methylbenzamide hydrochloride 3.25 440.2

Example 277: 842-hydroxy-2-phenylethyl)-12-phenyl-4-oxa-8,12-diazadispiro [2.1.5.3]tridecan-13-one

To a solution of example 97 (0.050 g, 0.128 mmol) in methanol (0.2 mL) cooled at 0° C., NaBH₄ (10 mg, 0.256 mmol) was added. The reaction mixture was stirred at r.t. for 2 h, and then the solvent was evaporated. NaHCO₃ sat solution was added and it was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) and then the product was purified again by flash chromatography. Ca, gradient aqueous NH₄HCO₃ (pH 8) to acetonitrile, to give the title compound (0.014 g, 28% yield). HPLC retention time: 3.94 min; MS: 393.2 (M+H).

This method was used for the preparation of example 278 starting from the corresponding example described above:

Ret time MS EX Structure Chemical name (min) (M + H) 278

9-(2-hydroxy-2-phenylethyl)- 4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 2.72 450.2

Example 279:12-(3-hydroxypropyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one hydrochloride

To a solution of example 186 (0.052 g, 0.128 mmol) in methanol (0.2 mL) cooled at 0° C., LiBH₄ (10 mg, 0.256 mmol) was added. The reaction mixture was stirred at r.t. overnight, and then the solvent was evaporated. NaHCO₃ aqueous sat, solution was added and the mixture was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄ filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound as its free base (0.023 g, 48% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 3.43 min; MS: 359.2 (M+H).

Example 280: 9-(2-(6-aminopyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

Step 1: 9-(2-(6-((diphenylmethylene)amino)pyridin-3-yl)ethyl)-2-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one. A mixture of example 113 (0.117 g, 0.284 mmol), sodium tert-butoxide (0.038 g, 0.398 mmol), tris(dibenzylideneacetone)dipalladium(0) (3 mg, 0.011 mmol), 2,2-bis(diphenylphosphino)-1,1′-binaphthalene (14 mg, 0.023 mmol) and benzophenone imine (0.062 g, 0.341 mmol) in dry toluene (3 mL) was heated in a sealed tube under an argon atmosphere at 100° C. for 2 days. The reaction mixture was cooled to r.t., NaHCO₃ aqueous sat. solution was added and it was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄ and concentrated under vacuum to give the title compound as a crude product, that was used in the following step without further purification. HPLC retention time: 4.74 min; MS: 545 (M+H).

Step 2: Title compound. A solution of the crude product obtained in step 1 in a 2:1 mixture of THF/10% HCl aqueous solution (6 mL) was stirred at r.t. overnight. 1M NaOH aqueous solution was added until pH >10 and the reaction mixture was extracted with ethyl acetate. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:9) to give the title compound (0.049 g. 45% yield for the two steps). HPLC retention time: 2.89 min; MS: 381.2 (M+H).

Example 281: 4-(2-fluorophenyl)-9-(2-(2-hydroxyethoxy)phenethyl)-2-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

A solution of example 297 (0.065 g, 0.152 mmol) ethylene carbonate (0.015 mL, 0.229 mmol) and K₂CO₃ (0.042 g. 0.305 mmol) in DMF (0.8 mL) was stirred at 110° C. in a sealed tube overnight. Water was added and the reaction mixture was extracted with ethyl acetate. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (39 mg, 55% yield). HPLC retention time: 4.45 min; MS: 471.3 (M+H).

This method was used for the preparation of example 282 starting from the corresponding example described above:

Ret time MS EX Chemical name (min) (M + H) 282

4-(2-fluorophenyl)-9-(3-(2- hydroxyethoxy)phenethyl)- 2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 3.54 443.2 The hydrochloride salt was prepared as described in example 1.

Example 283: 2-(hydroxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro [5.5]undecan-3-one

A mixture of example 19 (free base) (153 g, 3.26 mmol) and palladium hydroxide (306 mg, 20% wt on charcoal) in a mixture of THF/AcOH 9:1 (15 mL) was heated at 50° C. under 3 bars of H₂ overnight. The solids were filtered off and the solvent was evaporated to dryness. This hydrogenation cycle was repeated 3 times adding fresh catalyst each time until reaction completion. Finally, the solids were filtered off and the solvent was removed under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:9) to give the title compound (0.657 g, 53% yield). HPLC retention time: 3.44 mm; MS: 3812 (M+H).

Example 284: 4-((1H-imidazol-2-yl)methyl)-9-phenethyl-1-oxa-4,9-diazaspiro [5.5]undecan-3-one hydrochloride

A mixture of example 168 (free base) (0.051 g, 0.115 mmol), palladium (10 mg, 10% wt on charcoal) and some drops of AcOH in MeOH (2 mL) was heated at 65° C. under 5 bars of H₂ overnight. This hydrogenation cycle was repeated 3 times adding fresh catalyst and some drops of AcOH each time and heating at 65° C. under 3 bars of Hz until reaction completion. Finally, the solids were filtered off and the solvent was removed under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound as its free base (0.012 g, 30% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 2.90 min: MS: 355.2 (M+H).

Example 285: 9-benzyl-4-(2-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

To a solution of example 2 (0.119 g, 0.325 mmol) in dichloromethane (5 mL), boron tribromide solution (0.97 mL, 1M in dichloromethane, 0.97 mmol) was added dropwise at −78° C. The reaction mixture was allowed to warm to −40° C. over 2 h. Then, 8M NaOH aqueous solution was added until pH 12 and the reaction mixture was extracted with dichloromethane. The organic phases were combined, washed with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:9) to give the title compound (0.040 g, 35% yield). HPLC retention time (method B): 3.43 min; MS: 353.1 (M+H).

This method was used for the preparation of examples 286-302 starting from the corresponding examples described above:

Ret time MS EX Structure Chemical name (min) (M + H) 286

4-(2-hydroxyphenyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.50 (method B) 367.2 287

9-benzyl-4-(3- hydroxyphenyl)-1-oxa- 4,9-diazaspiro[5.5] undecan-3-one 3.39 (method B) 353.1 288

4-(3-hydroxyphenyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.77 367.2 289

9-(2-hydroxyphenethyl)- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.69 367.1 290

9-(4-hydroxyphenethyl)- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 2.91 367.1 291

9-(3-hydroxyphenethyl)- 4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.04 367.1 292

4-(2-(4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 9-yl)ethyl)phenol 3.75 353.2 293

4-(4-hydroxyphenyl)-2- methyl-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.59 381.2 294

4-(3-hydroxyphenyl)-2- methyl-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.67 381.2 295

9-(2-hydroxyphenethyl)- 2-methyl-4-phenyl-1-oxa- 4,9- diazaspiro[5.5]undecan- 3-one 4.09 381.2 296

4-(2-hydroxyphenyl)-2- methyl-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.78 381.2 297

4-(2-fluorophenyl)-9-(2- hydroxyphenethyl)-2- isopropyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 4.95 427.2 298

4-(2-fluorophenyl)-9-(3- hydroxyphenethyl)-2- methyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.49 399.2 299

2-(2-(4-benzyl-1-oxa-4,9- diazaspiro[5.5]undecan- 9-yl)ethyl)phenol 5.01 367.2 300

9-(2-hydroxyphenethyl)- 4-(pyridin-2-ylmethyl)-1- oxa-4,9- diazaspiro[5.5]undecan- 3-one hydrochloride 3.31 382.2 301

4-(2-fluorophenyl)-2- (hydroxymethyl)-9-(2- hydroxyphenethyl)-1-oxa- 4,9- diazaspiro[5.5]undecan- 3-one 3.51 415.2 302

4-(2-fluorophenyl)-2-(3- hydroxypropyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan- 3-one 3.82 427.2 Where indicated, the hydrochloride salts were prepared as described in example 1

Example 303: 9-(2-(2-aminothiazol-4-yl)ethyl)-4-(2-fluorophenyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

To a solution of example 140 (0.067 g, 0.13 mmol) in dichlormethane (0.5 mL) trifluoroacetic acid (0.1 mL, 1.32 mmol) was added. The reaction mixture was stirred at r.t. overnight and then it was concentrated to dryness. The residue was taken into water and dichloromethane, and the pH was adjusted to basic with 1N NaOH aqueous solution. The organic phase was separated and the aqueous phase was back extracted with dichloromethane. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound (0.028 g, 54% yield). HPLC retention time: 3.03 min; MS: 4051 (M+H).

This method was used for the preparation of examples 304-309 starting from the corresponding examples described above:

Ret time MS EX Structure Chemical name (min) (M + H) 304

9-(2-(2-aminothiazol-4- yl)ethyl)-4-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one 3.08 456.1 305

9-(2-(5-amino-1H-pyrazol-1- yl)ethyl)-2-methyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 2.68 370.2 306

9-(2-(2-aminothiazol-4- yl)ethyl)-4-(2-fluorophenyl)- 2-isopropyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one dihydrochloride 3.16 433.2 307

8-[2-(2-aminothiazol-4- yl)ethyl]-12-phenyl-4-oxa- 8,12- diazadispiro[2.1.5.3]undecan- 13-one dihydrochloride 3.11 399.2 308

8-[2-(2-aminothiazol-4- yl)ethyl]-12-{[5- (trifluoromethyl)pyridin-2- yl]methyl}-4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one trihydrochloride 3.43 482.2 309

9-(2-(2-aminothiazol-4- yl)ethyl)-2-methyl-4-(4- (trifluoromethyl)pyridin-3-yl)- 1-oxa-4,9- diazaspiro[5.5]undecan-3- one 2.98 456.1 Where indicated, the hydrochloride salts were prepared as described in example 1

Example 310: 12-(2-hydroxyethyl)-8-phenethyl-4-oxa-8,12-diazadispiro [2.1.5.3]tridecan-13-one hydrochloride

A solution of example 185 (0.105 g, 0.155 mmol) in a mixture of THF/1M HCl aqueous solution 1:1 (2 ML) was stirred at r.t. for 2 h. Then. NaHCO₃ sat solution was added until pH 8. The aqueous phase was extracted with dichloromethane and the organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound as its free base (0.036 g, 100% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 3.30 min; MS: 345.2 (M+H).

Example 311: 4-(2-fluorophenyl)-9-phenethyl-2-((tetrahydro-2H-pyran-4-yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride

A mixture of example 80 (0.054 g. 0.116 mmol) and palladium (16 mg, 10% wt on charcoal) in ethyl acetate (2 mL) was heated at 30° C. under 3 bars of H₂ overnight. Then, the solids were filtered off, and the solvent was removed under vacuum to give the title compound as its free base (0.049 g. 91% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 4.53 min; MS: 467.3 (M+H).

This method was used for the preparation of examples 312-314 starting from the corresponding examples described above:

Ret time MS EX Structure Chemical name (min) (M + H) 312

4-(2-fluorophenyl)-2- isopropyl-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 5.07 411.2 313

4-(2-fluorophenyl)-2- isopropyl-9-(2-(pyridin-2- yl)ethyl)-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.00 412.2 314

4-(2-fluorophenyl)-2-(3- methoxypropyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one hydrochloride 4.52 441.2

Example 315: N-methyl-2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro [5.5]undecan-9-yl)-N-phenylacetamide hydrochloride

To a solution of example 71 (24 mg, 0.170 mmol) in dry THF (2 mL), NaH (10 mg, 60 wt % in mineral oil, 0.069 mmol) was added. The reaction mixture was stirred at r.t. for 30 min, then iodomethane (0.067 mL, 0.170 mmol) was added and the resulting mixture was stirred at r.t. overnight. Dichloromethane was added to the reaction mixture and the organic phase was washed with NaHCO₃ sat solution and then with brine, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:9) to give the title compound as its free base (32 mg, 46% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 3.64 min; MS: 408.2 (M+H).

Example 316: 3-(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)phenol

To a solution of example 288 (0.055 g, 0.150 mmol) in THF (3.2 mL), LiAlH₄ solution (0.60 mL, 1M in THF. 0.60 mmol) was added dropwise. The reaction mixture was stirred at 70° C. for 2 h. Then, water and 1M NaOH aqueous solution were added. The resulting suspension was filtered through a pad of celite, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (0.5:9.5) to give the title compound (0,037 g, 70% yield). HPLC retention time: 3.89 min; MS: 353.2 (M+H).

This method was used for the preparation of examples 317-331 starting from the corresponding examples described above:

Ret time MS EX Structure Chemical name (min) (M + H) 317

9-phenethyl-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecane 5.01 (method B) 337.2 318

3-(9-benzyl-1-oxa-4,9- diazaspiro[5.5]undecan- 4-yl)phenol 3.88 339.2 319

2-(methoxymethyl)-9- phenethyl-4-phenyl-1- oxa-4,9- diazaspiro[5.5]undecane hydrochloride 4.77 381.2 320

9-(3-methoxyphenethyl)- 4-phenyl-1-oxa-4,9- dsazaspiro[5.5]undecane hydrochloride 4.65 367.2 321

2-(2-(4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 9-yl)ethyl)phenol 4.72 353.1 322

3-(2-(4-phenyl-1-oxa-4,9- diazaspiro[5.5]undecan- 9-yl)ethyl)phenol 3.90 353.2 323

2-(9-phenethyl-4-phenyl- 1-oxa-4,9- diazaspiro[5.5]undecan- 2-yl)ethanol hydrochloride 4.09 381.2 324

4-benzyl-9-phenethyl-1- oxa-4,9- diazaspiro[5.5]undecan- dihydrochloride 4.93 351.2 325

9-phenethyl-4-(thiazol-4- ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecane dihydrochloride 3.48 358.2 326

9-(2-methoxyphenethyl)- 4-(pyridin-2-ylmethyl)-1- oxa-4,9- diazaspiro[5.5]undecane 3.62 382.2 327

2-methyl-4-((1-methyl- 1H-imidazol-2-yl)methyl)- 9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecane dihydrochloride 3.60 369.2 328

2-methyl-4-((1-methyl- 1H-pyrazol-3-yl)methyl)- 9-phenethyl-1-oxa-4,9- diazaspiro[5.5]undecane dihydrochloride 3.64 369.2 329

2-(2-(4-(pyridin-2- ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecan- 9-yl)ethyl)phenol hydrochloride 3.71 368.2 330

2-methyl-9-phenethyl-4- (pyridin-2-ylmethyl)-1- oxa-4,9- diazaspiro[5.5]undecane hydrochloride 4.03 366.2 331

2-methyl-9-phenethyl-4- (2-(pyridin-3-yl)ethyl)-1- oxa-4,9- diazaspiro[5.5]undecane hydrochloride 4.02 380.2 Where indicated, the hydrochloride salts were prepared as described in example 1

Example 332: 9-(4-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane

To a solution of example 52 (0.150 g. 0.394 mmol) in THF (6.5 mL). LiAlH₄ solution (1.58 mL, 1M in THF, 1.58 mmol) was added dropwise. The reaction mixture was stirred at 70° C. for 2 h. Then, water and 1M NaOH aqueous solution were added. The resulting suspension was filtered through a pad of celite, dried over MgSO₄, filtered and concentrated to dryness. The residue was dissolved in ethanol (1.7 mL) and palladium (13 mg, 10% wt on charcoal) was added. The resulting mixture was stirred under 3 bars of H₂ at r.t. overnight. Then, the solids were filtered off, and the solvent was removed under vacuum. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane 1:9) to give the title compound (0,079 g. 55% yield). HPLC retention time: 4.56 min; MS: 367.2 (M+H).

This method was used for the preparation of examples 333-334 starting from the corresponding examples described above:

Ret time MS EX Structure Chemical name (min) (M + H) 333

4-(3-methoxyphenyl)-9- phenethyl-1-oxa-4,9- diazaspiro[5.5]undecane hydrochloride 4.64 367.2 334

9-(2-methoxyphenethyl)-4- phenyl-1-oxa-4,9- diazaspiro[5.5]undecane hydrochloride 4.65 367.2 The hydrochloride salts were prepared as described in example 1.

Example 335: 4-benzyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane dihydrochloride

To a solution of intermediate 9C (0.142 g, 0.518 mmol) and benzaldehyde (0.105 mL, 1.035 mmol) in THF (5 mL), acetic acid (0.064 mL, 1.138 mmol) was added. The reaction mixture was stirred at r.t. for 15 min. and sodium triacetoxyborohydride (0.219 g, 1.035 mmol) was added portionwise. The resulting mixture was stirred at r.t. overnight Water was added, the pH of the mixture was adjusted to 9 by addition of 1M NaOH aqueous solution and it was extracted with dichloromethane. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (19) to give the title compound as its free base (114 mg, 60% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 5.36 min. MS: 365.2 (M+H).

This method was used for the preparation of examples 336-339 using suitable starting materials and protection, deprotection steps:

Ret time MS EX Structure Chemical name (min) (M + H) 336

9-phenethyl-4-(pyridin-2- ylmethyl)-1-oxa-4,9- diazaspiro[5.5]undecane dihydrochloride 3.65 352.2 337

4,9-diphenethyl-1-oxa-4,9- diazaspiro[5.5]undecane dihydrochloride 4.84 365.2 338

3-(2-(4-benzyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)aniline 3.87 366.2 339

N-(3-(2-(4-benzyl-1-oxa-4,9- diazaspiro[5.5]undecan-9- yl)ethyl)phenyl)acetamide 3.90 408.2

Example 340: 3-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane hydrochloride

Step 1: 3-methyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane trifluoroacetate. To a solution of intermediate 11 (0,078 g, 0.225 mmol) in dichloromethane (0.8 mL), trifluoroacetic acid (0.16 mL, 9.1 mmol) was added, and the reaction mixture was heated at 40° C. for 2 h. The solvent was evaporated to dryness to give the title compound as a crude product (0.156 g, quant yield, 52 wt %), that was used in the following step without further purification. HPLC retention time: 2.79 min; MS: 247 (M+H),

Step 2: Title compound: To a solution of the crude product obtained in step 1 (0.156 g. 52 wt %, 0.22 mmol) and phenylacetaldehyde (0.054 g, 0.45 mmol) in THF (2 mL), acetic acid (0.028 mL, 0.48 mmol) was added. The reaction mixture was stirred at r.t. for 15 min., then sodium triacetoxyborohydride (0.095 g, 0.45 mmol) was added portionwise. The resulting mixture was stirred at r.t. overnight. Water was added, the pH of the mixture was adjusted to 9 by addition of 1M NaOH aqueous solution and it was extracted with dichloromethane. The organic phases were combined, dried over MgSO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography, silica gel, gradient dichloromethane to methanol:dichloromethane (1:4) to give the title compound as its free base (10 mg, 13% yield).

The previous compound was converted to its hydrochloride salt as described in example 1.

HPLC retention time: 5.04 min: MS: 351.2 (M+H).

Examples 341 to 343 were prepared according to the procedure described in Example 218, using suitable starting materials:

Ret time MS EX EST Structure Chemical name (min) (M + H) 341 EST0073428 A

8-(2,5-difluorophenethyl)- 12-(2- (trifluoromethyl)pyridin-3-yl)- 4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 4.49 482.2 342 EST0073447 A

8-(2,5-difluorophenethyl)- 12-(4- (trifluoromethyl)pyridin-3-yl)- 4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 4.43 482.2 343 EST0073472 A

8-(2,5-difluorophenethyl)- 12-(3- (trifluoromethyl)pyridin-2-yl)- 4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 13-one 4.59 482.2

Example 344: 12-benzyl-8-(2-(3-fluoropyridin-2-yl)ethyl)-4-oxa-8,12-diazadispiro [2.1.5.3]tridecane (EST0073850)

Example 344 was prepared according to the procedure described in Example 33, using suitable starting materials and refluxing ethanol as the solvent. HPLC retention time (method C): 4.72 min; MS: 3962 (M+H).

Example 345: 8-(2-(3-fluoropyridin-2-yl)ethyl)-12-(3-methylpyridin-2-yl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane (EST0074067.A)

Example 345 was prepared according to the procedure described in Example 316, using Example 220 as starting material HPLC retention time (method C): 5.00 min; MS: 396.2 (M+H).

Examples 346 to 348 were prepared according to the procedure described in Example 51, using suitable starting materials:

Ret time MS EX EST Structure Chemical name (min) (M + H) 346 EST0073425A

methyl 3-(12-benzyl-13-oxo- 4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 8-yl)propanoate 3.37 373.2 347 EST0073445A

methyl 3-(12-benzyl-4-oxa- 8,12- diazadispiro[2.1.5.3]tridecan- 8-yl)propanoate 4.19 359.2 348 EST0073446A

methyl 3-(13-oxo-12-phenyl- 4-oxa-8,12- diazadispiro[2.1.5.3]tridecan- 8-yl)propanoate 3.12 359.1

Examples 349 and 350: (R)-2-benzyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one (EST0074477.A) and (S)-2-benzyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one (EST0074478.A)

Starting from example 7, a chiral preparative HPLC separation (column: Chiralpak IA; temperature: ambient: flow: 55 mL/min; eluent n-Heptane/EtOH 96/04 v/v+01% DEA) was carried out obtaining examples 349 and 350.

HPLC retention time (method C): 3.84 min; MS: 323.1 (M+H)

Table of Examples with Binding to the μ-Oploid Receptor and the σ₁-Receptor:

Biological Activity Pharmacological Study Human Sigma 1 Receptor Radioligand Assay

To investigate binding properties of test compounds to human σ₁ receptor, transfected HEK-293 membranes and [³H](+)pentazocine (Perkin Elmer, NET-1056), as the radioligand, were used. The assay was carried out with 7 μg of membrane suspension, 5 nM of [³H](+)-pentazocine in either absence or presence of either buffer or 10 μM Haloperidol for total and non-specific binding, respectively. Binding buffer contained Tris-HCl 50 mM at pH 8. Plates were incubated at 37° C. for 120 minutes. After the incubation period, the reaction mix was then transferred to MultiScreen HTS, FC plates (Millipore), filtered and plates were washed 3 times with ice-cold 10 mM Tris-HCL (pH7.4). Filters were dried and counted at approximately 40% efficiency in a MicroBeta scintillation counter (Perkin-Elmer) using EcoScint liquid scintillation cocktail

Human μ-Opioid Receptor Radioligand Assay

To investigate binding properties of test compounds to human μ-opioid receptor, transfected CHO-K1 cell membranes and [³H]-DAMGO (Perkin Elmer. ES-542-C), as the radioligand, were used. The assay was carried out with 20 μg of membrane suspension, 1 nM of [³H]-DAMGO In either absence or presence of either buffer or 10 μM Naloxone for total and non-specific binding, respectively, Binding buffer contained Tris-HCl 50 mM, MgCl2 5 mM at pH 7.4. Plates were incubated at 27° C. for 60 minutes. After the incubation period, the reaction mix was then transferred to MultiScreen HTS, FC plates (Millipore), filtered and plates were washed 3 times with ice-cold 10 mM Tris-HCL (pH 7.4). Filters were dried and counted at approximately 40% efficiency in a MicroBeta scintillation counter (Perkin-Elmer) using EcoScint liquid scintillation cocktail.

Results:

As this invention is aimed at providing a compound or a chemically related series of compounds which act as dual ligands of the n receptor and the μ-opiod receptor it is a very preferred embodiment in which the compounds are selected which act as dual ligands of the σ₁ receptor and the μ-opiod receptor and especially compounds which have a binding expressed as K_(i) which is preferably <1000 nM for both receptors, more preferably <500 nM, even more preferably <100 nM.

The following scale as been adopted for representing the binding to the σ₁ receptor and the μ-opiod receptor expressed as K₁:

-   -   + Both K₁−μ and K₁−σ₁>=500 nM     -   ++ One K₁<500 nM while the other K₁ is >=500 nM     -   +++ Both K₁−μ and K₁−σ₁<500 nM     -   ++++ Both K₁−μ and K₁−σ₁<100 nM

All compounds prepared in the present application exhibit binding to the σ₁ receptor and the μ-opiod receptor, in particular the following binding results are shown:

μ and σ₁ dual Ex binding  1 ++  2 ++  3 ++  4 ++  5 +++  6 ++  7 ++  8 ++  9 ++++  10a ++++  10b ++++  11 ++++  12a +++  12b ++++  13 ++++  14 ++++  15 +++  16 ++  17 ++++  18 ++++  19 ++++  20 ++  21 +  22 +  23 +  24 +  25 +  26 +  27 +  28 ++++  29 +++  30 +  31 +++  32 ++  33 +++  34 +  35 ++  36 +  37 +++  38 +++  39 +  40 ++  41 ++  42 +  43 +  44 ++  45 ++++  46 +++  47 +++  48 +  49 ++  50 +++  51 ++++  52 ++  53 ++++  54 ++++  55 ++++  56 ++  57 ++++  58 ++++  59 ++  60 +++  61 +++  62 ++++  63 ++  64 +  65 +  66 +  67 +  68 +  69 ++  70 ++  71 +  72 ++  73 +++  74 +++  75 ++++  76 ++  77 ++  78 +  79 +++  80 +++  81 ++  82 +  83 ++++  84 ++  85 +  86 ++++  87 +  88 +++  89 +++  90 ++++  91 +++  92 +  93 +++  94 +++  95 +++  96 +++  97 +  98 +++  99 + 100 +++ 101 ++ 102 +++ 103 + 104 + 105 ++++ 106 + 107 + 108 + 109 ++++ 110 + 111 ++ 112 +++ 113 + 114 +++ 115 +++ 116 + 117 + 118 + 119 + 120 + 121 + 122 + 123 ++ 124 + 125 ++ 126 ++++ 127a ++ 127b ++++ 128 + 129 + 130 +++ 131 ++ 132 +++ 133 ++ 134 ++ 135 ++ 136 +++ 137 ++++ 138 ++++ 139 + 140 + 141 +++ 142 +++ 143 + 144 +++ 145 + 146 + 147 + 148 + 149 ++ 150 + 151a +++ 151b +++ 151c +++ 151d +++ 152 ++++ 153 ++++ 154 ++++ 155 ++++ 156 ++++ 157 ++++ 158 ++++ 159 ++++ 160 ++++ 161 +++ 162 +++ 163 ++ 164 ++++ 165 ++ 166 +++ 167 ++++ 168 ++ 169 ++ 170 + 171 +++ 172 ++ 173 ++++ 174 ++++ 175 +++ 176 +++ 177 ++++ 178 ++ 179 + 180 +++ 181 + 182 + 183 + 184 ++ 185 + 186 + 187 ++++ 188 ++ 189 +++ 190 +++ 191 +++ 192 ++++ 193 ++++ 194 +++ 195 +++ 196 ++ 197 ++ 198 ++ 199 + 200 ++ 201 ++ 202 +++ 203 ++ 204 ++ 205 ++ 206 ++++ 207 ++++ 208 ++++ 209 +++ 210 ++ 211 +++ 212 + 213 ++++ 214 ++++ 215 +++ 216 +++ 217 +++ 218 +++ 219 +++ 220 +++ 221 +++ 222a +++ 222b + 223 ++++ 224 ++++ 225 ++++ 226 ++++ 227 + 228 +++ 229 ++++ 230 ++ 231 + 232 ++ 233 +++ 234 +++ 235 + 236 + 237 + 238 ++++ 239 + 240 + 241 ++ 242 ++ 243 +++ 244a +++ 244b ++++ 245 ++ 246 +++ 247 ++ 248 ++ 249 + 250 + 251 +++ 252 + 253 + 254 ++ 255 + 256 +++ 257 +++ 258 ++ 259 + 260 +++ 261 +++ 262 +++ 263 +++ 264 +++ 265 ++ 266 +++ 267 + 268 + 269 + 270 + 271 ++ 272 ++ 273 + 274 +++ 275 + 276 +++ 277 ++++ 278 +++ 279 ++ 280 + 281 ++ 282 ++++ 283 +++ 284 + 285 ++ 286 ++ 287 ++ 288 +++ 289 +++ 290 ++ 291 +++ 292 ++ 293 ++ 294 ++ 295 ++++ 296 ++ 297 ++++ 298 ++++ 299 ++++ 300 ++ 301 ++ 302 +++ 303 +++ 304 +++ 305 + 306 ++ 307 +++ 308 ++ 309 + 310 + 311 +++ 312 ++++ 313 +++ 314 +++ 315 + 316 +++ 317 +++ 318 +++ 319 +++ 320 ++ 321 ++ 322 +++ 323 +++ 324 ++++ 325 +++ 326 +++ 327 +++ 328 ++ 329 ++++ 330 ++++ 331 ++ 332 ++ 333 ++ 334 ++ 335 ++++ 336 ++++ 337 ++ 338 + 339 ++++ 340 +++ 341 ++ 342 +++ 343 +++ 344 ++++ 345 +++ 346 ++ 347 +++ 348 + 349 + 350 + 

1. A compound of Formula I

wherein Y is

and Z is —CH₂—, —C(O)— or —CHR₉— or Y is

and Z is —CH₂— or —CHR₉—; m is 0 or 1; n is 1, 2 or 3; q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)_(r)—W—R_(1′); r is 0, 1 or 2; W is —CH₂O—, —CH₂C(O)NR_(5′)—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R₁ is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; wherein the aryl, heterocyclyl or cycloalkyl in R₁ or R_(1′), if substituted, also in alkylaryl or alkylheterocyclyl, are substituted with substituents selected from the group consisting of —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ and —S(O)₂R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl, heterocyclyl or cycloalkyl in R₂, if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, is substituted with substituents selected from the group consisting of —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, —NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, -haloalkoxy, —SR₅, —S(O)R₅ and —S(O)₂R₅; R₃ and R_(3′) are independently selected from the group consisting of H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, and substituted or unsubstituted alkylcycloalkyl; wherein the aryl, cycloalkyl and heterocyclyl as defined in R₃, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, if substituted, are substituted with substituents selected from the group consisting of —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅; R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R_(5′″) or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, wherein the aryl, cycloalkyl and heterocyclyl as defined in R₄, if substituted, are substituted with substituents selected from the group consisting of —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ and —S(O)₂R₅; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R_(5′) and R_(5″) are independently selected from the group consisting of H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5′″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc; R₆, R_(6′), R₇ and R_(7′) are independently selected from the group consisting of H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R_(8′) are independently selected from the group consisting of H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from the group consisting of H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted and unsubstituted C₂₋₆ alkynyl; wherein the alkyl, alkenyl and alkynyl as defined in R₁, R₁, R₂, R₃, R_(3′), R₄, R_(4′), R₆, R_(6′), R₇, R_(7′), R₈, R_(8′) and R₉, if substituted, are substituted with substituents selected from the group consisting of —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅, —S(O)₂R₅, C(O)OR₅ and C(O)NR₅R_(5′); optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two of stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
 2. The compound according to claim 1, wherein R₁ is —(CH₂)_(r)—W—R, or R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, or substituted or unsubstituted alkylheterocyclyl.
 3. The compound according to claim 1, wherein X is a bond; —C(R₄R_(4′))—; —C(O)O—; —C(O)NR₅—; —C(O)—; or —O—.
 4. The compound according to claim 1, wherein Y is


5. The compound according to claim 1, wherein m is 1, and n is
 2. 6. The compound according to claim 1, wherein R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, or —(CH₂)_(r)—W—R_(1′), wherein the aryl is phenyl, naphthyl, or anthracene; the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur; and the alkyl is C₁₋₆ alkyl.
 7. The compound according to claim 6, wherein R₁ is substituted or unsubstituted phenyl; substituted or unsubstituted pyridine, pyrazine, indazole, benzodioxane, thiazole, benzothiazole, morpholine, tetrahydropyran, pyrazole, or imidazole; substituted or unsubstituted benzyl; or substituted or unsubstituted alkylheterocyclyl, wherein the heterocyclyl is pyridine, pyrazine, indazole, benzodioxane, thiazole, benzothiazole, morpholine, tetrahydropyrane, pyrazole, or imidazole and the alkyl is methyl.
 8. The compound according to claim 1, wherein R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; wherein the aryl is phenyl, naphthyl, or anthracene; the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and the cycloalkyl is C₃₋₈ cycloalkyl.
 9. The compound according to claim 8, wherein R, is substituted or unsubstituted phenyl; substituted or unsubstituted morpholine or tetrahydropyran; or substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
 10. The compound according to claim 1, wherein R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl is phenyl, naphthyl, or anthracene; the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur in the ring; and the cycloalkyl is C₃₋₈ cycloalkyl.
 11. The compound according to claim 10, wherein R₂ is substituted or unsubstituted phenyl; substituted or unsubstituted pyridine, piperidine, thiazole, morpholine, tetrahydropyran, pyrazole, thiophene, indole, benzimidazole, pyrrolo[2,3b]pyridine, benzoxazole, oxopyrrolidine, or pyrimidine; substituted or unsubstituted cyclopropyl; substituted or unsubstituted methyl or isopropyl; substituted or unsubstituted ethenyl, propenyl, butenyl, pentenyl, or hexenyl; or substituted or unsubstituted ethynyl, propynyl, butynyl, pentynyl, or hexynyl.
 12. The compound according to claim 1, wherein R₃ and R_(3′) are independently selected from the group consisting of H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, and substituted or unsubstituted alkylcycloalkyl, wherein the alkyl is C₁₋₆ alkyl; the cycloalkyl is C₃₋₈ cycloalkyl; the aryl is phenyl, naphthyl, or anthracene; and the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
 13. The compound according to claim 12, wherein the C₁₋₆ alkyl is methyl or ethyl; the C₂₋₆ alkenyl is ethenyl, propenyl, butenyl, pentenyl, or hexenyl; the C₂₋₆ alkynyl is ethynyl, propynyl, butynyl, pentynyl, or hexynyl; the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; the aryl is phenyl; and the heterocyclyl is imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole, oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole or quinazoline.
 14. The compound according to claim 1, wherein R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R5′″, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, and R₄ is H or substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl), wherein the cycloalkyl is C₃₋₈ cycloalkyl; the aryl is from phenyl, naphthyl, or anthracene; and the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
 15. The compound according to claim 14, wherein the C₁₋₆ alkyl is methyl; the C₂₋₆ alkenyl is ethenyl, propenyl, butenyl, pentenyl, or hexenyl; the C₂₋₆ alkynyl is ethynyl, propynyl, butynyl, pentynyl, or hexynyl; the heterocyclyl is tetrahydropyran; the aryl is phenyl; and the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
 16. The compound according to claim 1, wherein R₅, R_(5′) and R_(5″) are independently H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5′″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc, wherein the alkyl is C₁₋₆ alkyl; and the aryl is phenyl, naphthyl, or anthracene.
 17. The compound according to claim 16, wherein the C₁₋₆ alkyl is methyl, ethyl, or isopropyl; the C₂₋₆ alkenyl is ethenyl, propenyl, butenyl, pentenyl, or hexenyl; the C₂₋₆ alkynyl is ethynyl, propynyl, butynyl, pentynyl, or hexynyl; and the aryl is phenyl.
 18. The compound according to claim 1, wherein R₆, R_(6′), R₇ and R_(7′) are independently selected from the group consisting of H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; wherein the cycloalkyl is C₃₋₈ cycloalkyl; the aryl is phenyl, naphthyl, or anthracene; and the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
 19. The compound according to claim 18, wherein the C₁₋₆ alkyl is methyl or ethyl; the C₂₋₆ alkenyl is ethenyl, propenyl, butenyl, pentenyl, or hexenyl; the C₂₋₆ alkynyl is ethynyl, propynyl, butynyl, pentynyl, or hexynyl; the heterocyclyl is tetrahydropyran; the aryl is phenyl or naphthyl; and the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
 20. The compound according to claim 1, wherein R₈ and R_(8′) are independently selected from the group consisting of H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl.
 21. The compound according to claim 20, wherein R₈ and R_(8′) are independently selected from the group consisting of substituted or unsubstituted methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; substituted or unsubstituted ethenyl, propenyl, butenyl, pentenyl, or hexenyl; or substituted or unsubstituted ethynyl, propynyl, butynyl, pentynyl, or hexynyl.
 22. (canceled)
 23. The compound according to claim 1, which is selected from the group consisting of: 2-methylene-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; 4-(2-fluorophenyl)-2-methylene-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; (Z)-4-(2-fluorophenyl)-9-phenethyl-2-((tetrahydro-2H-pyran-4-yl)methylene)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; 4-(2-fluorophenyl)-9-phenethyl-2-(propan-2-ylidene)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; 4-benzyl-9-(2-methoxyphenethyl)-1-oxa-4,9-diazaspiro[5.5]undecane; 12-phenyl-8-[2-(pyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 8-(3-nitrophenethyl)-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 8-(2-oxo-2-phenylethyl)-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 12-(4-methoxybenzyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one hydrochloride; tert-butyl (4-(2-(13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)ethyl)thiazol-2-yl)carbamate; 8-(3-nitrophenethyl)-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; tert-butyl (4-(2-(13-oxo-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)ethyl)thiazol-2-yl)carbamate; 4-benzyl-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecane; 4-(2-fluorophenyl)-2-(propan-2-ylidene)-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; 4-(2-fluorophenyl)-9-(2-(4-methylthiazol-5-yl)ethyl)-2-(propan-2-ylidene)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; (Z)-4-(2-fluorophenyl)-2-(3-methoxypropylidene)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; 8-(2-fluorophenethyl)-12-(4-methoxybenzyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 12-(3-methoxypropyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; N,N-dimethyl-3-[13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-12-yl]propanamide; 12-(2-methoxyethyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 12-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; methyl 3-(13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-12-yl)propanoate; 8-phenethyl-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 8-(2-fluorophenethyl)-12-(2-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 8-(2-fluorophenethyl)-12-(3-(trifluoromethyl)pyridin-2-yl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one hydrochloride; 8-(2-fluorophenethyl)-12-(4-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one hydrochloride; 12-(2-Fluorophenyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 8-phenethyl-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 8-(3-aminophenethyl)-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 8-(3-aminophenethyl)-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; N-[3-(2-{13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)phenyl]acetamide; N-[3-(2-{13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)phenyl]methanesulfonamide; {3-[2-(13-oxo-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)ethyl]phenyl}urea; N-methyl-3-[13-oxo-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-12-yl]propanamide; 8-(2-hydroxy-2-phenylethyl)-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 12-(3-hydroxypropyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 4-(2-(4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol; 2-(2-(4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol; 8-[2-(2-aminothiazol-4-yl)ethyl]-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 8-[2-(2-aminothiazol-4-yl)ethyl]-12-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 12-(2-hydroxyethyl)-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 3-(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)phenol; 9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane; 3-(9-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)phenol; 2-(methoxymethyl)-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane; 9-(3-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane; 2-(2-(4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol; 3-(2-(4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol; 2-(9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-2-yl)etanol; 4-benzyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane; 9-phenethyl-4-(thiazol-4-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecane; 9-(2-methoxyphenethyl)-4-(pyridin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecane; 2-methyl-4-((1-methyl-1H-imidazol-2-yl)methyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane; 2-methyl-4-((1-methyl-1H-pyrazol-3-yl)methyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane; 2-(2-(4-(pyridin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenol; 2-methyl-9-phenethyl-4-(pyridin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecane; 2-methyl-9-phenethyl-4-(2-(pyridin-3-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecane; 9-(4-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane; 4-(3-methoxyphenyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane; 9-(2-methoxyphenethyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane; 4-benzyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane; 9-phenethyl-4-(pyridin-2-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecane; 4,9-diphenethyl-1-oxa-4,9-diazaspiro[5.5]undecane; 3-(2-(4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)aniline; N-(3-(2-(4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide; 3-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane; 8-(2,5-difluorophenethyl)-12-(2-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 8-(2,5-difluorophenethyl)-12-(4-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 8-(2,5-difluorophenethyl)-12-(3-(trifluoromethyl)pyridin-2-yl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one; 12-benzyl-8-(2-(3-fluoropyridin-2-yl)ethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane; 8-(2-(3-fluoropyridin-2-yl)ethyl)-12-(3-methylpyridin-2-yl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane; methyl 3-(12-benzyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)propanoate; methyl 3-(12-benzyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)propanoate; and methyl 3-(13-oxo-12-phenyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)propanoate; optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.
 24. A process for the preparation of a compound of formula Ia

wherein Z is —CH₂— or —CHR₉—; m is 0 or 1; n is 1, 2 or 3; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)_(r)—W—R_(1′); r is 0, 1 or 2; W is —CH₂O—, —CH₂C(O)NR_(5′)—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; wherein the aryl, heterocyclyl or cycloalkyl in R₁ or R_(1′) if substituted, also in alkylaryl or alkylheterocyclyl, are substituted with substituents selected from the group consisting of —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, haloalkoxy, —SR5, —S(O)R₅ and —S(O)₂R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl, heterocyclyl or cycloalkyl in R₂, if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, is substituted with substituents selected from the group consisting of —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, —NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, -haloalkoxy, —SR₅, —S(O)R₅ and —S(O)₂R₅; R₃ and R_(3′) are independently selected from the group consisting of H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, and substituted or unsubstituted alkylcycloalkyl; wherein the aryl, cycloalkyl and heterocyclyl as defined in R₃, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, if substituted, are substituted with substituents selected from the group consisting of —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ and —S(O)₂R₅; R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R_(5″) or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted cycloalkyl, wherein the aryl, cycloalkyl and heterocyclyl as defined in R₄, if substituted, are substituted with substituents selected from the group consisting of —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ and —S(O)₂R₅; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R_(5′) and R_(5″) are independently selected from the group consisting of H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, and unsubstituted aryl and unsubstituted alkylaryl; R_(5′″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc; R₈ and R_(8′) are independently selected from the group consisting of H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl and substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from the group consisting of H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl and substituted or unsubstituted C₂₋₆ alkynyl; wherein the alkyl, alkenyl and alkynyl as defined in R₁, R_(1′), R₂, R₃, R_(3′), R₄, R_(4′), R₈, R_(8′), and R₉, if substituted, are substituted with substituents selected from the group consisting of —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅, —S(O)₂R₅, C(O)OR₅ and C(O)NR₅R_(5′); which comprises the steps of (a) reacting a compound of formula Va

with a compound of formula VI

wherein LG is a leaving group, to obtain a compound of formula VIIa

and (b) Carrying out a cyclisation of the resulting compound in a suitable solvent, in the presence of a strong base and at a temperature comprised between −78° C. and the reflux temperature.
 25. A process for the preparation of a compound of general formula Ifx

wherein Z is —CH₂—, —C(O)— or —CHR₉—; m is 0 or 1; n is 1, 2 or 3; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)_(r)—W—R_(1′); r is 0, 1 or 2; W is —CH₂O—, —CH₂C(O)NR_(5′)—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; wherein the aryl, heterocyclyl or cycloalkyl in R₁ or R_(1′), if substituted, also in alkylaryl or alkylheterocyclyl, are substituted with substituents selected from the group consisting of —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, haloalkoxy, —SR5, —S(O)R₅ and —S(O)₂R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl, heterocyclyl or cycloalkyl in R₂, if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, is substituted with substituents selected from the group consisting of —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, —NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, -haloalkoxy, —SR₅, —S(O)R₅ and —S(O)₂R₅; R₃ and R_(3′) are independently selected from the group consisting of H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, and substituted or unsubstituted alkylcycloalkyl; wherein the aryl, cycloalkyl and heterocyclyl as defined in R₃, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, if substituted, are substituted with substituents selected from the group consisting of —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ and —S(O)₂R₅; R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R_(5″) or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted cycloalkyl, wherein the aryl, cycloalkyl and heterocyclyl as defined in R₄, if substituted, are substituted with substituents selected from the group consisting of —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ and —S(O)₂R₅; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R_(5′) and R_(5″) are independently selected from the group consisting of H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, and unsubstituted aryl or unsubstituted alkylaryl; R_(5′″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc; R₈ and R_(8′) are independently selected from the group consisting of H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl and substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from the group consisting of H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl and substituted or unsubstituted C₂₋₆ alkynyl; wherein the alkyl, alkenyl and alkynyl as defined in R₁, R_(1′), R₂, R₃, R_(3′), R₄, R_(4′), R₈, R_(8′), and R₉, if substituted, are substituted with substituents selected from the group consisting of —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅, —S(O)₂R₅, C(O)OR₅ and C(O)NR₅R_(5′); and R₇ and R_(7′) are hydrogen; which comprises (a) the dehydration of a compound of formula XIXx

wherein R₆ and R_(6′) are hydrogen; followed by (b) the cyclopropanation of a compound of formula Icx


26. A pharmaceutical composition which comprises the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
 27. A method of treating pain in a subject in need thereof, comprising administration of an effective amount of the compound of Formula (I)

wherein Y is

Z is —CH₂—, —C(O)— or —CHR₉—; m is 0 or 1; n is 1, 2 or 3; q is 1, 2, 3, 4, 5 or 6; R₁ is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl or —(CH₂)_(r)—W—R_(1′); r is 0, 1 or 2; W is —CH₂O—, —CH₂C(O)NR_(5′)—, —CH₂C(O)O—, —CH₂C(O)— or —C(CH₃)₂O—; R_(1′) is H, —CN, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or R₅; wherein the aryl, heterocyclyl or cycloalkyl in R₁ or R_(1′) if substituted also in alkylaryl or alkylheterocyclyl are substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, haloalkoxy, —SR5, —S(O)R₅ or —S(O)₂R₅; X is a bond, —C(O)O—, —C(O)NR₅—, —C(O)—, —O— or —C(R₄R_(4′))—; R₂ is H, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; wherein the aryl, heterocyclyl or cycloalkyl in R₂ if substituted also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl is substituted with substituents selected from —R₅, —OR₅, halogen, —CN, —NO₂, —NR₅R_(5′″), —C(O)OR₅, —NR₅C(O)R_(5′), —C(O)NR₅R_(5′), —NR₅S(O)₂R_(5′), ═O, —OCH₂CH₂OH, —NR₅C(O)NR_(5′)R_(5″), —S(O)₂NR₅R_(5′), —NR₅S(O)₂NR_(5′)R_(5″), haloalkyl, -haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅; R₃ and R_(3′) are independently selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, and substituted or unsubstituted alkylcycloalkyl; wherein the aryl, cycloalkyl and heterocyclyl as defined in R₃ also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅; R₄ is H, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, —COOR₅, —CONR₅R_(5′), —NR₅COR_(5′), —NR₅R_(5′″) or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, wherein the aryl, cycloalkyl and heterocyclyl as defined in R₄ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅ or —S(O)₂R₅; R_(4′) is H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂_6 alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₅, R_(5′) and R_(5″) are independently selected from H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted aryl or unsubstituted alkylaryl; R_(5′″) is H, unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc; R₆, R_(6′), R₇ and R_(7′) are independently selected from H, halogen, —OR₅, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl; R₈ and R_(8′) are independently selected from H, —OR₅, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; R₉ is selected from H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl; and wherein the alkyl, alkenyl and alkynyl as defined in R₁, R_(1′), R₂, R₃, R_(3′), R₄, R_(4′), R₆, R_(6′), R₇, R_(7′), R₈, R_(8′) and R₉ if substituted are substituted with substituents selected from —OR₅, halogen, —CN, haloalkyl, haloalkoxy, —SR₅, —S(O)R₅, —S(O)₂R₅, C(O)OR₅ or C(O)NR₅R_(5′); optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
 28. The method according to claim 27, wherein the pain is selected from the group consisting of medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain, neuropathic pain, allodynia, and hyperalgesia. 